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1.0 INTRODUCTION AND BACKGROUND 
The Human Research Program (HRP) delivers human health and performance countermeasures, 
knowledge, technologies, and tools to enable safe, reliable, and productive human space exploration. 
This Integrated Research Plan (IRP) describes the program’s research activities that are intended to 
address the needs of human space exploration and serve HRP customers. The timescale of human 
space exploration is envisioned to take many decades. The IRP illustrates the program’s research 
plan through the timescale of early lunar missions of extended duration. 
The document serves several purposes for the Human Research Program:  
The IRP provides a means to assure that the most significant risks to human space explorers are 
being adequately mitigated and/or addressed, 
The IRP shows the relationship of research activities to expected outcomes and need dates, 
The IRP shows the interrelationships among research activities that may interact to produce products 
that are integrative or cross defined research disciplines, 
The IRP illustrates the non-deterministic nature of research and technology activities by showing 
expected decision points and potential follow-on activities, 
The IRP shows the assignments of responsibility within the program organization and, as practical, 
the intended solicitation approach, 
The IRP shows the intended use of research platforms such as the International Space Station, 
NASA Space Radiation Laboratory, and various space flight analogs. 
The IRP does not show all budgeted activities of the Human research program, as some of these are 
enabling functions, such as management, facilities and infrastructure. 
1.1 CONTEXT OF THE INTEGRATED RESEARCH PLAN 
There are three foundational documents to the HRP: 1) The Program Requirements Document 
(PRD), 2) the Evidence Book, and 3) the Integrated Research Plan (IRP). The PRD describes the 
high-level requirements that the program must meet. The Evidence Book provides the scientific 
basis for the risks that are contained in the PRD, and the IRP describes the approach to addressing 
the requirements in the PRD. The relationship of these key HRP documents is illustrated in the 
graphic below. 
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1.2 PROGRAM REQUIREMENTS DOCUMENT 
The HRP PRD documents WHAT risks and standards the HRP addresses.   
 
The top-level requirements on the Human Research Program are maintained in the Exploration 
Systems Mission Directorate (ESMD) Exploration Architecture Requirements Document (EARD), 
ESMD-EARD-08-07 Rev.-. The purpose of the EARD is to translate the expectations of 
stakeholders, both outside and inside NASA, for the next generation U.S. Space Exploration 
mission, into requirements that will flow down to the implementing organizations.  The EARD 
carries the following top requirements for the HRP: 
• [Ex-0061] NASA's Human Research Program (HRP) shall develop knowledge, capabilities, 
countermeasures, and technologies to mitigate the highest risks to crew health and 
performance and enable human space exploration. 
• [Ex-0062] NASA's HRP shall provide data and analysis to support the definition and 
improvement of human spaceflight medical, environmental and human factors standards. 
• [Ex-0063] HRP shall develop technologies to reduce medical and environmental risks and to 
reduce human systems resource requirements (mass, volume, power, data, etc.). 
The PRD decomposes those requirements into lower level requirements that can be allocated to the 
HRP Element level. It is comprised of two main sections, Standards and Risks; 
 1.2.1 Standards 
The PRD requires that the HRP make recommendations for updates to the Space Flight 
Human System Standards (SHSS). The SHSS, Volume 1 was first baselined in March 5, 
2007 by the Office of the Chief Health and Medical Officer (NASA-STD-3001, Vol. 1).  It 
describes, among other things, Levels of Care required for human spaceflight missions, and 
Human Health and Performance Standards for crew members on exploration missions.  
Essentially, these standards define an acceptable level of risk for human health and 
performance associated with spaceflight.  By comparing these standards with the existing 
evidence and knowledge base, the HRP can identify and quantify the risks associated with 
human exploration missions, and derive the research necessary to lower the risk. 
SHSS, Volume 2 provides the comprehensive set of requirements associated with Human 
Factors and Habitability.  These standards must be met by the Constellation program in 
development of each vehicle and supporting equipment utilized in space exploration.  
Through comparison of these standards with the state of the art in engineering design, the 
HRP can identify areas where research is necessary to help the Constellation program meet 
these requirements. 
The HRP has two main responsibilities concerning the standards. In some cases the SHSS 
have a wide band of uncertainty. In these cases, the HRP must conduct research to help 
refine and narrow the uncertainty associated with the standard. In other cases, emerging 
evidence or knowledge may indicate that the standards are not written in a way that captures 
a complete set of relevant considerations.  In these cases the HRP is required to inform the 
modification of the standard.  Additional research may be required to facilitate this. 
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 1.2.2 Risks 
The PRD decomposes the top-level requirements into the specific risks and standards 
required to be addressed. It allocates the requirements of addressing each the risks and 
relevant standards to the appropriate Element within the HRP. The PRD, however, does not 
establish priority for the risks. 
The risks in the PRD are arranged in two groups (“Table 1” risks and “Table 2” risks) based 
on the level of available evidence; Table 1 risks are those for which substantial evidence 
exists, while Table 2 risks are of concern that cannot be supported or refuted by available 
information. This Integrated research plan addresses each or of risks in the PRD in the 
priority order described below. 
1.3 EVIDENCE BOOK 
The HRP Evidence Book documents WHY the risks are contained in the PRD. It is the record of 
what the state of knowledge is for each risk in the PRD and provides the basis for analysis of the 
risk likelihood and consequence.  As such, the Evidence Book makes these important data 
accessible and available for periodic review. 
The documentation of evidence for each risk in the PRD is in the form of a brief review article that 
is aimed at a scientifically-educated, non-specialist reader.  The body of each risk review contains a 
narrative discussion of the risk and its supporting evidence.  Declarative statements concerning the 
risk are supported by a description of the evidence, whether published or unpublished.  Relevant 
published references are listed at the end of the white paper.  Data that are significant or pivotal are 
summarized in text, tables and charts in sufficient detail to allow the reader to critique and draw 
conclusions, especially when a published reference is not available. In a similar fashion, the authors 
indicate whether the data are from human, animal or tissue/cell/molecular studies.  Evidence from 
spaceflight (including biomedical research, Medical Requirements Integration Document [MRID] 
data, and operational performance or clinical observations) is presented first, followed by ground-
based evidence (including space analog research and non-space analog biomedical or clinical 
research). When evidence is from ground-based studies, authors discuss why these results are likely 
to be applicable in the space environment, offering available validation information for the use of 
these ground-based systems.  
The baseline of the Evidence Book is anticipated in 2008. The National Academies of Sciences 
Institute of Medicine will review the evidence white papers to validate that the evidence is 
adequately and completely described.  
As new evidence is gathered, the Evidence Book will be updated.  If new evidence indicates that a 
risk should be retired or that a new risk should be added, the HRP will, after thorough review take 
the appropriate action to modify the PRD and update the Evidence Book accordingly. 
1.4 THE INTEGRATED RESEARCH PLAN 
The IRP documents WHAT activities are necessary to fill knowledge gaps, WHEN those activities 
will be accomplished, WHERE they will be accomplished (e.g. use the International Space Station, 
use a ground analog), WHO will accomplish them (which project or organization within the HRP), 
and WHAT is being produced. 
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1.4.1 Priority 
The research plan laid out in this document has been arranged in risk priority order. This 
priority was assigned by program management to achieve a consistency with definitions and 
qualitative criteria. 
This approach has the advantage of illustrating the critical risks first and gives the sense of 
how the research program is focused.  
This organization also brings with it a feature that detracts from this sense of focus. Each risk 
has been previously analyzed to expose gaps in knowledge that need to be better understood. 
When a risk is prioritized at a certain level, at least one of the gaps is prioritized at that level 
However not all of the gaps for a particular might share that priority. A risk may have gaps 
that are lower priority than the overall risk priority level. Future versions of the IRP will be 
prioritized at the gap and/or activity level. 
Criticality of a risk for Lunar or Mars mission alone is not sufficient to determine the 
optimum level of activity (or budget) or timing of research investments. Many other factors 
combine to determine the critical path: limited availability of certain critical resources like 
the Space Shuttle and the ISS, or the exceptionally long lead times needed improve 
understanding and mitigation of radiation risks. All of the factors needed to determine the 
critical path are not explicitly represented in the IRP, only the resultant research plan. 
For example, the retirement of the Space Shuttle will introduce significant logistics 
constraints to and from the International Space Station (ISS). The ISS has resource 
limitations such as crew-time, imposing a strong planning constraint on research involving 
human interaction, or the human as a subject. Given this environment, these complex 
constraints affect the research planning. Conversely a well developed research plan assures 
that research that requires space flight conditions are clearly prioritized to optimize the use of 
the platforms.   
Three categories of prioritization have been developed for the risks: 1) Desirable; 2) 
Important, and 3) Critical.  Each of these categories is applied to two different mission 
scenarios, the Lunar mission(s) (including the Lunar outpost missions) and the Mars mission.  
For reference, each risk heading in this document is labeled with an abbreviated version of 
the Lunar X Mars priority. 
Criteria for prioritization of the risks applicable to the Lunar mission(s) are: 
• Desirable to Quantify and Reduce Prior to the Lunar Mission: The absence of data or 
risk mitigation countermeasures in this area (beyond what is available at the baseline 
date of this document) would not delay the Lunar mission even if all other elements 
of the mission were ready (e.g., if the launch systems, EVA systems, landing and life 
support systems were ready), but quantifying and reducing the risk would reduce the 
risk for that particular discipline. Engineering or operational workarounds/constraints 
could be avoided if this risk were quantified and/or reduced. 
 
• Important to Quantify and Reduce Prior to the Lunar Mission. The absence of 
additional data or risk mitigation countermeasures in this area (beyond what is 
available at the baseline date of this document) would likely not delay Lunar Mission 
even if all other elements of the mission were ready (e.g., if the launch systems, EVA 
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systems, landing and life support systems were ready), but would leave the mission 
with significant residual or unknown risk. Mission Loss or major impact to post-
mission crew health could occur if this risk is not quantified and reduced. 
 
• Critical to Quantify and Reduce Prior to the Lunar Mission. The absence of 
additional data or risk mitigation countermeasures in this area (beyond what is 
available at the baseline date of this document) would likely delay Lunar Mission 
even if all other elements of the mission were ready (e.g., if the launch systems, EVA 
systems, landing and life support systems were ready). The lack of this data or an 
adequate additional mitigation would leave NASA with unacceptable uncertainty in 
the residual risk, and/or with unacceptable absolute risk to human health and 
performance, thus precluding NASA’s ability to embark on the mission. 
 
Criteria for prioritization of the risks applicable to the Mars mission(s) are: 
• Desirable to Quantify and Reduce Prior to the Mars Mission: The absence of data or 
risk mitigation countermeasures in this area (beyond what is available at the baseline 
date of this document) would not delay the Mars mission even if all other elements of 
the mission were ready (e.g., if the launch systems, EVA systems, landing and life 
support systems were ready), but quantifying and reducing the risk would reduce the 
risk for that particular discipline. Engineering or operational workarounds/constraints 
could be avoided if this risk were quantified and/or reduced. 
 
• Important to Quantify and Reduce Prior to the Mars Mission. The absence of 
additional data or risk mitigation countermeasures in this area (beyond what is 
available at the baseline date of this document) would likely not delay the Mars 
Mission even if all other elements of the mission were ready (e.g., if the launch 
systems, EVA systems, landing and life support systems were ready), but would 
leave the mission with significant residual or unknown risk. Mission Loss or major 
impact to post-mission crew health could occur if this risk is not quantified and 
reduced. 
 
• Critical to Quantify and Reduce Prior to the Mars Mission. The absence of additional 
data or risk mitigation countermeasures in this area (beyond what is available at the 
baseline date of this document) would likely delay the Mars Mission even if all other 
elements of the mission were ready (e.g., if the launch systems, EVA systems, 
landing and life support systems were ready). The lack of this data or an adequate 
additional mitigation would leave NASA with unacceptable uncertainty in the 
residual risk, and/or with unacceptable absolute risk to human health and 
performance, thus precluding NASA’s ability to embark on the mission. 
 
Ultimately, prioritization of the risks, the gaps and the activities can be conducted through a 
Probabilistic Risk Assessment that integrates and compares the reduction of the overall risk 
to the mission, given different mission scenarios, research approaches, and outcomes. The 
HRP will use the RMAT tool to categorize and assess the risks and gaps according to 
priority. At present though, there is not an integrated or validated PRA tool that will allow 
the use of the RMAT data to do the cross-comparison or the prioritization of risks or gaps. 
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Until the availability of such a tool, the HRP relies on expert opinion, with consideration of 
the existing evidence. The HRP’s Science Management Office has the task of prioritizing the 
HRP’s research portfolio as described in the HRP Science Management Plan (HRP-47053) 
Paragraph 3.1. 
1.5 SCHEDULE DRIVERS AND CONTEXT CONSIDERATIONS FOR THE READER 
Research is inherently non-linear. The one constant about the IRP is that it will change. As 
knowledge is gained, our understanding of the required approach changes. This document 
represents the best plan available at this moment in time. It would be impractical to assume a linear 
approach with respect to future research plans. The IRP will be revised and updated yearly based 
on available resources, Constellation and other schedule constraints, and a consideration of new 
evidence that was gained in the previous year. 
The fidelity of the research plan is related to the timeframe for which it is planned. For instance, the 
fidelity of requirements for the research described in this plan for 2008-2009 is high. On the other 
hand, the fidelity of requirements for activities listed in this plan beginning in 2020 is lower. The 
yearly update will allow these descriptions to change as new evidence is considered and key 
milestones are achieved. 
This version (#1) represents the initial definition of an integrated research plan based upon the 
HRP’s current research portfolio. Future versions of the IRP should include a more detailed review 
of the ties of the knowledge gaps to the evidence base for each risk.  
NASA has laid out some very specific schedule milestones for implementation of the Vision for 
Space Exploration (VSE). The Shuttle retirement in 2010, the Orion vehicle in 2014, and the first 
Lunar sortie by 2020 together create urgency for the acquisition of knowledge. The use of the 
Shuttle and ISS platforms, in several cases, is critical to obtaining the required knowledge to build 
products supporting longer, more challenging missions. In some cases, research is accelerated to 
take advantage of the availabilities of those vehicles. 
This plan is NOT intended to mitigate risks associated with the ISS. The ISS is used as a platform 
to conduct research aimed at mitigating risks to the exploration missions. Some of the research may 
identify countermeasures, engineering or operational solutions that would enhance the ISS and 
reduce risk in use of that platform. In those cases, the HRP identifies the necessary deliverables and 
insertion points for the ISS. However, the focus of this document is to identify deliverables 
necessary to complete the exploration (Lunar and Mars) missions. 
This plan includes activities that are more than “Research or Technology Development”. In some 
cases, the activities reported in this document are not explicitly “research” or “technology 
development”, but are included to ensure logical completeness in describing those activities 
necessary to mitigate the risks. Examples are data mining activities, the results of which are pivotal 
in defining further steps in the research path, and hardware evaluations which would further our 
engineering approach to mitigating a risk. 
Human health and performance risks can best be mitigated through the space system design. The 
HRP works closely with the Constellation program to communicate the areas of human health and 
performance risks, and to help advise in the engineering and development of the Constellation 
systems. Mitigation of many human health and performance risks can be accomplished through 
engineering design and operational constraints, and do not need further research. Decision points in 
the research schedules are placed to evaluate whether the engineering design approaches are 
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adequate, or whether other countermeasures are necessary. As a rule, engineering should be the 
first method of dealing with these issues; however, much of the research may continue to be 
necessary to relieve overly burdensome engineering or operational constraints. 
A flight resource analysis is necessary. A key next step for this document is to identify the flight 
resources required to implement the described research and compare those resource requirements 
with the projected availability. If a shortfall exists, the HRP will work with the ISS program to 
develop the appropriate approach. If it is found that the HRP complement of research cannot fit into 
the available flight resources, the prioritization will be used to identify those investigations most 
critical to facilitate exploration. 
Key Decision Points are built into the research plan. At these points the HRP will evaluate data 
pertaining to likelihood and consequences and perform risk analysis to determine the proper 
approach. In some cases likelihood with existing countermeasures will not be high enough to 
warrant proceeding with more research.  
2.0 SUMMARY OF THE RESEARCH PLAN (THIS SECTION IS TBD) 
The development of this document has been evolutionary. The HRP recognizes that the format of 
this document, while comprehensive in its scope requires an additional high-level summary to 
facilitate a quick understanding of the overall research plan. Further, the integration of research 
across discipline lines has yet to be completed. A future version of this section is intended to provide 
a high-level summary of the research approach and planning for each risk. It will also describe how 
the HRP is performing the integration of research activities across risks.  
For each risk in this document, a summary paragraph, an outline of the major gaps, and a short 
description of the research approach to fill the gaps will be given. 
Many activities described in this document address multiple gaps. A different and easier way of 
viewing their applicability will help to understand the integrated nature of the particular research 
approach. This section will capture the activities that address multiple gaps, describe the general 
approach, how each of these activities relates temporally to the research planning and how it relates 
to the relevant risks. Examples of these activities are the post-flight functional task performance test, 
the 6-degree head-down bedrest testing environment, and the Lunar bedrest environment. 
3.0 ELEMENTS INPUT DESCRIPTION 
The format for the Elements’ inputs will include graphical depiction via Gantt charts and written 
discourse to clarify the Element position. Each input follows the same form. The Risk is reported, 
the Operational Relevance is described, the risk priority is given, the gaps in knowledge are reported 
with a brief description and for each gap, and the activity or activities necessary to address the gap 
are described. For each activity, the resulting product/deliverable is described and each required 
delivery milestone for the deliverable is given along with the required platform and Project or 
organization responsible for implementing the activity. 
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3.1 RISKS 
Each text description has a description of the risk. These descriptions are verbatim from the 
Program Requirements Document and are reprinted in the IRP as a matter of convenience for the 
reader. 
3.2 CONTEXT OF RISK FOR EXPLORATION 
After each risk description is a paragraph entitled Operational Relevance and Risk Context. In this 
paragraph, a description of the relevance to the exploration mission is given. This section gives the 
context within which the research plan is built for that risk and describes the need for the research 
at a very high level. 
3.3 PRIORITY 
The priority for the risk for each mission is given. This priority uses the criteria described in the 
section above. 
3.4 GAPS 
Gaps in our knowledge or evidence base exist for each risk. These gaps have several different 
forms. A gap may exist in our evidence base, which leaves greater uncertainty regarding the 
likelihood of the risk.  A gap may exist in the identification of the appropriate countermeasure. For 
others, the gap may be in the flight validation of the appropriate countermeasure. For the purposes 
of this IRP, the gaps are not delineated by type; rather they are simply identified as a gap that must 
be filled before the risk is mitigated. In some cases, the gap may not require research to fill it, but 
rather can be avoided altogether through selection of a specific Constellation design. 
3.5 ACTIVITIES 
Under each gap are one or more activities required to fill the gap. The activity is named and a short 
description is given. In some cases an activity can address multiple gaps perhaps across many 
different risks. To limit the size of this document, an activity that addresses many different gaps is 
named and described once and the description is referred to in the other gaps that it is intended to 
fill.  
3.6 PRODUCT/DELIVERABLES 
Each activity is designed to culminate in a product or deliverable. These deliverables are structured 
to feed into the Constellation program, the Office of the Chief Health and Medical Officer or the 
Mission Operations Directorate. Several different types of deliverables exist. An activity can result 
in recommended updates to the Space Flight Human System Standards. In that case, the HRP 
forwards the recommendation to the Chief Health and Medical Officer for incorporation into the 
standards. Some deliverables result as information to a particular operations constraint. The HRP 
will identify the appropriate Mission Operations organization (Medical Operations, Flight 
Operations, Ground Operations or the Operations Office) within the Constellation Program to 
which changes in their operational approach will be recommended.  Other deliverables take the 
form of requirements. In those, the HRP will recommend requirements changes for the 
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Constellation program documentation.  Another deliverable takes the form of countermeasures. 
These are approaches, whether physical or pharmaceutical, that is used to mitigate the risk. 
3.7 REQUIRED DELIVERY MILESTONE 
Key milestones within the Constellation Program development drive the required date for the HRP 
deliverables. For instance, design requirements typically must be defined by the appropriate System 
Requirements Review. Design solutions and technology typically must be defined to a TRL6 level 
by the Preliminary Design Review. This section documents the schedule drivers for the delivery 
milestones. 
3.8 REQUIRED PLATFORMS 
This section defines the platform required to perform the research. Platforms can be designated as 
Ground analog environments, such as NEEMO, Antarctica, etc, or the platform may be a space 
based one, such as STS or the ISS. Also, the Lunar surface is a platform that is anticipated in some 
research efforts. 
3.9 PROJECT OR ORGANIZATION RESPONSIBLE FOR THE IMPLEMENTATION 
OF ACTIVITY 
Within the HRP elements, there are one or many projects chosen to implement the element research 
plan. The project is identified in this section.  In some cases, organizations outside the element are 
responsible for implementation of the research, such as the NSBRI or even an international partner. 
These organizations are identified in this section. 
This section identifies the project with primary responsibility for implementing the activity. In 
some cases the project is not within the element responsible for the risk. The element responsible 
for the risk will coordinate with the appropriate project in those cases.   
Discipline teams include participation of operations personnel, the NASA research discipline 
experts, and the NSBRI. In several cases, the primary responsibility is shown as that of NASA, 
however, that does not mean that the NSBRI is not participating at all.  The NSBRI participates 
through the discipline teams as well as through future solicitations. 
3.10 GRAPHIC INPUT 
Each graphic is supported with text that provides a more thorough level of detail. Figure 2 shows 
an example Gantt chart and labels each section of the chart.  Each Gantt chart is associated with 
one of the 33 PRD Risks. The element to which the risk is allocated is identified in the upper left 
corner. For each risk, the research gaps are identified by name and number along the left side.  
Under each gap are the identified activities required to fill the gap. Each activity is identified by 
name and the acronym of the project or organization responsible for implementing the activity. In 
some cases, the organization responsible for implementing the activity may not be directly 
controlled by the element responsible for the risk. The schedule of each activity is shown on the 
graphic and an arrow shows deliverables resulting from the activity. The activities are color coded, 
gold for STS/ISS activities, green for ground activities, purple for data analysis, and yellow for 
Lunar activities. Cross-hatched colors represent activities conducted by the NSBRI. Small text 
identifies each deliverable. A number on each text deliverable description relates the deliverable to 
the need date, shown by the gray numbered arrows at the top of the chart.  
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11 
3.11 DECISION POINTS 
Several key decision points have been placed in the plan. At these key decision points the 
appropriate forward path for the research will be reevaluated. The decision points are cast in a 
“Yes/No” form, and it is anticipated that at these points, the responsible element will review the 
overall current state of the evidence, and review the appropriate approach to the forward plan. 
Where applicable, the Science Management Office will concur and, if necessary, the appropriate 
Project Standing Review Panel may be convened to deliberate and make recommendations. Criteria 
for making the decision will be determined on a case by case basis and will be consistent with the 
overall management structure documented in the Science Management Plan. The process will be 
implemented consistent with the Program Implementation Plan. In many cases, an activity 
addresses more than one risk.  
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4.0 RISK OF INABILITY TO ADEQUATELY TREAT AN ILL OR 
INJURED CREW MEMBER I X C 
Mission architecture limits the amount of equipment and procedures that will be available to treat medical 
problems. Resource allocation and technology development must be performed to ensure that the limited 
mass, volume, power, and crew training time be efficiently utilized to provide the broadest possible treatment 
capability. This allocation must also consider that not all medical conditions are treatable, given the limited 
resources, and some cases may go untreated. 
 
Operational Relevance and Risk Context  
NPD 8900.3F - The immediate and long-term responsibilities of NASA with regard to the human space flight 
program require that the Agency provide medical and dental care, observation, and study to astronauts, 
payload specialists, and other space flight participants while on active duty with NASA. This care, 
observation (to include health monitoring), and study will be provided, utilizing the best current guidelines 
for the clinical practice of medicine and dentistry, and will be comprehensive in scope as applicable to the 
NASA mission. It will encompass all aspects related to the mission, including certification and training, and 
will include all space flight mission phases (pre-, in-, and post-flight). 
 
Priority 
Lunar Outpost Mission (Level of Care 4): Important to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission (Level of Care 5): Critical To Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
ExMC1: Data and Information that make up the NASA medical evidence base used for risk assessment 
and planning are not all in a form that supports easy access and analysis. 
 
Activity: 
Mission Medical Information System 
Incorporate medically relevant clinical information into a database system for use in operations as 
well as for research support. The data sources to be incorporated include MRID as well as other 
mission data. Currently the data resides on an FTP server, in flight surgeon files, some in the 
Electronic Medical Record (EMR), and some in the database for the Longitudinal Study of 
Astronaut Health (LSAH). Structured data sources such as the EMR and LSAH will not be 
duplicated, but rather joined. Effort is aimed at getting data into structured form first and then work 
on data entry at the point of collection. Effort is co-funded 50/50 with Crew Health and Safety. 
 
Product/Deliverables: 
Structured Information System fully populated with NASA medical space flight data and 
information. 
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Required Delivery Milestone: 
Operational Mission Medical Information System in FY2013 to meet Orion operations. 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NASA JSC 
 
ExMC2: Planning tool not available that correlates in-flight medical hardware/consumables to medical 
risks. 
 
Activity: 
Integrated Medical Model 
Due to limited resource volume constraints of the mission designs (including volume, mass, power, 
crew time, and crew skills), only the most critical medical equipment will be stored onboard the 
space vehicles to treat illnesses or injuries. In addition, pre-flight crew training is limited to those 
medical procedures most likely to occur.  Because the astronauts are not likely to be trained 
medical clinicians, their skill level must be considered in the treatment of medical procedures. The 
likelihood of critical patient conditions occurring along with the required resources (including those 
listed above) to treat the conditions must be analyzed to determine the level of risk to the astronauts 
in a quantitative manner. This allows management tradeoffs between resources and acceptable risk 
levels for various mission scenarios. The Integrated Medical Model (IMM) is intended to provide 
this quantitative risk assessment. 
 
Product/Deliverables: 
Validated model 
Required Delivery Milestone: 
First release FY2010 to inform decisions for the Orion medical kit contents 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NASA JSC and GRC 
 
ExMC3: Lack of complete and accessible repository of space flight biomedical data 
 
Activity: 
Life Sciences Data Archive 
NASA's Life Sciences Data Archive (LSDA) is a work in progress that provides information and 
data from spaceflight experiments funded by the National Aeronautics and Space Administration 
(NASA). The archive includes investigations from 1961 (Mercury Project) through current 
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missions (International Space Station and Shuttle) involving human, plant and animal studies.   
Effort includes a process to streamline access while protecting confidentiality. 
 
Product/Deliverables: 
Archive flight and relevant ground experiments 
Retrospective data entry 
Required Delivery Milestone: 
Ongoing 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NASA JSC and ARC 
 
ExMC4: Improved techniques for crewmember to conduct medical procedures in necessary time 
 
Activity: 
Assisted Procedures Techniques 
Due to the limited medical skills and training of the crew, techniques to help the crewmembers 
perform medical procedures will be required. This will reduce the time required to perform the 
procedure, allow the crew to refresh their training skills during the mission, and provide the crew 
with audio and visual information to guide them through the procedure efficiently. This may 
develop into a decision support system. 
 
Product/Deliverables: 
“Guideview” software that is compatible with Constellation Personal Data Assistant (PDA) 
platform that will replace the standard “medical checklist”. 
Voice recognition technology integration 
Required Delivery Milestone: 
FY2011 release for Orion use; updates and voice recognition for Lunar missions 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NASA JSC 
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ExMC5: Improved ability to monitor crewmembers physiological data during a mission 
 
Activity: 
Biomedical Sensors 
By monitoring crewmembers’ physiological data flight surgeons may be able to detect emerging 
medical problems.  During EVAs and periodic IVA activities, the flight surgeons need the ability to 
monitor key physiological signals that indicate the crew’s work load and other physiologic 
parameters.  The current system for donning the sensors is time consuming and inconvenient, 
requiring shaving, application of electrodes, and signal checks.  A more efficient system will save 
crew time and reduce the overhead of stowing additional supplies.  This system will be achieved 
through the integration of small, easy to use biomedical sensors capable of measuring, storing and 
transmitting physiologic parameters (ECG, SPO2, heart rate, BP, ETCO2, temp, etc) during 
operational and ambulatory activities.  Such a system could also provide a wealth of data for the 
medical and research communities.  Coordination with the HHC element for an overall medical and 
research biomedical sensing plan will occur. 
 
Product/Deliverables: 
Requirements and up to TRL 6 prototype systems for EVA and IVA sensing. 
Required Delivery Milestone: 
Requirements for EVA and IVA system SRR’s, TRL 6 prototype systems in advance of EVA 
and IVA system PDRs 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NASA JSC, EPSP ARC and GRC; negotiations with Cx EVA Project ongoing for 
responsibilities 
 
Activity: 
Non-invasive Biosensor Algorithms for Continuous Metabolic Rate Determination 
Develop and validate algorithms to accurately calculate VO2 from NIR spectra collected from 
muscle; 2. Develop and validate algorithms to simultaneously calculate muscle temperature; 3. 
Support incorporation of the sensor algorithms into the EVA suit testing for non-invasive 
continuous metabolic rate assessment during Lunar EVA.  
 
Product/Deliverables: 
1. New software to measure VO2 using the NIRS-monitor hardware currently in use at JSC 
and improved hardware when available – 9/30/2011; 
2. New software to measure muscle temperature using the NIRS-monitor hardware currently 
in use at JSC and improved hardware when available – 3/1/2011; 
3. Documentation of validation studies performed before, during and after bed rest rest. – 
9/30/2011;  
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4. Recommendation for sensor placement sites for use during lunar EVAs to best estimate 
whole body VO2. – 9/30/2011. 
      Required Delivery Milestone: 
TRL 6 system for EVA Configuration 2 PDR 
      Required Platforms: 
      Ground based 
                      Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC, EPSP and ARC.  Negotiations with Cx EVA Project ongoing for 
responsibilities. 
 
Activity: 
Lightweight, Wearable Metal Rubber-Textile Sensor for In-Situ Lunar Autonomous Health 
Monitoring (SBIR)  
Develop and demonstrate a low-weight, non-invasive, reliable and comfortable autonomous health-
monitoring system for use by astronauts during long-duration space missions and extravehicular 
activities (EVAs).  
 
      Product/Deliverables: 
Technical Task 1 (Month 0-1): Define Program Parameters and Plan for Materials 
Synthesis.  
Technical Task 2 (Month 1-3): Fabricate Nanocluster Precursor Materials for Self-Assembly of 
Metal Rubber™ Textile Sensors / Interconnects.  
Technical Task 3 (Month 3-6): Construct Health Monitoring Shirt Demo using Metal Rubber™ 
Sensors and Interconnects.  
Technical Task 4 (Month 6-10): Fully Characterize the Ability for the Metal Rubber™ Textile 
Shirt to Monitor Physiological Parameters, such as EKG, Heart Rate, and Body Core 
Temperature.  
Technical Task 5 (8-12): Design and Develop a Wearable Data Acquisition / Sensor Response 
Storage System for Physiological Data.  
Technical Task 6 (Month 12-16): Based on Characterization and Input from NASA COTR and 
Commercial Collaborators, Improve Sensor Shirt Design and Reconstruct with Data Capture 
Component.  
Technical Task 7 (Month 15-18): Fully Characterize the Improved MR™ Smart Shirt Similar 
to Task 4 and Compare Performance.  
Technical Task 8 (Month 15-20): Analyze the MR™ Smart Shirt Performance to NASA Space 
Based Standards and Relevant FDA Standards.  
Technical Task 9 (Month 20-24): Increase Manufacturability and TRL Level.  
Technical Task 10 (Month 22-24): Work with NASA and LM-MS2 to Implement Phase III 
Required Delivery Milestone: 
End of 2-year funding period 
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Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
SBIR, NASA JSC, EPSP and ARC.   
 
Activity: 
Wearable Health Monitoring Systems (TBR-1 SBIR)  
To build a working prototype of the wearable health monitoring system that will demonstrate: 1) 
the integration of medical sensors, electrodes, electrical connections, circuits, and power supply 
into a single wearable assembly to simplify donning and doffing, 2) the distribution of electrical 
circuits around the human torso to reduce bulk and enable it to be worn underneath an LCVG, 3) 
the facility to easily replace electrodes attached to the skin, 4) the ability to measure biological 
sensor data and transmit it to an external computing device, and 5) the simplicity of adding medical 
sensors to the system through use of a digital data-bus to reduce overall wiring count. 
 
      Product/Deliverables: 
Part 1. Design and physical construction of a wearable health monitor for the purposes of initial 
testing.  
Part 2. Design and coding of a software system for operating the wearable health monitor.  
Part 3. Rigorous testing of the wearable health monitor system.  
Part 4. Design and testing of specific medical sensors integrated within the wearable health 
system. 
      Required Delivery Milestone: 
End of 2-year funding period.  
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
SBIR, NASA JSC, EPSP and ARC. 
 
ExMC6: Lack of options for providing waste management and pharmaceutical delivery for the 
contingency scenario of a crewmember being in their EVA suit for up to 144 hours. 
 
Activity: 
Advanced Medical Fluids 
Research and development of technologies for integration into the EVA suit architecture to manage 
fluids in a contingency requiring extended stays in the suit. 
 
Product/Deliverables: 
Improved Maximum Absorbency Garment (MAG) for waste management 
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Vacuum-rated injectable medications 
Required Delivery Milestone: 
MAG: FY2012 – TRL6 for Cx EVA Suit 2 PDR  
Vacuum-rated injectables:  FY2011 – TRL6 for Orion Medical Kit PDR 
Required Platforms: 
Possible use of the ISS for validation of fluid systems that can’t be validated in reduced gravity 
aircraft.   
Project/Organization Responsible for Implementation of Activity: 
NASA GRC, EPSP 
 
ExMC7: Inability to analyze biological samples during exploration missions with minimum 
consumables. 
 
Activity: 
Lander/Outpost Inflight Lab Analysis 
Analyzing body fluids (urine, blood, saliva) on the lunar surface will reduce launch/return 
mass/volume and provide the data near real-time.  A system to perform this analysis inflight is 
necessary to meet these requirements.  NASA has conducted several trade studies analyzing 
hardware available and developed an Excel-based tool to quantify the ability of hardware to meet 
mission requirements.  To reduce system mass and volume, beginning with the FY 2007 SBIR call 
and the FY2008 budget year, NASA will begin developing concepts and hardware for reusable 
systems of this type. 
Such miniaturized systems are dependent upon space medical standards and requirements.  These 
standards and requirements are critical for engineering and medically qualifying the appropriate 
system for remote space applications.  The results of the recent Sample Return Analysis task may 
be considered in the near-term for potential ExMC leveraging opportunities.  In addition to 
microfluidic processing systems, non-invasive monitoring devices may be considered. 
 
Product/Deliverables: 
TRL 6 system for lunar lander and outpost medical system PDR’s. 
Required Delivery Milestone: 
TRL6 unit available in FY2015 to support Lunar missions 
Required Platforms: 
Require the ISS for, micro-g validation in an operational environment. 
Project/Organization Responsible for Implementation of Activity: 
NASA ARC and GRC 
 
Activity: 
   Handheld Body-Fluid Analysis System for Astronaut Health Monitoring 
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Development and demonstration of an automated handheld blood count instrument that is capable 
to perform white blood cell count on a nanoliter sized blood sample using MEMS technology and is 
easy to operate. The system should analyze a minimum of 1,000 RBCs and 200 WBCs which 
corresponds to processing sample volume ~50-100 nL of whole blood. Ability to provide both 
blood count and differential will be demonstrated. 
 
Product/Deliverables: 
A monolithic chip will be developed to perform the measurement of red blood cell (RBC) 
count, mean cell volume (MCV), hematocrit, white blood cell (WBC) count and at least a 2-
part differential (lymphocytes versus granulocytes).  
Required Delivery Milestone: 
End of funding period 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC and ARC 
 
Activity: 
Development of a Modular, Fiber Optic Surface Plasmon Resonance Sensor for Quantitation of 
Diagnostic Proteins for Healing of Burns and Wounds 
Development of a fiber optic system utilizing surface plasmon resonance for detection of clinically 
relevant levels of diagnostic proteins 
 
Product/Deliverables: 
Modular fiber optic sensor platform capable of measuring multiple analytes for assessment of 
biomarker detection 
       Required Delivery Milestone: 
End of funding period 
Required Platforms: 
Ground based 
      Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC and ARC. 
 
ExMC8: Lack of Advanced Medical Life Support Equipment to Treat a Crewmember 
 
Activity: 
Lightweight Trauma Module 
Onboard advanced medical life support hardware will be required to treat the crewmembers on an 
emergency basis.  Technologies which are smaller, lighter, reliable, and user-friendly will be 
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required to fit within the limited space of the spacecraft vehicles.  Currently on the ISS, the 
crewmember’s source of additional oxygen if needed is the onboard oxygen tanks.  The system 
provides 100% oxygen to the crewmember continuously, exceeding the spacecraft oxygen limit 
within minutes.  For the smaller Constellation vehicles, close interface with spacecraft designers 
and fire safety experts will be required to ensure safety margins are met.  A system which 
concentrates the oxygen within the cabin environment and provides the required concentration of 
oxygen to the crewmember based on their oxygen saturation level will be necessary to meet these 
requirements. 
 
Product/Deliverables: 
TRL 6 model for Lunar missions, coordination with the military 
Required Delivery Milestone: 
Lunar surface model, TRL6 ready in FY2015 
Required Platforms: 
Ground 
ISS flight model will be developed as part of the Health Maintenance System upgrade 
Project/Organization Responsible for Implementation of Activity: 
NASA JSC 
 
Activity: 
Determination of Oxygen Requirements in Hypoxic Environments 
To determine oxygen requirements during the first week of hospitalized patients with illness and or 
injury most likely to occur in spaceflight 
To define oxygen requirements and risk of hypoxemia of critically ill/injured warfighters requiring 
mechanical ventilation and transport in a hypobaric/hypoxic environments 
 
Product/Deliverables: 
Research demonstrating the actual oxygen requirements for crewmembers requiring ventilation 
Market research on current O2 concentrators and their specifications 
Required Delivery Milestone: 
End of funding period 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC 
 
Activity: 
Guided High Intensity Focused Ultrasound (HIFU) for Mission-Critical Care (TBR-2 NSBRI) 
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Develop engineering prototypes of an image-guided HIFU device that would demonstrate the 
(separate) capability of inducting acoustic hemostasis (in vivo), tumor ablation (in vivo), and stone 
comminution (in vitro) (by end of currently funded project; i.e., 7/31/08). Develop an engineering 
prototype that would demonstrate in a porcine model the capability of detecting and inducing 
acoustic hemostasis, tumor ablation, and stone comminution in a single, integrated, image-guided, 
HIFU device (by end of project renewal; i.e., 7/31/12). 
 
Product/Deliverables: 
Engineering prototypes of an image-guided HIFU device that would demonstrate the (separate) 
capability of inducting acoustic hemostasis (in vivo), tumor ablation (in vivo), and stone 
comminution (in vitro) (by end of currently funded project; i.e., 7/31/08). An engineering 
prototype that would demonstrate in a porcine model the capability of detecting and inducing 
acoustic hemostasis, tumor ablation, and stone comminution in a single, integrated, image-
guided, HIFU device (by end of project renewal; i.e., 7/31/12). 
Required Delivery Milestone: 
Technical report of progress toward project goals—7/31/08  
Engineering prototypes (by end of project renewal; i.e., 7/31/12) 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC 
 
ExMC9: Inadequate IV Fluids to Treat Emergency Medical Conditions 
 
Activity: 
Mixed Water Generation & IV Drug Mixing 
Currently, limited quantities of IV fluid are launched, stowed, and disposed of (or returned to Earth 
due to limited life) on the International Space Station.  These IV fluids take up valuable launch 
mass/volume, stowage volume onboard the ISS, and waste disposal volume.  The ability to generate 
Water for Injection on-demand will minimize these resource impacts.  The Water for Injection will 
be mixed with the necessary medications during the mission for immediate use. 
 
Product/Deliverables: 
DTO model for ISS test 
FDA approval 
Required Delivery Milestone: 
ISS model ready for flight in FY2010 
Required Platforms: 
ISS DTO model required for validation 
Project/Organization Responsible for Implementation of Activity: 
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NASA JSC, ISSMP and GRC 
 
ExMC10:  Lack of Advanced Diagnostic Imaging Capability for Exploration 
 
Activity:   
Ultrasound/Braslet 
This project will enable further understanding of steady-state space cardiovascular physiology in 
long-duration space flight. This investigation will develop and validate appropriate methodology 
for studying cardiovascular responses to disturbances (for example, gravity change, volume 
overload, hemorrhage and others) using existing ISS resources. Future use of this methodology will 
yield valuable physiological and operational data for planning and support of missions to the moon 
and other remote destinations.   
 
Product/Deliverables: 
Flight certification and support for ISSMC flight. 
Required Delivery Milestone: 
Data for Space Medicine to decide whether or not to pursue Braslet as a countermeasure 
Required Platforms: 
ISS  
Project/Organization Responsible for Implementation of Activity: 
NASA JSC and IBMP  
 
Activity: 
A Scanning Confocal Acoustic Diagnostic System for Non-Invasively Assessing Bone Quality 
The objectives of this study are to further develop a unique scanning confocal acoustic diagnostic 
(SCAD) system for bone quality assessment.  This system will provide improved resolution, faster 
scan times (< 5 min for the scan), portability, and the ability to scan multiple sites of the skeleton.  
In addition, this project will validate image-based characterization of bone’s physical properties to 
true bone quality as based on material testing. This next phase of research will focus on developing 
the SCAD prototype as a real-time, high-resolution and portable bone-imaging modality for 
determining bone quality and prediction of fracture risk. Measuring bone structural and strength 
properties in the cadaver samples, using SCAD, microCT and mechanical testing for bone quality 
prediction will be performed. Clinical diagnostic assessment will include comparison of SCAD and 
DXA in osteoporosis and disuse subjects. 
  
Product/Deliverables: 
SCAD prototype as a real-time, high-resolution and portable bone-imaging modality for 
determining bone quality and prediction of fracture risk 
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Required Delivery Milestone: 
Technical report of progress toward project goals — 10/31/08. Small, portable device that uses 
ultrasound, not X-rays, to determine bone density and quality 
Required Platforms: 
Ground 
Bed rest study 
Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC 
 
Activity: 
Ground-Based Measurement of Bone Loss in Astronauts Using Advanced Multiple Projection Dual 
Energy X-ray Absorptiometry (AMPDXA) Ground-Based Clinical System 
To produce an operational instrument that can be transferred to the NASA-Johnson Space Center 
for use in the pre- and postflight bone mineral density (BMD) and bone structure measurements on 
astronauts. 
 
Product/Deliverables: 
Device to measure bone density and quality using lower X-ray exposure than current devices. 
Size and power requirements optimized for space use. 
Required Delivery Milestone: 
End of funding period 
Required Platforms: 
Ground based 
Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC 
 
Activity: 
               Prototype Testing for Non-Invasive Determination of Intracranial Pressure (ICP) (TBR-3 NSBRI) 
Development of non-invasive intracranial monitoring methodology and nn-invasive monitoring of 
cerebral blood flow using ultrasound.   
                     Product/Deliverables: 
Useful nICP model by end of year three that will be finalized in year four 
Required Delivery Milestone: 
End of funding period 
Required Platforms: 
Ground  
Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC 
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Activity: 
Improved Bubble Detection for EVA (TBR-4 NSBRI) 
To improve EVA efficiency and safety by developing and validating new bubble detection 
technology using dual-frequency ultrasound.  To create dual-frequency instrument (CDFI) that can 
detect and size bubbles through the chest wall as they move through the heart. Also, signals 
consistent with bubbles can be detected in tissue. Potentially, this technology could be used to: (a) 
characterize bubble dynamics during decompression sickness (DCS), (b) detect the earliest stages 
of DCS, (c) develop and evaluate non-compressive countermeasures for DCS, (d) diagnose DCS in 
tissue or joints, and (e) mitigate DCS risk by improving preventive strategies such as oxygen pre-
breathing and limiting activity at particular times. Developing improved techniques to evaluate 
DCS countermeasures like oxygen prebreathe. 
 
Product/Deliverables: 
Dual-frequency instrument (CDFI) that can detect and size bubbles 
Required Delivery Milestone: 
End of funding period 
Required Platforms: 
Ground  
Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC 
 
Activity: 
               Intuitive Ultrasound Catalog Grant for Autonomous Medical Care 
Develop an intuitive ultrasound image cataloging system which incorporates ground acquired 
ultrasound whole body images.  The catalog will acquire ground-based crewmember images to use 
for medical diagnosis in space.  
Develop a mathematical coupling model based on existing ground/in-flight ultrasound data which 
will allow microgravity associated morphometric and topographic changes to be predicted. Assess 
the ability of non-physician crew medical officers (CMO) to acquire and interpret complex 
ultrasound examinations autonomously or with remote guidance.   
 
Product/Deliverables: 
Ultrasound Image Catalog coupled with just-in-time training methods 12/31/11 
Required Delivery Milestone: 
2011 
Required Platforms: 
Ground  
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Project/Organization Responsible for Implementation of Activity: 
NSBRI, NASA JSC 
 
ExMC11:  Lack of Terrestrial Testbed for Lunar/Mars Transits 
 
Activity:   
ISS Flight Tests 
As medical technology developments mature, the ISS will be used as a validation step for critical 
items necessary for transits to/from the Moon or Mars.   
 
Product/Deliverables: 
TRL 7-8 Protoflight units for ISS test of designs for medical hardware that will be needed in 
Lunar or Mars transits. 
Required Delivery Milestone: 
TBD 
Required Platforms: 
ISS  
Project/Organization Responsible for Implementation of Activity: 
NASA JSC 
  
Activity: 
In-flight Flow Cytometer Project 
Product/Deliverables: 
In-flight flow cytometer capable of various immunology/hematology support 
Required Delivery Milestone: 
Required Platforms: 
STS, ISS, ground analog 
Project/Organization Responsible for Implementation of Activity: 
International Space Station Medical Project (ISSMP)
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5.0 RISK FACTOR OF INADEQUATE NUTRITION -D X C 
It is critical that crewmembers be adequately nourished before and during missions.  Critical research areas 
within this risk include: validation of the correct nutritional needs; assessment of the stability of nutrients 
during long-duration flight; correct packaging and preservation techniques; effects of countermeasures on 
nutrition; and use of nutrients as countermeasures. 
 
Operational Relevance and Risk Context
As mission duration increases, the risk of nutrient deficiencies becomes greater. Nutritional countermeasures 
can influence all systems. 
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar Mission 
Mars Mission: Critical to Quantify and Reduce Prior to the Mars Mission 
 
Gaps 
 
N1: Are nutrients in food stable during space flight? 
 
Activity: 
Stability of Pharmacotherapeutic and Nutritional Compounds: Stability SMO (Flight) 
See Risk of Inadequate Food System – Gap AFT2 
 
Activity: 
Assessment of Nutrient Stability in Space Using Ground-based Simulation of Spacecraft 
Environmental Factors: Stability SMO (Ground) 
See Risk of Inadequate Food System – Gap AFT2 
 
Activity: 
Thermostabilized shelf-life 
See Risk of Inadequate Food System – Gap AFT2. 
 
Activity: 
Advanced Packaging Material Development 
See Risk of Inadequate Food System – Gap AFT5. 
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N2: What is the optimal dose of vitamin D supplementation? 
 
Activity: 
Vitamin D Status in an Antarctic Ground Analog of Space Flight 
This task will support a vitamin D supplementation study which will evaluate efficacy in this 
model.  Ultimately, the findings will provide long-duration space flight crewmembers with 
evidence-based vitamin D supplement recommendations for optimal vitamin D status before, 
during, and after flight. 
 
Product/Deliverables: 
Initial product is ground-based study to determine optimal vitamin D dosing.   
Required Delivery Milestone: 
Study completion and final report of findings in 2009; delivery of improved countermeasure 
to medical operations in 2009. 
Required Platforms: 
Ground-based models with limited sunlight exposure are necessary for evaluating vitamin D 
supplementation efficacy.  One such model is subjects spending the winter in Antarctica, 
where UV-B radiation levels are zero during the winter.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
Activity: 
Nutrition Status Assessment – SMO O16E: Nutrition SMO  
See Risk of Accelerated Osteoporosis – Gap N7 for details. 
This is a directed study that seeks to expand the Medical Requirement 016L testing in three ways:  
1) in-flight blood and urine collection and analysis, 2) expand nominal testing to include normative 
markers of nutritional assessment, and 3) add an R+30 session to allow evaluation of post-flight 
nutrition and implications for rehabilitation.  Additional markers of bone metabolism (helical 
peptide, OPG, RANKL, IGF-1) will be measured to better monitor bone health and countermeasure 
efficacy.  New markers of oxidative damage will be measured (8-iso-prostaglandin F2a, protein 
carbonyls, oxidized and reduced glutathione) to better assess the type of oxidative insults during 
spaceflight.  The array of nutritional assessment parameters will be expanded to include serum 
folate, plasma pyridoxal 5'-phosphate, and homocysteine to better understand changes in folate, 
vitamin B6 status, and related cardiovascular risk factors during and after flight.  Additionally, 
stress hormones and hormones that affect bone and muscle metabolism will be also measured 
(DHEA, DHEA-S, cortisol, testosterone, estradiol).  This additional assessment would allow for 
better health monitoring, and allow for more accurate recommendations to be made for crew 
rehabilitation.  These additional parameters were added due to the recommendation of an 
extramural panel that met to define nutritional standards and requirements in 2005.  If data indicate 
countermeasures are necessary for cardiovascular issues and/or bone loss, additional ground-based 
studies will be initiated.  These countermeasures will be validated on board the ISS. 
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Product/Deliverables: 
The SFHSS nutrition standard will be validated/updated  
Required Delivery Milestone: 
The SFHSS nutrition standard will be validated/updated in 2011 and again in 2018. 
Required Platforms: 
ISS is required to ensure that the data represents space normal and for validation of potential 
countermeasures.  The bed rest ground analog (6° head down tilt) is required for ground 
studies for countermeasure development. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
Activity: 
Nutrition Status Assessment – SMO O16E: Nutrition SMO  
  See Risk of Accelerated Osteoporosis – Gap N7 for details. 
 
N3: How do nutritional status/nutrition requirements change during space flight? 
 
Activity: 
Nutrition Status Assessment – SMO O16E: Nutrition SMO  
 See Risk of Accelerated Osteoporosis – Gap N7 for details.   
 
N6: What impact does flight have on oxidative damage? 
N15: Can nutrition/nutrients mitigate O2/radiation risks? 
 
Activity: 
NEEMO Rapid Operational Investigation (ROI) study:  Characterization of Oxidative Damage 
during a 12-day Saturation Dive 
Oxidative damage resulting from radiation and or oxygen exposure (e.g., during EVAs) is a 
concern for space travelers.  The underwater analog, NEEMO, is a valuable ground-based model 
for space flight in terms of oxidative damage and changes in iron metabolism.  In six (6) subjects 
from NEEMO5, there was evidence of oxidative damage similar to what is observed during long-
duration space flight.  In this study, the main objective is to confirm and extend the physiological 
systems that were affected during the previous NEEMO study.  Oxidative damage will be assessed 
before, during, and after the 12-day mission in the NEEMO habitat.  As a result of this study, we 
will have a better understanding of the type of oxidative damage that occurs in an elevated oxygen 
environment, and the data can be used to better design countermeasures against this type of 
damage.   
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Product/Deliverables: 
Initial product is completion of NEEMO study and final report of findings. Study results will 
be combined with other ground studies (i.e. to-be-solicited cataract study) to determine if a 
countermeasure is needed against oxidative damage from an elevated oxygen environment.  
If a countermeasure is needed, ground-based studies will be solicited, followed by flight 
validation studies. 
Required Delivery Milestone: 
Study and final report completed by 2009; if countermeasure is needed, ground-based studies 
solicited and performed 2013-2016. Mission operations will be informed on countermeasure 
delivery by 2020. 
Required Platforms: 
Ground-based studies, NEEMO underwater analog facility, ISS required to validate any 
needed countermeasures. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
Activity: 
Cataract Study – TBD 
Current 2007 NRA solicitation (NNJ07ZSA002N) requesting research to understand, quantify and 
prevent oxidative damage resulting from the environment of space and to arrest the effects of 
elevated oxygen environments necessary for operational activities routinely performed during 
flight, EVA and surface operations. Analytical methods should include specific cellular and/or 
blood markers that may be assessed during flight to monitor oxidative damage potential as well as 
measures to arrest progression of disease states known to be associated with high oxygen exposure 
levels (e.g., cataracts). 
 
Product/Deliverables: 
Initial product will be ground-based studies.  Study results will be combined with other 
ground studies (i.e. NEEMO Oxidative Damage study) to determine if a countermeasure is 
needed against oxidative damage from an elevated oxygen environment.  If a countermeasure 
is needed, ground-based studies will be solicited, followed by flight validation studies. 
Required Delivery Milestone: 
Study will be completed by 2013 and data compiled with other oxidative studies. If 
countermeasure is needed, ground-based studies solicited and performed 2013-2016. Follow-
on flight validation studies will be performed 2017-2020 and countermeasures delivered by 
2020. If a countermeasure to protect for cataracts is required, it is needed as soon as possible. 
Required Platforms: 
Ground-based studies, ISS required for validation of any needed countermeasures 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
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Activity: 
EVA Oxidative Damage Study – TBD  
Current 2007 NRA solicitation (NNJ07ZSA002N) requests studies to determine whether 
performance of EVA increases oxidative damage.  The study should examine if antioxidant 
supplements mitigate risks of in-flight oxidative damage without untoward negative side effects 
and if extravehicular activities increase oxidative damage.   
 
Product/Deliverables: 
Initial product will be ground-based studies.  Study results will determine if a countermeasure 
is needed against oxidative damage from EVA performance.  If a countermeasure is needed, 
ground-based studies will be solicited, followed by flight validation studies. 
Required Delivery Milestone: 
Study will be completed by 2013 and if countermeasure is needed, ground-based studies will 
be solicited and performed 2013-2016. Follow-on flight validation studies will be performed 
2017-2020 and countermeasures delivered by 2020. If a countermeasure to protect against 
oxidative damage is required, it is needed as soon as possible. 
Required Platforms: 
Ground-based studies, ISS required for validation of any needed countermeasures 
Project/Organization Responsible for Implementation of Activity: 
NSBRI – via NRA 
 
N8: What are the energy/nutrient requirements of EVA?  What is the best delivery system for these 
nutrients? 
EPSP5: What are the energy/hydration requirements and associated waste management requirements 
of EVA, and what kind of integrated delivery/management systems can be supported in an EVA suit?  
 
Activity: 
Determine Energy, Nutrient, Hydration and Waste Management Requirements 
Work with flight surgeons and with experts in the JSC Nutritional Biochemistry Lab and the JSC 
Water and Food Lab to analyze data collected in EPSP3 and EPSP4 to quantify the water and 
nutrients required for surface EVA operations.  These data will then drive requirements for waste 
management systems and EVA food/hydration requirements (SHFH). 
The results of this analysis will be compared with Level II requirements addressing nutrition and 
hydration that are currently in the Human Systems Integration Requirements (HSIR) document 
(CxP 70024) and will be used to generate Level III and Level IV requirements.  
 
Product/Deliverables: 
Recommendations for nutrition and hydration requirements 
Recommendations for waste management system requirements  
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Required Delivery Milestone: 
Analysis will be complete by FY10 to provide inputs to Suit Configuration 2 Systems 
Requirements Review which will take place in FY11.    
Required Platforms: 
Statistical analysis and modeling 
Project/Organization Responsible for Implementation of Activity: 
EPSP 
 
Activity: 
Evaluate Concepts for Nutrient and Water Delivery System 
Work with experts in Advanced Food Technology Project and the JSC Nutritional Biochemistry 
Lab to develop concepts for the format of nutrition and hydration sources (energy bar, gel, etc.).  
Work with crew office to evaluate concepts and get crew consensus. 
Work with suit design team to develop concepts for nutrition and hydration delivery systems and 
waste management systems.  Evaluate concepts in ground tests.      
 
Product/Deliverables: 
Recommendations for nutrient and water delivery systems 
Recommendations for waste management systems 
Required Delivery Milestone: 
A majority of the studies will be completed by the end of FY09 in order to provide inputs to 
Suit Configuration 1 (initial capability: launch/abort/entry and microgravity EVA) Interim 
Design Review (FY09) and Suit Configuration 2 (lunar surface operations) Systems 
Requirements Review (FY10).  Follow-on studies will be conducted as needed to provide 
inputs to subsequent design reviews in FY11-FY15.  Where needed, preliminary data will be 
used for inputs to Suit Configuration 1 Preliminary Design Review (end of FY08).      
Required Platforms: 
lunar analog testing environments 
Project/Organization Responsible for Implementation of Activity: 
EPSP 
 
Activity: 
Evaluate Nutrient Delivery Systems and Waste Management Systems in Suit. 
Evaluate nutrition/hydration delivery systems and waste management systems in prototype and 
qualification unit suits.  Follow-on flight validation and optimization studies with flight suits will 
occur during lunar surface operations. 
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Product/Deliverables: 
Evaluation of prototype, qualification unit and flight article suits per standard measures with 
inputs to design updates as needed.  
Required Delivery Milestone: 
Suit Configuration 1 development and qualification testing will be complete by the System 
Acceptance Review in 2012.  Suit Configuration 2 development and qualification testing will 
be complete by the System Acceptance Review in 2017.  Evaluation of flight article suits will 
occur during lunar surface operations. 
Required Platforms: 
Lunar analogs such as Partial Gravity Simulator (Pogo) and parabolic flight 
Lunar surface operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Constellation EVA Systems Project Office 
 
N4: Do countermeasures impact nutrition? 
 
Activity: 
The HHC Element will collaborate with the Space Medicine Division (SD) to determine how 
various countermeasures impact nutrition (TBR-5). 
 
Product/Deliverables: 
TBD 
Required Delivery Milestone: 
TBD  
Required Platforms: 
TBD 
Project/Organization Responsible for Implementation of Activity: 
SD 
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6.0 RISK OF INADEQUATE FOOD SYSTEM -D X C 
Note: This risk encompasses two different risks from the PRD, “Risk Factor of Inadequate Nutrition” and 
“Risk Factor of Inefficient Food System”.  When the PRD was baselined, an action was given to assess these 
risks for possible combination.  This combination is the result of that assessment. 
 
If the food system does not adequately provide for food safety, nutrition and acceptability, then crew health 
and performance and the overall mission may be adversely affected.  Furthermore, if the food system uses 
more than its allocated mission resources, then total required mission resources may exceed capabilities, the 
mission deemed unfeasible, or allocation of resources to other systems may be unduly constrained. 
 
Operational Relevance and Risk Context  
The paramount importance of the food system in a long duration manned exploration mission should not be 
underestimated. The food system provides not only the nutrients needed for the survival and health of the 
astronauts but it also enhances the psychological well being of the crew by being a familiar element in an 
unfamiliar and hostile environment.  Inadequacy of a food system can be influenced by four criteria: safety, 
nutrition, acceptability and an imbalance of vehicle resources such as mass, volume and crewtime.  Since 
quality loss, including nutrition and acceptability, will occur over the shelf life of the food, efforts are needed 
to improve understanding of the nutritional content of the food when consumed and how much variety, 
acceptability, and ease of use is required for different duration missions.  Research areas may include: shelf 
life studies including the effects of time, temperature and radiation, improvement in food preservation, 
improvement in food packaging, and testing to determine effects of the space environment and length of 
mission on food acceptability, variety, and ease of use.  Research is also required for the food system required 
during EVA and contingency suited operations.  The research will consider requirements to comply with the 
mission resources such as mass, volume, power, and crewtime.   
 
Priorities 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Critical To Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
AFT1: What are the nutrient-dense foods that could support the high metabolic rates of lunar EVAs?   
 
Activity: 
Nutrient-Dense Food Development 
Once nutritional requirements have been determined, and the requirements for food bars or 
beverages have been established, then the development of a nutrient dense food system can be 
developed for in-suit consumption.  The initial work will concentrate on determining whether 
commercially available items are available.  If that is not the case, then food items will be 
developed.  Support for the in-suit delivery system integration will also be provided. 
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Product/Deliverables: 
• Specifications for the in-suit food items 
• Development of an adequate number of in-suit food items per mission scenarios with the 
appropriate nutrition, acceptability and shelf life 
• Packaging that will integrate with the EVA suit 
Required Delivery Milestone: 
Requirements for EVA Foods in 2011; Integrate with in-suit delivery system FY2014 
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
AFT  
 
AFT2: What are the nutrition and acceptability of space foods at the time of crew consumption? 
The nutrition requirements, determined by the Human Health and Countermeasures Element, are delivered 
via the food system and through supplementation.  Packaged foods are processed, which can reduce the 
nutritional content.  In addition, the crew often does not consume all of their food during a mission.  It is 
expected that improving the nutritional content and the acceptability of the food system will increase crew 
consumption which will ensure good nutritional status. 
 
Activity: 
Effect of the Retort Process on Nutritional Content of Food 
The nutritional content of the flight food items is not measured. The actual macronutrients and 
some minerals are determined chemically.  However, the other nutrients such as vitamins are only 
determined through a computer program which calculates the combined nutritional content based 
on the food products formulation.  The computer program does not take into account the loss of 
nutrients during the thermostabilization process.  
 
Product/Deliverables: 
Review literature to better understand what are the potential effects of the retort process. 
Optimize time/temperature processing conditions for each specific thermostabilized food 
product that NASA produces.   
Measure nutrient content of the finished product. 
Required Delivery Milestone: 
FY2015 – Required as a design solution to support the food system for operations on the lunar 
surface. However, if information is available prior to this, it could be used to influence the food 
system for the ISS.  
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
AFT 
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Activity: 
Effect of the Freeze-drying Process on Nutritional Content of Food 
The nutritional content of the flight food items is not measured. The actual macronutrients and 
some minerals are determined chemically.  However, the other nutrients such as vitamins are only 
determined through a computer program which calculates the combined nutritional content based 
on the food products formulation.  The computer program does not take into account the loss of 
nutrients during the freeze drying process.  
 
Product/Deliverables: 
Review literature to better understand what the potential effects are. 
Optimize time/temperature processing conditions for each specific freeze-dried food product 
that NASA produces.   
Measure nutrient content of the finished product. 
Required Delivery Milestone: 
FY2015 – Required as a design solution to support the food system for operations on the lunar 
surface. However, if information is available prior to this, it could be used to influence the food 
system for the ISS.  
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
AFT 
 
Activity: 
Stability of Pharmacotherapeutic and Nutritional Compounds: Stability SMO (Flight) 
This protocol involves investigative physical/chemical analyses of both medications and food items 
returned from STS and ISS along with corresponding lot-matched controls stored on ground in a 
controlled environment.  This experiment has two (2) sub-payloads attached to it.  See the Risk of 
Therapeutic Failure Due to Ineffectiveness of Medications for the Pharmacology sub-payload.  The 
Nutritional Sub-Payload will identify vitamins and amino acids at risk for degradation in space 
food supply; identify changes in fatty acids of foods flown on ISS; and characterize degradation 
profiles of the unstable nutrients.  This study will provide critical information about the 
preservation of vitamins and nutrients in food during space flight and susceptibility of vitamins in 
the space food system to adverse environmental factors and storage encountered during space 
missions. 
 
Product/Deliverables: 
The initial product is an ISS study. 
Required Delivery Milestone: 
ISS Stability study performed from 2006-2009. 
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Required Platforms: 
ISS required for proper radiation doses on food samples. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study; with collaboration with the Advanced Food Technology Project 
 
Activity: 
Assessment of Nutrient Stability in Space Using Ground-based Simulation of Spacecraft 
Environmental Factors: Stability SMO (Ground) 
Nutritious food and effective medication availability on the spacecraft remains a critical issue for 
mission success and crew health and safety.  Ground-based evidence indicates that many vitamins 
are destroyed and fatty acids are oxidized (and therefore rendered dangerous or useless) by 
different types of radiation and during long-term storage.  This study uses radiation exposure to test 
the stability of various food and pharmaceutical components and will be compared to ongoing 
flight data that is being collected.  
 
Product/Deliverables: 
The initial product is a radiation study using ground-based radiation sources (Brookhaven, 
university or hospital facilities).   
Required Delivery Milestone: 
Ground Stability study performed from 2006-2010;  
Required Platforms: 
Ground-based radiation sources (Brookhaven, university or hospital facilities) required for 
assessment of radiation doses on food samples. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study; with collaboration with the Advanced Food Technology Project 
 
Activity: 
Effect of Space Radiation on Nutrition and Acceptability 
Preliminary results from some NASA-funded research indicate that some functionality and quality 
changes occur in foods and food ingredients at lower radiation levels.  If results from the ground 
and flight Stability Studies indicate nutrient loss due to radiation, further research will be required 
to determine quality changes at appropriate dosage levels for Mars and lunar missions and the 
appropriate countermeasures. 
 
Product/Deliverables: 
Summary of radiation effects on food using literature and external NASA-funded research. 
Conduct shelf life test to determine the changes in quality and nutritional content of foods over 
time when exposed to the appropriate dose of radiation. 
Food system design solutions to countermeasure the effects of radiation. 
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Required Delivery Milestone: 
Constellation Program informed of food system requirements in 2010; Mission operations 
informed in 2014 of any food system design solutions.  The food system requirements are 
needed by FY13 to support implementation of the food system in mission operations 
development.  
Required Platforms: 
Ground based study. 
Further ISS or lunar testing may be required depending on results from ISS Stability Study and 
other data collected. 
Project/Organization Responsible for Implementation of Activity: 
AFT 
 
Activity: 
Effect of Time and Temperature on Nutrition and Acceptability; Thermostabilized Shelf-Life Test 
to Determine Shelf-Life of Food Items Stored at Room Temperature 
Shelf-live on the current thermostabilized food products have never been determined.  Thirteen 
food items with varied formulations have been placed in accelerated shelf life testing.  In addition 
three bulk ingredients (for preparation of a lunar outpost mission) were placed into accelerated 
shelf life testing.  Sensory and analytical changes are measured over the three year test. 
 
Product/Deliverables: 
This will ultimately result in a list of foods and/or preparation methods that support lunar 
operations. 
Required Delivery Milestone: 
FY2015 – Required as a design solution to support the food system for operations on the lunar 
surface. However, if information is available prior to this, it could be used to influence the food 
system for the ISS.  
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
AFT 
 
AFT3: What are the psychosocial requirements for the food system for different mission lengths (TBR-
6)? 
If the food is not acceptable to the crew, then the crew will not eat an adequate amount of the food and will be 
compromised nutritionally.  Anecdotal reports have suggested that the food does not taste the same in 
microgravity. Other reports indicate that the crew craves different foods on-orbit as compared to on-Earth.  In 
addition, the crew has reported that they tire of certain foods over the 6-month ISS mission. 
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Activity: 
Sensory Qualities in Microgravity 
Determine effect of changes in aroma detection due to fluid shift and lack of convection of air in 
microgravity. 
Determine effects of “long term acceptability”. 
Validate with ISS Study incorporating surveys of food taste. 
 
Product/Deliverables: 
Requirements on the food system for long-duration operations 
Required Delivery Milestone: 
~FY2019 (Note, Need date for Lunar Outpost SRR is TBD.)- Required to define requirements 
on food system for long-duration Lunar outpost and Mars Missions.  However, if information is 
available prior to this, it could be used to influence the food system for the ISS. 
Required Platforms: 
Ground 
Validation on ISS 
Project/Organization Responsible for Implementation of Activity: 
AFT- Directed Study 
 
Activity: 
Variety, Acceptability, and Usability Requirements Development (TBR-7) 
Determine requirements on the food system for variety of foods, taste acceptability and usability 
(performed primarily through taste panels and surveys). 
 
Product/Deliverables: 
Requirements on the food system for long-duration operations 
Required Delivery Milestone: 
~FY2019 (Note, Need date for Lunar outpost SRR is TBD) - Required to define requirements 
on food system for long-duration Lunar outpost and Mars Missions.  However, if information is 
available prior to this, it could be used to influence the food system for the ISS. 
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
AFT- Directed Study 
 
Activity: 
Psychosocial Requirements of Food Operations (eating together, holiday foods, etc) 
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Requirements and guidelines development process requiring little if any research. This 
requirements development will consist of recommendations to mission ops for times for eating, 
eating together, special foods, holiday foods, etc. Requirements will be developed in conjunction 
with the crew office and AFT lab. 
 
Product/Deliverables: 
Requirements on food system and mission operations 
Required Delivery Milestone: 
~FY2019 (Note, Need date for Lunar outpost SRR is TBD) - Required to define requirements 
on food system for long-duration Lunar outpost and Mars Missions.  However, if information is 
available prior to this, it could be used to influence the food system for the ISS. 
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
BHP – Directed Study 
 
AFT4: Can a 5-year shelf life packaged food system be developed for extended NASA missions? 
Shelf-life criteria are safety, nutrition, and acceptability.  Any of these criteria can be the limiting factor in 
determining the shelf-life.  The ISS food system currently has an 18 month shelf life.  To achieve that shelf 
life, some foods are over wrapped with a high barrier material.  Results from ongoing shelf life studies of 
thirteen thermostabilized food items suggest that the shelf life of the foods range from 16 months to 8 years, 
depending on formulation. 
 
Activity: 
Department of Defense (DoD) Collaboration 
Although the commercial food industry requirements are not compatible with NASA’s 
requirements, the Combat Feeding Program (DoD) requirements are compatible with NASA.  Both 
NASA and DoD require long shelf life, shelf stable food items with high barrier packaging.  Both 
also require minimal packaging.  The DoD Combat Feeding Program when conducting their 
research uses collaborations of industry, government, and academia experts.  Currently, the DoD 
has an active packaging research program as well as a program investigating emerging preservation 
technologies.  These preservation technologies should result in FDA approval of high pressure 
processing and microwave sterilization for shelf stable products. 
 
Product/Deliverables: 
Recommendations for advanced food packaging and preservation technologies for shelf stable 
foods 
Required Delivery Milestone: 
~FY2023 (Note, Need date for Lunar outpost CDR is TBD) - Required to meet requirements on 
food system packaging for long-duration Lunar outpost and Mars Missions.  However, if 
information is available prior to this, it could be used to influence the ISS food system if it 
would positively influence its long-term nutrient stability or reduce food logistics. 
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Required Platforms: 
Ground Laboratory 
Project/Organization Responsible for Implementation of Activity: 
AFT in collaboration with DoD 
 
AFT5: How can package mass and volume be reduced without compromising food quality?   
The food system is a significant contributor to the mass and volume in the vehicle.  A reduction in mass and 
volume through formulation or packaging would benefit the program.  
 
Activity: 
Advanced Packaging Material Development 
Currently the packaging used for freeze-dried foods and natural form foods does not have adequate 
oxygen and moisture barrier properties to allow for an 18-month shelf life for ISS.  Therefore, those 
foods are over wrapped with a second foil-containing package which has higher barrier properties. 
The packaging material used for the thermostabilized, irradiated, and beverage items contain a foil 
layer to maintain product quality over at least the required 18 month shelf life.  Although foil in the 
packaging material provides excellent oxygen and moisture barrier properties, it is not compatible 
with microwave sterilization and high pressure processing.  .  The foil layer within the food 
package may also provide complications if the decision is made to incinerate the trash on the lunar 
or mars surface.  These emerging preservation technologies have the potential of providing NASA 
with a higher quality food system Therefore, research to develop a packaging material that has the 
barrier properties of foil without the foil is necessary. 
• Packaging Shelf Life Study - determine whether any current flight packaging can be used 
as the primary package for freeze-dried and natural form foods. 
• Packaging Workshop – determine which emerging or commercially available technologies 
can be used for NASA Exploration missions. 
• External Research Project – development of new high barrier, foil-free packaging material 
 
Product/Deliverables: 
Food packaging technologies that reduce the overall mass and volume required for the food 
system 
Required Delivery Milestone: 
FY2015 – Required as a design solution to support the food system for operations on the lunar 
surface. However, if information is available prior to this, it could be used to influence the food 
system for the ISS to reduce food logistics.  
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
AFT, - Directed Study 
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Activity: 
Reduced Mass in Food 
In order to provide a lower mass and volume food system for the Constellation Program, changes in 
product formulation may be necessary.  Changes to consider are removing some water from the 
total food system, increasing fat content, or increasing nutrient density of the food items.   
 
Product/Deliverables: 
Trade studies to consider options to reduce mass of food.  Determine best case scenario for 
further development.  
Determine commercial availability of foods with preferred scenario.  
Develop technologies for food product development if not commercially available.  
Required Delivery Milestone: 
FY10 – Required for first ISS Orion mission (Justification – Current food system overweight.  
Challenged to reduced mass from 4 lbs to 2.5 lbs per day)
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
AFT- Directed Study 
 
AFT6:  How can the mass and volume of the Lunar food system be reduced and how can it serve as a 
test bed for future Mars missions (TBR-8)? 
By incorporating plant growth, food processing and food preparation, the mass and volume of the food 
system could be reduced. 
 
Activity: 
Partial Gravity and Atmospheric Effects on Food Processing and Preparation 
Heat and mass transfer are affected by partial gravity and reduced atmospheric pressure. When 
preparing raw foods into edible ingredients, it is necessary to reach a certain temperature/time 
combination to insure safety and certain functionality. It is being proposed that the lunar habitat 
will maintain an 8 psi atmospheric pressure.  At that pressure, the boiling temperature for water is 
181oF.  Research needs to be conducted to determine whether the 1/6 G of the lunar surface and the 
8 psi of the habitat will result in incomplete heating. If incomplete heating does occur, research will 
be required to determine countermeasures.  
Determine whether there is incomplete cooking.  
If there is incomplete cooking, what is the mitigation strategy? 
Product/Deliverables: 
Used as an input to the trade study (see next activity). 
Ultimately results in requirements on the Lunar Outpost Food System regarding food 
preparation and/or processing equipment. 
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Required Delivery Milestone: 
Completion of study by FY2013 to support trade study. 
If the decision is to develop a food system with surface processing and preparation, then this 
decision would be required by FY 2015 to prepare for the ultimate delivery ~FY2019 (Note, 
Need date for Lunar outpost SRR is TBD) to define requirements on food system for long-
duration Lunar outpost and Mars Missions.  This study supports this decision process. 
Required Platforms: 
Ground with validation on ISS or lunar surface 
Project/Organization Responsible for Implementation of Activity: 
AFT - Directed Study or RFP 
 
Activity: 
Food Processing vs. Packaged Food System Trade Study (TBR-9) 
Preliminary studies suggest total mass of the food system can be reduced if the food system moves 
more towards a bioregenerative food system. In a bioregenerative food system vegetables and fruit 
would be freshly grown on the lunar or Mars surface and baseline crops such as soybeans, wheat, 
rice, peanuts, and dried beans would be grown or launched in bulk from Earth. The baseline crops 
would be processed into edible ingredients. The edible ingredients and freshly grown fruits and 
vegetables would be used in preparing meals in the galley. Some packaged food would likely be 
required. 
Further studies are required to determine the magnitude of mass savings and the effect on other 
mission resources such as power, crewtime, and recycling of water used in the processing. These 
studies will also identify the equipment that would be required to be built for the lunar surface test.    
Trade study that considers efficiencies and adequacies of the two food systems with a 
recommendation to the Program 
 
Product/Deliverables: 
Requirements on the Lunar Outpost Food System regarding food preparation and/or processing 
equipment 
Required Delivery Milestone: 
If the decision is to develop a food system with surface processing and preparation, then this 
decision would be required by FY 2015 to prepare for the ultimate delivery ~FY2019 (Note, 
Need date for Lunar outpost SRR is TBD) to define requirements on food system for long-
duration Lunar outpost and Mars Missions.  This trade study supports this decision process. 
Required Platforms: 
Ground 
Project/Organization Responsible for Implementation of Activity: 
AFT – Directed Study 
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Activity: 
Develop Processing and Preparation Equipment and Procedures 
If a bioregenerative food system is used, then miniaturized processing equipment will need to be 
built. It is unlikely that there will be commercial equipment appropriately sized for a lunar or Mars 
mission. The preparation equipment for the galley will likely be commercially available gourmet 
kitchen appliances that will need to be modified for the Lunar missions. 
• Technology Development for several pieces of food processing equipment and procedures 
to develop safe and high quality edible ingredients for further preparation in galley 
• Technology Development for several pieces of food preparation equipment and procedures 
to develop safe and high quality recipes in galley 
 
Product/Deliverables: 
Food system processing technologies for a Lunar outpost or Mars mission. 
Required Delivery Milestone: 
~FY2019 (Note, Need date for Lunar outpost SRR is TBD) to provide design solution for the 
food system for long-duration Lunar outpost and Mars Missions.   
Follow-on validation and optimization for Mars missions to occur in lunar ops (Date TBD). 
Required Platforms: 
Ground with validation on lunar surface 
Project/Organization Responsible for Implementation of Activity: 
AFT – Directed Study or RFP 
 
Activity: 
Vegetable Growth 
In order to provide the crew with fresh food on surface Lunar and Mars missions, fruits and 
vegetables will be grown hydroponically in environmentally-controlled growth chambers.  
Significant research has been conducted to determine growth conditions and plant sensitivities to 
environmental changes. However, further research is required to finalize the environmental 
conditions for the plant growth.   
Since these fruits and vegetables may be consumed uncooked, research is required to determine the 
handling procedures pre- and post-harvest to insure safety.   
 
Product/Deliverables: 
Growth procedures for fresh vegetables and fruits 
Handling procedures to ensure safe, uncooked foods 
Required Delivery Milestone: 
~FY2019 (Note, Need date for Lunar outpost SRR is TBD) to provide design solution for the 
food system for long-duration Lunar outpost and Mars Missions.   
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Required Platforms: 
Ground with validation on lunar surface 
Project/Organization Responsible for Implementation of Activity: 
AFT and/or Crop Systems team (TBD) 
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7.0 RISK OF BEHAVIORAL AND PSYCHIATRIC DISORDERS -D X C  
Behavioral issues are inevitable among groups of people, no matter how well selected and trained. 
Space flight demands can heighten these issues. The Institute of Medicine (IOM) report, Safe 
Passage, notes that Earth analog studies show an incidence rate of behavioral problems ranging from 
3-13 percent per person per year. The report transposes these figures to 6-7 person crews on a 3-year 
mission to determine that there is a significant likelihood of psychiatric conditions emerging. 
Impacts of behavioral issues are minimized if they are identified and addressed early. The HRP must 
provide the best measures and tools to monitor and assess mood and to predict risk for, and 
management of, behavioral and psychiatric conditions prior, during and following space flight. 
 
Operational Relevance and Risk Context  
BHP research addresses the risk of behavioral and psychiatric conditions developing during or 
following an Exploration Mission.  Early detection of stress or other risk factors during spaceflight 
is imperative to deter development of behavioral or psychiatric conditions which could seriously 
harm and negatively impact the individual or the crew, and pose serious consequences for 
accomplishing mission objectives or jeopardizing the mission altogether. Toward this end, BHP is 
developing methods for monitoring behavioral health during a Lunar and Mars Mission, and 
adapting/refining various tools and technologies for use in the spaceflight environment. These 
measures and tools will be used to monitor, detect and treat early risk factors. BHP will utilize 
analogs to test, further refine, and validate these measures for Exploration Missions. BHP also 
develops countermeasures for maintaining behavioral health and enhancing performance during 
long duration isolated, confined, and highly autonomous missions; provides recommendations 
regarding BHP best practices; and, provides updates for behavioral health and performance 
Standards.   
The BHP element includes two additional risks – increased human performance errors due to sleep 
loss, fatigue, work overload, and circadian desynchronization; and, increased errors due to poor 
team cohesion and performance, inadequate selection/team composition, inadequate training, and 
poor psychosocial adaptation. The three risks are highly interrelated; the occurrence or mitigation of 
one risk can be a contributing factor affecting another. As a result, BHP gap-related activities and 
deliverables may sometimes address more than one risk.   
  
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission   
Mars Mission: Critical to Quantify and Reduce Prior to the Mars Mission 
 
Gaps 
 
BHP 3.1.1: What are the best assessment measures to detect behavioral and psychiatric 
disorders? (Priority 1) 
BHP 3.2.1: What countermeasures can be developed to maintain behavioral health during 
spaceflight missions? (Priority 2) 
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Currently a computerized “psychologist” is under development through the NSBRI, in conjunction 
with Medical Operations and the Astronaut Office; this “smart” technology allows a crewmember 
on a long duration Lunar or Mars Mission to evaluate signs or symptoms of early depression and 
anxiety, and receive therapy as desired.  
The computer-based aid for addressing depression (based on problem-solving therapy), is not 
designed to replace the clinician; rather, it will complement the service of the aerospace psychiatrist 
during a long duration Exploration Mission. The tool enhances privacy, confidentiality, and support 
of the astronaut during autonomous missions such as the Mars Mission which will have considerable 
communication delays between space crew and ground support.  It allows the astronaut to educate 
him/herself, augmenting the one-on-one private physician consultation. At times when such 
consultation is not feasible, it will serve as a diagnostic tool and autonomous countermeasure that is 
available 24/7, with feedback to the individual, aerospace psychiatrist, and the crew surgeon.   
 
Activity: 
Refine and Validate Tool for Early Detection and Mitigation of Depression (TBR-10) 
Ground based studies (laboratories and analogs) 2008-2010 to refine and test the effectiveness 
and feasibility of tool. Flight validation 2011-2013. If technology is not effective or feasible, 
subsequent research activity will pursue other measures.  
 
Product/Deliverables: 
1) Tool to detect and treat depression early. 
2) Updates to Standards. 
Required Delivery Milestone: 
Tools to detect and treat depression delivered in 2013. Standard updated by 2012.  
Tools required by 2014 for Mission Ops implementation.  
Required Platforms: 
Use of space analogs to refine and validate tool (2008-2010). 
Flight validation on ISS; the ISS will emulate the transit environment to Mars.  
Project/Organization Responsible for Implementation of Activity: 
NSBRI 
 
Due to the delayed communication that will exist between the space crew and the ground 
during an Exploration Missions, flight surgeons have stated the need for unobtrusive 
monitoring tools, transparent to the flight crews, that will help detect if an astronaut is 
demonstrating or otherwise evidencing high levels of stress and fatigue. These tools are to 
require minimal crew time and effort. The tools will allow the crewmember the ability for 
self-assessment, providing immediate feedback so that countermeasures can be administered 
in a timely manner, if necessary.  
Currently, two monitoring technologies are planned. These technologies, to be adapted 
specifically for Exploration Missions, are already under development through previous work 
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of the researchers with other agencies. NASA is able to leverage such technologies, and 
with some refinement, adaptations, and validation, provide these tools for Lunar and Mars 
Missions.  
 
Activity: 
Refine/Adapt Unobtrusive Monitoring Technologies  
Facial Monitoring Technology 
Laboratory studies are evaluating whether optical computer recognition algorithms based on 
changes in facial expressions can discriminate stress induced by low versus high workload. 
Following refinement of the tool to detect changes despite fluid shifts that can occur during 
spaceflight, it is anticipated that the tool will be validated in analog environments (including 
NEEMO and HMP), then validated on ISS.  
Voice Acoustics Monitoring Technology  
This speech monitoring technology will automatically and unobtrusively monitor the effects of 
stress and neurological impairment on astronauts’ ability to perform in extended missions. The 
system detects cognitive decrements resulting from hypoxia and radiation, and can discriminate 
between high and low stress conditions. 
Research activities include continued use of space analogs to adapt and validate effectiveness 
of the tool for the spaceflight environment. It is anticipated that the technology will also 
undergo in-flight validation on ISS. 
 
Product/Deliverables: 
1) Facial Monitoring Technology, (i.e., the Optical Computer Recognition Tool - 
unobtrusive, passive technology that assesses individual responses to stress) 
2) Voice Acoustics Monitoring Technology (unobtrusive, passive technology that assesses 
individual responses to stress, as well as radiation and hypoxia effects) 
3) Updates to Standards (if applicable). 
Required Delivery Milestone: 
Technologies to be validated in-flight by 2012; if effective, Crew Health Standards to be 
updated by 2012 and technologies to be delivered by 2012. The effectiveness of the tools 
largely depends on ISS validation phase, as technologies that monitor an individual’s coping 
involve analyzing facial movements and acoustic patterns, which can be affected by 
microgravity or other aspects of the isolated confined space environment.  
Technologies are required for Mission Operations Implementation by 2014. 
Required Platforms: 
Ground studies to adapt technologies for spaceflight; analogs include NEEMO, Haughton 
Mars Project (HMP), Mt. Everest, and potentially other Isolated, Confined and Extreme 
(ICE) Environments. Require the ISS for validation because of the parameters being 
monitored may be affected by microgravity. The ISS will emulate the transit environment to 
Mars. Involves collaboration with NSBRI. 
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Project/Organization Responsible for Implementation of Activity: 
NSBRI  
 
BHP 3.1.2: What aspects of cognition decline or change during LDM spaceflight, during stays 
on surfaces, and following LDM, as a function of LDM itself or specific activities during 
LDM? (Priority 2) 
 
Activity: 
Assess Cognitive and Neurostructural Changes 
Evidence Gathering 
Evidence gathering and review from space analogs and spaceflight. A questionnaire 
administered to crews returning from long duration missions in space, and mining of existing 
data from spaceflight will offer insight into potential clinical cognitive changes.  
Evidence gathering and review from space analogs, pre-flight, in-flight, and post-flight. A 
review of medical data from analogs may reveal whether physical neurostructural changes 
exist after long duration missions in extreme conditions, and may propose potential 
measurement methods for upcoming missions to the Moon and Mars. Collaborative studies on 
animals with radiation may also provide evidence. 
If evidence reveals that additional countermeasures are required beyond what BHP has 
developed/is developing, subsequent research activity will ensue to develop additional 
countermeasures. 
 
Product/Deliverables: 
1) Recommendations based on evidence gathered regarding clinical cognitive changes. 
2) Recommendations based on evidence gathered of neuro-structural changes. 
3) Update Standards. 
Required Delivery Milestone: 
Standards update in 2012. Recommendations (clinical cognitive changes) delivered by 
2013. Recommendations (neurostructural changes) delivered by 2016. Continued evidence 
gathering through Constellation operations.  
Recommendations for Mission Ops Requirements Definition for long duration Lunar 
Missions and Mars Missions, due by 2023.  
Required Platforms: 
Evidence gathering is primarily a ground based effort utilizing analogs with long duration 
capability such as Antarctica, with some evidence gathered from long duration ISS (to 
detect potential clinical cognitive changes). 
Project/Organization Responsible for Implementation of Activity: 
Directed Study / Collaboration with Radiation 
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BHP 3.2.2 What are the most appropriate and effective ways for crews to use behavioral 
health medications in spaceflight? (Priority 3) 
Space analogs, such as Antarctica, confirm mood deterioration and increased stress occur in 
individuals in isolated, confined and extreme environments (ICE); some crewmembers on MIR 
Missions and ISS have reported similar experiences. Psychotropic medications may be considered 
helpful in mediating these deleterious effects and in treating behavioral or psychiatric conditions that 
may arise during Exploration Missions.  
Over the next decade, the field of psychopharmacology will undoubtedly continue to develop new 
medications for the treatment of behavioral and psychiatric disorders. In preparation for long 
duration Exploration Missions, BHP will collaborate with Medical Operations to review state-of-
the-art medications and provide a compendium of best practices. A pharmaceutical armamentarium 
that covers a broad range of mental disorders, produces minimal side effects, requires no laboratory 
monitoring and have minimal storage requirements will be needed for long duration Exploration 
Missions.  
 
Activity: 
Develop Electronic Medications Database 
In collaboration with Medical Operations and Subject Matter Experts, workshop and data 
mining to review literature on performance, safety, and side effects of state-of-the-art 
medications for behavioral and psychiatric disorders.  
 
Product/Deliverables: 
Electronic Behavioral Medications Database.  
Required Delivery Milestone: 
Activity to begin in 2018 and be delivered by 2020, with subsequent updates every 
four years. Due date for Lunar Mission Ops for Lunar Habitat is 2023.  
Required Platforms: 
Primarily a ground based effort.  
Project/Organization Responsible for Implementation of Activity: 
TBD 
 
BHP 3.3.1 What selection and assignment criteria are needed for Exploration Missions? 
(Priority 3) 
 
Activity: 
Develop Selection Criteria for Exploration Missions  
New criteria may be necessary for astronaut selection for Exploration Missions.  
Neuropsychiatric assessment may be helpful in this process, as the biological basis of mood 
disorders suggests neural biomarkers may provide a more objective method for assessing 
some psychiatric conditions such as depression.  
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A current NSBRI effort is evaluating and validating a neuroimaging technology for its 
ability to detect biomarkers of depression and its severity, as well as indicators of treatment 
resistance. 
BHP will collaborate with Med Ops to determine what additional assessment may be 
utilized. A review of preferred measures within other agencies where crews or small groups 
embark on expeditions in extreme environments (such as the military) will establish an 
evidence base for informing BHP screening recommendations prior to Exploration Missions 
assignment. 
These neuropsychiatric screening measures will establish a baseline for each astronaut, 
which will be helpful if medical issues occur in-flight or post-flight. 
 
Product/Deliverables: 
1) Recommendations regarding best measures for neuropsychiatric 
assessment/treatment. 
2) Inform Standards.  
Required Delivery Milestone: 
Recommendations for Mission Ops to be delivered by 2013; recommendations due 
to Mission Ops by 2013 
Required Platforms: 
This ground effort primarily involves evidence gathering and collaboration with 
identified stakeholders. 
Project/Organization Responsible for Implementation of Activity: 
TBD 
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8.0 RISK OF RADIATION CARCINOGENESIS FROM SPACE RADIATION – I X I
 
9.0 RISK OF ACUTE OR LATE CENTRAL NERVOUS SYSTEM EFFECTS 
FROM SPACE RADIATION – I X I
 
10.0 RISK OF DEGENERATIVE TISSUE OR OTHER HEALTH EFFECTS 
FROM SPACE RADIATION – I X I
 
11.0 ACUTE RADIATION RISKS FROM SPACE RADIATION – I X I 
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1.4 Acute Radiation Risks from Space Radiation 
2.0 Operational Relevance Assessment and Recommendations 
3.0 Gaps, Mitigation, Deliverables, Platforms, and Responsibility 
3.1 Radiation Carcinogenesis 
3.1.1 Priority 
3.1.2 Gaps 
3.1.3 Description of Research Approach 
3.1.4 Activity 
3.1.5 Product/Deliverables/Milestones 
3.1.6 Required Platform 
3.1.7 Project/Organization Responsible for Implementation of Activity 
3.2 Radiation CNS 
3.2.1 Priority 
3.2.2 Gaps 
3.2.3 Description of Research Approach 
3.2.4 Activity 
3.2.5 Product/Deliverables/Milestones 
3.2.6 Required Platform 
3.2.7 Project/Organization Responsible for Implementation of Activity 
3.3 Radiation Degenerative 
3.3.1 Priority 
3.3.2. Gaps 
3.3.3 Description of Research Approach 
3.3.4 Activity 
3.3.5 Product/Deliverables/Milestones 
3.3.6 Required Platform 
3.3.7 Project/Organization Responsible for Implementation of Activity 
79 
 HRP-47065 
3.4 Radiation Acute 
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Appendix B:  Gantt Charts of SRPE Research Plan (attached) 
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1.0 Space Radiation Risks 
 
1.1 Risk of Radiation Carcinogenesis from Space Radiation 
Space radiation exposure increases cancer morbidity and mortality risk in astronauts. This risk may be 
influenced by other space flight factors including microgravity, environmental contaminants, nutritional issues, 
and psychological and physiological stress. Current space radiation risks estimates are based on human 
epidemiology data for X-rays and gamma-ray exposure scaled to the types and flux-rates in space using 
radiation quality factors and dose-rate modification factors, and assuming linearity of response. There are large 
uncertainties in this approach and experimental models imply additional detriment due to the severity of the 
phenotypes of cancers formed for the heavy ion component of the galactic cosmic rays compared to cancers 
produced by terrestrial radiation. A Mars mission may not be feasible (within acceptable limits) unless 
uncertainties in cancer projection models are reduced allowing shielding and biological countermeasures 
approaches to be evaluated and improved, or unless mission durations are constrained. 
 
1.2 Risk of Acute or Late Central Nervous System Effects from Space Radiation  
Acute and late radiation damage to the central nervous system (CNS) may lead to changes in motor function 
and behavior, or neurological disorders. Radiation and synergistic effects of radiation with other space flight 
factors may affect neural tissues, which in turn may lead to changes in function or behavior. Data specific to the 
spaceflight environment must be compiled to quantify the magnitude of this risk using animal models and 2-
dimensional or 3-dimensional cell culture models of human or other vertebrate cells. If this is identified as a risk 
of high enough magnitude then appropriate protection strategies should be employed. 
 
1.3 Risk of Degenerative Tissue or other Health Effects from Space Radiation 
Space radiation exposure may result in degenerative tissue diseases (non-cancer or non-CNS) such as cardiac, 
circulatory, or digestive diseases, and cataracts. Hereditary risks to the first and subsequent generations of crew 
off-spring also are a concern. The mechanisms and the magnitude of influence of radiation leading to these 
diseases are not well characterized. Radiation can cause increased molecular, cellular, and ultimately tissue 
damage, which may lead to acute or chronic disease of susceptible organ tissues. Data specific to the 
spaceflight environment must be compiled using appropriate cell culture and small animal models and an 
approach to extrapolate this data to humans developed in order to quantify the magnitude of this risk to 
determine if additional protection strategies are required. 
 
1.4 Acute Radiation Risks from Space Radiation 
Radiation and synergistic effects of radiation may place the crew at significant risk for acute radiation sickness 
including prodromal risks, significant skin injury as well as death  from a major solar event (SPE) or combined 
SPE and galactic cosmic rays, such that the mission or crew survival may be placed in jeopardy. Crew health 
and performance may be impacted by a large SPE or the cumulative effect of GCR and SPEs. Beyond Low 
Earth Orbit, the protection of the Earth's magnetic field is no longer available, such that increased shielding and 
protective mechanisms are necessary in order to prevent acute radiation sickness and impacts to mission 
success or crew survival. The primary data available at present are derived from analysis of medical patients 
and persons accidentally exposed to high doses of radiation. Data more specific to the spaceflight environment 
must be compiled to quantify the magnitude of increase of this risk and to develop appropriate protection 
strategies. 
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2.0 Operational Relevance Assessment and Recommendations 
 
Permissible exposure limits (PEL) for each space radiation risk limit prevent acute risks (sickness, death or 
significant loss of function) and limit the risks of late effects such as cancer and degenerative risks to the heart 
or CNS. The PEL’s protect against the upper 95% percent confidence level in the career radiation limits 
because the uncertainties in risk projection models are significant (>4-fold) such that the use of a median risk 
estimate could greatly over-estimate or under-estimate the actual risk to crews.  
 
Mission, vehicle, and crew selection requirements are outcomes of the Space Radiation PELs, including 
requirements on vehicle design and mass, mission duration, and age, gender, or past mission history on crew 
selection. Current estimates of limitation on mission duration that result from cancer fatality risks alone are 
shown in Table 1. Table I also shows estimates made in 2001 without the benefit of the most recent research 
knowledge. 
 
Age, yr Females Males 
  Previous
(2001) 
days 
Current 
(2006) 
days 
Previous 
(2001) 
days 
Current 
(2006) 
days 
30 54 112 91 142 
35 62 132 104 166 
40 73 150 122 186 
45 89 182 148 224 
50 115 224 191 273 
 
Table 1. Increasing safe days in space with reduction in uncertainties. 
 
Research to reduce uncertainties in risk projection models are expected to increase NASA’s ability to select 
crew, extend mission duration, and reduce cost through possible reductions in shielding requirements. Improved 
knowledge of dose-rate and radiation effects will allow for EVA time lines to be extended in deep space and on 
the lunar or Mars surface. Furthermore, research approaches that narrow uncertainties in risk models will no-
doubt evolve into countermeasure discovery and validation approaches that have large benefits on crew 
members.  
The operational relevance of the research is further described by the following formal objectives as documented 
in the HRP Program Requirements Document: 
 
Objective 1:   Enable the development and validation of NASA’s health, medical, and human performance 
standards in time for Exploration mission planning & design 
Trace:  HRP PRD (HRP-47052) Section 4.1  
Objective 2:   Quantify the human health & performance risks associated with human spaceflight or 
Exploration missions 
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Trace:  HRP PRD (HRP-47052) Section 5.1 
Objective 3:   Develop countermeasures & technologies to prevent or mitigate adverse outcomes of human 
health & performance risks 
Trace:  HRP PRD (HRP-47052) Section 5.2 
Objective 4:   Develop countermeasures & technologies to monitor and treat adverse outcomes of human 
health & performance risks 
Trace:  HRP PRD (HRP-47052) Section 5.3 
Objective 5:   Ensure that project processes & products comply with NASA policy directives & NASA 
procedural requirements 
Trace:  HRP PRD (HRP-47052) Section 6.3 
 
3.0 Gaps, Mitigation, Deliverables, Platforms, and Responsibility 
The following gaps associated with the 4 major Space Radiation risks are a culmination of gaps identified 
through the Bioastronautics Roadmap Development, National Academy of Science - Institute of Medicine 
Review, National Council for Radiation Protection Reviews, Recommendations and Reports, Radiation 
Discipline Working Group advisory panel recommendations, annual Radiation PI workshops, and the Sept '06 
Discipline Review.  Note that timeframes/schedules associated with implementation of this Research Plan are 
found in Appendix A. 
 
3.1. Radiation Carcinogenesis 
 
3.1.1  Priority  
 
3.1.2.1 Lunar Outpost Mission (Priority Level I) 
Important: This risk is accepted on current ISS missions. Lunar mission length is similar, but the mission is 
outside the protection of LEO. Risk still has significant uncertainty and would have to be reported as a 
significant contributor to risk of mission 
 
3.1.2.2 Mars Mission (Priority Level I) 
Important: This risk has considerable uncertainty associated with it, and would need to be reported as a 
significant contributor to the risk to a Mars mission without tightening the uncertainty bands. 
 
3.1.2  Gaps 
Gaps areas are listed in the following Table, and in Gantt chart form illustrating the expected research time-line 
in Appendix B. A narrative description of the Gaps and Gantt charts are provided below. 
 
3.1.2.1: What are the probabilities for increased carcinogenesis from space radiation as a function of NASA’s 
operational parameters (age at exposure, age, latency, gender, tissue, mission, radiation quality, and dose-rate)?  
3.1.2.2: How can tissue specific risk models be developed using human 3D cell culture or animal models for the major 
cancer sites, including lung, leukemia’s, breast, colorectal, stomach, liver, esophageal, skin, brain, and bladder? 
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3.1.2.3: How can the roles of initiation, promotion, and progression in space radiation carcinogenesis be best 
determined, and how do they influence the risk projection assumptions such as linearity, additivity, scaling, RBE, and 
DDREF? 
3.1.2.4: How can the mechanisms of cancer risk such as aberrant DNA damage processing, CA, cell cycle, extra-
cellular matrix and growth controls, genomic instability, aberrant signal transduction, epigenetic effects including 
methylation patterns, persistent oxidative damage, altered senescence, and non-targeted effects be determined? 
What surrogate endpoints results from this research? 
3.1.2.5: How can the projections of tissue specific cancer risk for simulated SPE and GCR be validated using NSRL's 
EBIS capability? 
3.1.2.6: What quantitative procedures or theoretical models are needed to extrapolate molecular, cellular, or animal 
results to determine the risks of specific cancers in astronauts? How can human epidemiology data best support these 
procedures or models? 
3.1.2.7: How can systems biology approaches be used to integrate research on the molecular, cellular, and tissue 
mechanisms of radiation damage to improve the prediction of the risk of cancer? 
3.1.2.8: How can genetic factors that contribute to individual’s sensitivity to radiation carcinogenesis be estimated? 
3.1.2.9: How can epigenetic factor that contribute to individual sensitivity to radiation carcinogenesis be estimated?  
3.1.2.10: How can the mechanisms of biomedical countermeasures for space radiation be discovered? Would 
countermeasures for low-LET radiation have similar efficiency for high-LET radiation? 
3.1.2.11: How can 3D cell culture models or animal models developed for space radiation cancer risk determination be 
extended to validate biomedical or dietary countermeasure approaches to mitigate cancer risk? What testing regime is 
required at NSRL? 
3.1.2.12: What level of cancer risk requires aggressive biomedical countermeasures? And what projection uncertainty 
in countermeasure effectiveness is required for operational use at NASA? 
3.1.2.13: How can the Risk Assessment Projects system biology models of cancer risk be used to project the likely 
effectiveness of specific biological countermeasures? 
3.1.2.14: How can 3D cell culture models or animal models developed for space radiation cancer risk determination be 
extended to be used as a biomarker approach for Exploration missions?  
3.1.2.15: Are there significant synergistic effects from other spaceflight factors (microgravity, stress, altered circadian 
rhythms, changes in immune responses, depressed nutritional, bone loss, etc.) that modify the carcinogenic risk from 
space radiation? 
3.1.2.16: Are space validation experiments needed for verifying knowledge of carcinogenic risks prior to long-term 
deep space missions, and if so what experiments should be under-taken? 
3.1.2.17: What are the most effective shielding approaches to mitigate cancer risks, how do we know, and implement? 
3.1.2.18: What level of accuracy is required of NASA’s free space environment models and radiation transport codes 
to accurately describe the radiation environments on the surface of the moon and Mars?  
3.1.2.19: What is the most effective approach to use data from robotic Mars probes on the atmospheric, soil, and 
magnetic properties of the red planet for estimating carcinogenesis risk, and designing effective shielding or biological 
countermeasures? 
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3.1.2.20: How can ISS physical and biological dosimetry data be used to validate components of transport codes and 
cytogenetic damage descriptions for exploration? 
3.1.2.21: What are the most effective approaches to integrate radiation shielding analysis codes with collaborative 
engineering design environments used by spacecraft and planetary habitat design efforts? 
 
 
3.1.3. Description of Research Approach 
 
3.1.3.1 Overview  
Near-term goals for cancer research focus on reducing the uncertainties in risk projections through the 
development of tissue specific models of cancer risks, the underlying mechanistic understanding of these 
models, and appropriate data collection at the NSRL. In the long-term extensive validation of these models with 
mixed radiation fields is envisioned and research on biological countermeasures and biomarkers will be pursued 
if needed. Research on improving cancer projections has two major emphases: 1) establishing the correctness of 
the NCRP model and 2) reducing the uncertainties in the coefficients that enter into the cancer projection model. 
Research on the validity of the NCRP model relies on studies at the NSRL observing qualitative differences in 
biological damage between HZE nuclei and gamma-rays and the establishment of how these differences relate 
to cancer risk. This research will form the basis for an approach to modify or replace the NCRP model..  
The level of tolerance in projection model uncertainties depends on the acceptable level of mortality risk (3%) 
and the projection of risk for each class of mission. Cancer projections for 40-yr females on STS, ISS, 180-day 
lunar, and Mars missions are currently estimated at about 0.01, 0.35, 0.7, and 5%, respectively. Therefore, a 
much lower tolerance can be accepted for lunar or Mars mission than mission in LEO to assure risk acceptance 
levels are not exceeded, and more accurate and mechanistic models of risk must be developed for these 
missions. This constraint leads to a major goal for research approaches followed by SRPE with uncertainties less 
than 2-fold needed for long-term lunar stays, and less than +50% for a Mars mission.  
In order to understand whether research has achieved the level of tolerance in cancer risk projections required, 
interactions between risk assessment research and biological mechanisms and data research is needed. The Gantt 
first chart in Appendix B shows a major decision point in the research plan related to assessment of uncertainty 
reduction. If sufficient uncertainty reduction is achieved in the near-term, research on biological 
countermeasures and minor tissue sites is envisioned to occur in 2014 and out.  
The Gantt charts in Appendix B describe research products and deliverables that are listed in detail below. 
Collaborative research with the DoE Low Dose Research Program is a key component of the SRPE strategy. 
The DoE program focus is on low LET irradiation; however collaborative grants are selected from proposals 
that contain one or more Specific Aims addressing NASA interests using the NSRL. This research augments 
SRPE research with a large number of grants using state-of-the art approaches including genetics, proteomics, 
and transgenic animal models. The DoE research is an important part of the SRPE goal to identify biomarkers of 
cancer risk.  
 
3.1.3.2 Biological Mechanisms & Data 
The large number of GCR nuclei type, energies, SPE doses and dose-rates, in combination with the multiple  
tissue and cancer types makes the performance of large scale animal or 3D human cell culture studies of cancer 
risk at NSRL prohibitive. Therefore a mechanistic approach is needed and has been segmented into major 
mechanistic research areas (Gaps 3.1.2.3, 3.1.2.4., and 3.1.2.5). These areas may find synergy in the types and 
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range of biological models employed, however will differ in the complicated hypothesis questions being 
addressed. Ultimately, mechanistic studies must progress to determine quantitative data sets for estimating 
probabilities for increase risk of carcinogenesis (Gap 3.1.2.1) that in conjunction with research on Risk 
Assessment models will be use to extrapolate risks from experimental model to risks in astronauts on specific 
exploration missions. 
There are distinct mechanisms of cancer induction across and within major tissue sites; thus uncertainty 
reduction requires tissue specific risk estimates (Gap 3.1.2.2). NRA and NSCOR selections focus is on current 
estimates of major sites for cancer risks, which include lung, breast, colon, stomach, esophagus, the blood 
system (leukemia’s), liver, bladder, skin, and brain. There are differences in radiation sensitivity based on 
genetic and epigenetic factors (Gaps 3.1.2.8 and 3.1.2.9) and research in these areas aids the development of 
tissue specific cancer models. Hypothesis directed studies to establish the underlying mechanisms for the risks, 
and the possibility of synergistic effects with SPE’s or other flight factors may also be considered. NRA, 
NSCOR, or joint DoE-NASA studies in this area will use state-of-the art animal models (including transgenic 
mice) and genetically engineered human cell culture models to answer a variety of questions related to the Gaps 
in biological mechanisms. These studies are critical in establishing the level of proof that underlies NASA risk 
projection models.  
As research understanding is improved, extended duration validation studies with a finite number of animal or 
3D human cell culture models using mixed fields representing GCR and SPE will be performed at NSRL using 
the existing exposure cave or potentially a new cave with improved capability for extended duration GCR 
simulations (3.1.2.5 and 3.1.2.16).  
The cancer risk related NSCOR studies are 5-year studies and allow for long-term animal or sequential 
mechanistic studies with multiple components. The current NSCOR studies may be renewed dependent on 
progress and review findings.  
 
3.1.3.3 Risk Assessment 
The SRPE approach to uncertainty reduction is based on studying the current model NASA uses as model 
recommended by the NCRP for projecting cancer incidence and mortality risks for space missions. This model 
employs the double-detriment life table for calculating the risk of radiation induced cancers against the 
background of cancers in the general population and competing mortality risks. The cancer rate (Hazard 
function) is the key quantity in the evaluation; representing the probability at a given age and years since 
exposure of observing a cancer. The NCRP model assumes the cancer incidence or mortality rate is scalable to 
human epidemiology data for gamma-rays using a linear-energy transfer dependent radiation quality factor, 
Q(LET), and a dose and dose-rate reduction factor (DDREF). Other assumptions in the model are made with 
regard to the transfer of risk across populations, the use of average rates for the US population, the age and age-
after exposure dependence of risk on radiation quality and dose-rate, etc. These models will be updated as new 
data from biological mechanism and data are obtained as described by Gap 3.1.2.6. 
Systems biology models provide a framework to integrate mechanistic studies of cancer risk across multiple 
levels of understanding (molecular, cellular, and tissues), and are the most likely approach to replace the NCRP 
model. Systems biology models are being developed by the Risk Assessment Project and several NSCOR’s, and 
in conjunction with data collection will improve the descriptions of cancer risk and to lay a framework for future 
biological counter-measure evaluations and biomarker identification (Gap 3.1.2.7). 
 
3.1.3.3  Shielding Physics & Dosimetry 
The evaluation of radiation shielding effectiveness for GCR is currently hindered by data on radiation quality 
effects and the shape of the dose-response curve for cancer induction. However, controlling secondary neutron 
components through material selections and developing computer tools for shielding evaluations is a near-term 
focus for spacecraft design applications as carried out by the Design Tools project under Gap 3.1.2.17 and 
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3.1.2.21. A goal of the Design Tools project is to provide fast and reliable tools for optimization in support of 
engineering shielding designs. Radiation physics improvements will be developed in support of these analysis 
efforts (Gap 3.1.2.18) Space radiation dosimetry will be advanced through NSBRI efforts on fast, reliable tissue 
equivalent or silicon based technologies (Gap 3.1.2.20). SRPE will also support tasks that integrate data from 
lunar or Martian robotic probes to improve analysis capabilities (Gap 3.1.2.19)  
 
3.1.3.4  Biological Countermeasures 
The long-term phase of research will likely involved research on biological counter-measure (BCM) evaluation, 
however is a lower priority in the current phase of the program for three reasons: 1) The uncertainties in cancer 
projections prevent the evaluation of the need for BCM. 2) An improved understanding of the mechanisms of 
cancer risk is needed to be able to extrapolate results from BCM studies in experimental models to astronauts on 
exploration missions, and 3) identify effective surrogate markers to perform testing of potential BCMs. Research 
related to Gaps 3.1.2.10, 3.1.2.11, to 3.1.2.12 will evolve from new knowledge gained from biological 
mechanisms and risk assessment research. Current NRA studies with anti-oxidants and related agents may be 
expanded to target specific molecular pathways and tissues, which make the largest contribution to cancer risks. 
Cell and animal models and appropriate endpoints will be identified and combined with new systems biology 
tools to obtain quantitative projections of BCM effectiveness for astronauts in specific exploration missions.  
 
3.1.4 Activities to mitigate the gaps: 
• Peer-reviewed and directed research (in coordination with ops) 
• Integration of research results into Risk Assessment Tool / Design Tool 
 
3.1.5  Product/Deliverables/Milestones: 
• PI annual/final reports and peer-reviewed journal articles 
• Updated R/A Model for lunar missions  (Customer SOMD) Sept 2010  
– (will support both short and long mission trade studies prior to SRR) 
• Updated Recommendations on Human System Standards and PELs for lunar radiation 
environment.  (Customer OCHMO) Feb 2011  
– (approximately 1 year prior to LSAM SRR)  
• Provide scientific basis and recommendations on radiation protection requirements for short 
duration lunar missions (input to SRR). Customer: Constellation   Dec 2011 
– (6 mos prior to LSAM SRR) 
• Updated Recommendations on Human System Standards and PELs for lunar radiation environment  
(Customer OCHMO)   Sep 2014 
–  (or approximately 1 year prior to LSH SRR) 
• Provide scientific basis and recommendations on radiation protection requirements for long duration 
lunar missions (input to SRR). (Customer: Constellation)   June 2014  
– (6 mos prior to LSH SRR) 
• Updated Risk Assessment Model for long duration lunar stays (Customer: RHO, SOMD)  Sept 2015  
– (approx. 12-18 mos. prior to LSH PDR) 
• Baseline enhanced computational design tools for vehicle design assessment (Customer SOMD) March 
2010  
– (will support both short and long mission trade studies prior to SRR) 
• Enhanced Phase C/D Simulation Tool source code and documentation  (Customer: SOMD)  March 
2012  
– (Supports mission ops SRR and PDR) 
87 
 HRP-47065 
• Final Validated & Verified Transport code (Phase II completion) 2014  (Customer SRPE R/A and Design 
Tool) 
– (supports Mars Architecture trade studies and identification pre-cursor needs) 
• Countermeasure delivery  (Customer SOMD)  ~2014 and subsequent years  
• Support LAT and MAT as required 
 
3.1.6  Required Platforms: 
• NASA Space Radiation Lab (NSRL); 
• Mars Robotic Precursor mission/MSL-RAD  (Mars2009 & 2017 for solar min) 
• ISS (existing nominal ops (MRID) and measurement data) (i.e. NOT research/experimental) 
 
3.1.7  Project/Organization Responsible for Implementation of Activity: 
• SRPE 
– Via NRAs, NSCORs, NASA-DoE Collaborative Research 
 
3.2 Acute and Late Risks to the CNS 
 
3.2.1  Priority  
 
3.2.1.1 Lunar Outpost Mission (Priority Level I) 
Important: This risk is accepted on current ISS missions. Lunar mission length is similar, but the mission is 
outside the protection of LEO. Risk still has significant uncertainty and would have to be reported as a 
significant contributor to risk of mission. 
 
3.2.1.2 Mars Mission (Priority Level I) 
Important: This risk has considerable uncertainty associated with it, and would need to be reported as a 
significant contributor to the risk to a Mars mission without tightening the uncertainty bands. 
 
3.2.2  Gaps 
Gaps areas are listed in the following Table, and in Gantt chart form illustrating the expected research time-line 
in Appendix B. A narrative description of the Gaps and Gantt charts are provided below. 
 
3.2.2.1: Is there a significant probability that space radiation would lead to immediate or acute functional changes in 
the CNS due to a long-term space mission and if so what are the mechanisms of change? Are there threshold doses 
for these effects?  
3.2.2.2: Is there a significant probability that space radiation exposures would lead to long-term or late degenerative 
CNS risks if so what are the mechanisms of change?  
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3.2.2.3: How does individual susceptibility including hereditary pre-disposition (Alzheimer’s, Parkinson’s, apoE) and 
prior CNS injury (concussion or other) alter significant CNS risks? Does individual susceptibility modify possible 
threshold doses for these risks in a significant way?  
3.2.2.4: What are the most effective biomedical or dietary countermeasures to mitigate CNS risks? By what 
mechanisms are the countermeasures likely to work? 
3.2.2.5: How can new knowledge and data from molecular, cellular, tissue or animal models of acute CNS risks, 
including altered motor and cognitive function and behavioral changes be used to provide significant data for 
estimating estimate space radiation risks to astronauts? 
3.2.2.6: How can new knowledge and data from molecular, cellular, tissue or animal models of late CNS risks, 
including loss of neurons, altered morphology, role of neuronal and non-neuronal cells, integrated cellular responses, 
and damage to the vasculature, be best used to efficiently and accurately estimate potential risks to astronauts? 
3.2.2.7: Does chronic space radiation exposures or SPE exposure result in significantly increased cell death 
(apoptosis and necrotic) and if so what are the molecular and cellular pathways and, if so are there any functional 
consequences? 
3.2.2.8: What quantitative procedures or theoretical models are needed to extrapolate molecular, cellular, or animal 
results to predict CNS risks in astronauts? How can human epidemiology data best support these procedures or 
models? 
3.2.2.9: What are the best shielding approaches to protect against CNS risks, and are shielding approaches for CNS 
and cancer risks synergistic?  
3.2.2.10: Are space validation experiments needed for verifying knowledge of CNS risks prior to long-term deep space 
missions, and if so what experiments should be under-taken? 
3.2.2.11 Are there significant CNS risks from combined space radiation and other physiological or space flight factors 
(e.g., bone loss, microgravity, immune-endocrine systems or other)? 
3.2.2.12: How can the individual’s sensitivity to radiation induced CNS damage be estimated? 
 
3.2.3 Description of Research Approach 
CNS risks from GCR are a concern due to the possibility of single HZE nuclei traversals causing tissue damage 
as evidenced by the light-flash phenomenon first observed during the Apollo missions. Also, as survival 
prognosis for patients irradiated for brain tumor treatment has improved, patients have shown persistent CNS 
changes at long times after treatment with gamma-rays suggesting a possible CNS risk for a large SPE. 
Furthermore, animal studies of behavior and performance with HZE radiation suggest detrimental changes may 
occur during long-term GCR exposures. Currently, there is no projection model for CNS risks of concern to 
NASA. Research at NSRL is using a variety of animal and cellular models to study the dose and radiation 
quality dependence of CNS risks. The extrapolation of model data to astronauts will be the major focus of CNS 
research in the immediate future. 
The Gantt charts in Appendix B describe research products and deliverables for the CNS risks that are listed in 
detail below.  
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3.2.3.1 Biological Mechanisms & Data 
A critical question for the current phase of research is to establish possible threshold doses for specific CNS 
risks. It is likely that although acute CNS risks occur only above a dose threshold (Gap 3.2.2.1), and that the 
lifetime risks for CNS diseases, such as Alzheimer’s, will  have a distinct dose dependence with the additional 
questions related to latency to disease of primary interest (Gap 3.2.2.2). The values of possible thresholds for 
CNS risks and knowledge on how to extrapolate possible thresholds to individual astronauts will be a key 
milestone in the long-term research plan.  An important component of this research is to factor the variation of 
CNS risk with genotype or other CNS injury (Gaps 3.2.2.3 and 3.2.2.12). A variety of mechanisms must be 
understood including the roles of neurodegeneration, inflammation, micro-vasculature damage, and changes to 
specific neuron-chemical pathways. These research areas will have overlaps in usage of NSRL, and potential 
animal or cellular models employed, however individual NRA or NSCOR projects will pursue distinct 
hypothesis driven research questions leading to distinct endpoints and biological assays. Hypothesis directed 
studies to establish the underlying mechanisms for the risks (Gap 3.2.2.7), and the possibility of synergistic 
effects with SPE’s or other flight factors will also be considered (Gaps 3.2.2.7 and 3.2.211). 
The CNS risk related NSCOR study is a 5-year study allowing for long-term animal or sequential mechanistic 
studies with multiple components. The current CNS NSCOR may be renewed dependent on progress and review 
findings. 
 
3.2.3.2 Risk Assessment 
Research approaches are establishing the biochemistry of CNS impacts by HZE nuclei. Since projection based 
on scaling to human data as done for cancer risk is not possible, a systems biology approach for individual CNS 
risks may be needed to form a basis for animal to human extrapolation, and will rely on understanding of 
biochemical changes in the CNS caused by space radiation (Gap 3.2.2.5 and 3.2.2.6, and 3.2.2.8). In the long-
term research on validation of models may be required (3.2.2.10). This area is under review by the NCRP. 
Because of the large number of GCR nuclei types and energies, comprehensive studies under mixed-field SPE 
or GCR simulation conditions for extended time periods (hours to a few weeks) may be needed at NSRL. 
Extended duration studies will be useful in addressing SRPE gaps in synergistic risks from other spaceflight 
factors and radiation damage to the CNS.  
 
3.2.3.3  Biological Countermeasures 
Biological countermeasure and biomarker research for CNS risks is a lower priority in the near-term research 
strategy until the nature and magnitude of the CNS risk is more firmly established. Several studies on oxidative 
damage and anti-oxidants are supported. The future level of need for BCM research will be driven by the levels 
of risk are determined such risk may be transition to become a major long-term focus. It is expected that the 
mechanistic understanding acquired from near-term research will set the course for effective countermeasures 
approaches in the future as needed (Gap 3.2.2.4).  
 
3.2.3.4  Shielding Physics 
The development of new biological understanding of CNS risks will determine if shielding protection for CNS 
is distinct from other shielding approaches to other radiation risks. Preliminary assessments suggest HZE nuclei 
with Z>10 or slow neutrons may be a higher relative concern for CNS than other risks, and may place more 
emphasis on shielding these components (Gap 3.2.2.9).  
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3.2.4 Activity: 
− Peer-reviewed and directed research (in coordination with ops) 
− Integration of research results into Risk Assessment Tool 
 
3.2.5 Product/Deliverables/Milestones:  
• PI annual/final reports and peer-reviewed journal articles 
• Updated Recommendations on Human System Standards and PELs for lunar radiation environment.  
(Customer OCHMO) Charter Feb 2011  
– (approximately 1 year prior to LSAM SRR)  
• Provide scientific basis and recommendations on radiation protection requirements for short 
duration lunar missions (input to SRR). Customer: Constellation  Dec 2011  
– (~6 mos prior to LSAM SRR) 
• Updated Recommendations on Human System Standards and PELs  for lunar radiation 
environment. Sep 2014   
– (~approximately 1 year prior to LSH SRR) 
• Provide scientific basis and recommendations on radiation protection requirements for long duration 
lunar missions (input to SRR). Customer: Constellation June 2014 –  
– (~6 mos prior to LSH SRR) 
• Updated Risk Assessment Model for long duration lunar stays (Customer: RHO, SOMD)  Sept 2015  
– ( ~ approx. 12-18 mos. prior to LSH PDR) 
• Countermeasure delivery   (Customer SOMD)  ~2020 and subsequent years  
 
3.2.6 Required Platforms: 
• NASA Space Radiation Lab (NSRL); 
 
3.2.7 Project/Organization Responsible for Implementation of Activity: 
• SRPE 
– Via NRAs, NSCORs, NASA-DoE Collaborative Research 
 
3.3  Degenerative Risks 
 
3.3.1  Priority  
 
3.3.1.1 Lunar Outpost Mission (Priority Level I) 
Important: This risk is accepted on current ISS missions. Lunar mission length is similar, but the mission is 
outside the protection of LEO. Risk still has significant uncertainty and would have to be reported as a 
significant contributor to risk of mission. 
 
3.3.1.2 Mars Mission (Priority Level I) 
Important: This risk has considerable uncertainty associated with it, and would need to be reported as a 
significant contributor to the risk to a Mars mission without tightening the uncertainty bands. 
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3.3.2 Gaps 
Gaps areas are listed in the following Table, and in Gantt chart form illustrating the expected research time-line 
in Appendix B. A narrative description of the Gaps and Gantt charts are provided below. 
 
3.3.2.1: What are the probabilities for specific degenerative tissue risks from SPE and GCR as a function of NASA’s 
operational parameters (age at exposure, age and time after exposure, gender, tissue, mission, radiation quality, 
dose-rate)? 
3.3.2.2: How can tissue specific risk models be developed using human 3D cell culture or animal models for the major 
degenerative tissue sites, including heart, circulatory, endocrine, digestive, lens and other tissue systems?  
3.3.2.3: What are the mechanisms of degenerative tissues risks in the heart, circulatory, endocrine, digestive, lens 
and other tissue systems? What surrogate endpoints do they suggest? 
3.3.2.4: What are the progression rates and latency periods for degenerative risks, and how do progression rates 
depend on age, gender, radiation type, or other physiological or environmental factors 
3.3.2.5: How can the projections of tissue specific degenerative risk for simulated SPE and GCR be validated using 
NSRL's EBIS capability? 
3.3.2.6: What quantitative procedures or theoretical models, including systems biology approaches,  are needed to 
extrapolate molecular, cellular, or animal results to predict degenerative tissue risks in astronauts? How can human 
epidemiology data best support these procedures or models?  (e.g. Are there unique degenerative risks that only 
occur for the high LET components of GCR and SPE (high charge and energy nuclei, proton and helium stoppers, or 
neutrons) leading to infinite RBE and other difficulties in risk models? ) 
3.3.2.7: What are the most effective biomedical or dietary countermeasures to degenerative tissue risks? By what 
mechanisms are the countermeasures likely to work? (post PPBE) 
3.3.2.8: Will countermeasures for cancer, CNS, and degenerative risks be additive, synergistic or antagonistic to each 
risk? 
3.3.2.9: Are there significant synergistic effects from other spaceflight factors (microgravity, stress, altered circadian 
rhythms, changes in immune responses, etc.) that modify the degenerative risk from space radiation? 
 
3.3.3  Description of Research Approach 
Cataracts have long been a research focus of SRPE. More recently several epidemiological studies, including 
results from the atomic-bomb survivors and nuclear reactor workers, have identified a significant risk of stroke 
and coronary heart disease (CHD) for low LET radiation at doses comparable to those of an extended lunar 
mission or a Mars mission, or a short-duration lunar mission incurring a large SPE. Because the risk of heart 
disease is a recent finding, preliminary SRPE studies in these areas are seeking to establish possible distinctions 
in mechanisms for this risk between protons and HZE nuclei and gamma-rays. Furthermore, SRPE will take 
advantage of studies supported by the European Union in this area, which is supporting large scale mouse 
studies of CHD. These studies should present new insights into the nature of the low LET (gamma-ray) risk at 
low dose-rates comparable to space conditions, and identify appropriate mouse strains to be used in future SRPE 
studies. 
The Gantt charts in Appendix B describe research products and deliverables for the Degenerative Risks that are 
listed in detail below. Timelines to begin research on BCM for the Degenerative Risks are dependent on 
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progress in Cancer and CNS research within the current SRPE research prioritization plans, and perhaps on the 
findings of the initial biological mechanisms research phase of the research plan. 
 
3.3.3.1 Biological Mechanisms & Data 
Preliminary assignments of PEL’s for Degenerative risks have been assigned based on human epidemiology 
data for gamma-ray or x-ray irradiation. Cell or animal models of degenerative risks will be developed and 
applied to determine the mechanisms for degenerative risks and to determine appropriate risk assessment data 
for models including relative biological effectiveness and dose-rate dependencies for different space radiation 
ions at NSRL. In the near-term NRA research will support a small number of studies on heart and lens risks. A 
long term-focus will be to support an NSCOR in this area in 2014 and beyond. As mission duration increases 
there could be degenerative risks to other tissues related to digestive diseases and pulmonary changes that 
become a concern. A long-term goal will be to consider such possible changes in animal validation studies made 
at a possible extended duration GCR facility developed at NSRL in the future. The NASA Study of Cataracts in 
Astronauts (NASCA) is collecting valuable data on the incidence and progression rates of cataracts in over 230 
current or retired astronauts.  
 
3.3.3.2  Risk Assessment 
Risk assessment models for cataract risk will be developed (Gap 3.3.2.6) through biophysical models of new or 
existing radiobiology data. New models for other degenerative risks will be developed after studies of biological 
mechanism and data research have matured.  
 
3.3.3.3 Biological Countermeasures 
An increased risk of cataracts associated with low dose space radiation from past NASA Missions has been 
reported and is being followed up with a clinical study (NASCA) of cataract progression rates in current or 
retired astronauts. Several NSRL studies of cataract risks are supported to improve the understanding of how 
proton and HZE nuclei induce cataracts, and to identify possible countermeasure approaches. The NASCA study 
and NSRL research will be used by the Risk Assessment Project to project cataract risks for specific space 
missions. Research on BCMs (Gap 3.3.2.7) for other degenerative risks is envisioned after studies of biological 
mechanism and data research have matured. 
 
3.3.4 Activity: 
− Peer-reviewed and directed research 
− Integration of research results into Risk Assessment Tool  
 
3.3.5 Product/Deliverables/Milestones: 
• PI annual/final reports and peer-reviewed journal articles 
• Updated R/A Model for lunar missions.  Charter  Sept 2010 
– (will support both short and long mission trade studies prior to SRR) 
• Updated Recommendations on Human System Standards and PELs for lunar radiation environment.  
(Customer OCHMO) Charter Feb 2011  
– (~ approximately 1 year prior to LSAM SRR)  
• Provide scientific basis and recommendations on radiation protection requirements for short 
duration lunar missions (input to SRR). Customer: Constellation Dec 2011 
– (~6 mos prior to LSAM SRR) 
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• Updated Recommendations on Human System Standards and PELs  for lunar radiation 
environment. Sep 2014 
– (~approximately 1 year prior to LSH SRR) 
• Provide scientific basis and recommendations on radiation protection requirements for long duration 
lunar missions (input to SRR). Customer: Constellation June 2014 
– (~6 mos prior to LSH SRR) 
• Updated Risk Assessment Model for long duration lunar stays (Customer: RHO, SOMD) Sept 2015 
–  ( ~12-18 mos. prior to LSH PDR) 
• Countermeasure delivery   (Customer SOMD)  ~2015 and subsequent years  
 
3.3.6 Required Platforms: 
• NASA Space Radiation Lab (NSRL); 
• Note:  next generation TEPC will require ISS validation 2010-2012 but this phase is NOT part of the 
SRPE scope – handed off to ops with minimal oversight from SRPE) 
 
3.3.7 Project/Organization Responsible for Implementation of Activity: 
• SRPE  
-  Via NRAs, NSCORs, NASA-DoE Collaborative Research 
 
3.4 Acute Radiation Syndromes 
 
3.4.1  Priority  
 
3.4.1.1 Lunar Outpost Mission (Priority Level I) 
Important: This risk is accepted on current ISS missions. Lunar mission length is similar, but the mission is 
outside the protection of LEO. Risk still has significant uncertainty and would have to be reported as a 
significant contributor to risk of mission. 
 
3.4.1.2 Mars Mission (Priority Level I) 
Important: This risk has considerable uncertainty associated with it, and would need to be reported as a 
significant contributor to the risk to a Mars mission without tightening the uncertainty bands. 
 
3.4.2  Gaps 
Gaps areas are listed in the following Table, and in Gantt chart form illustrating the expected research time-line 
in Appendix B. A narrative description of the Gaps and Gantt charts are provided below. 
 
3.4.2.1: What are the probabilities or RBE’s for various acute effects from the GCR and SPE’s? 
3.4.2.2: How can the dose-rate modifying factors for acute risks of concern be determined from experimental model 
systems? 
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3.4.2.3: What are the molecular, cellular and tissue mechanisms of acute radiation damage (DNA damage processing, 
oxidative damage, cell loss through apoptosis or necrosis, cytokine activation, etc.)? 
3.4.2.4: What quantitative procedures or theoretical models are needed to extrapolate molecular, cellular, or animal 
results to predict acute radiation risks in astronauts? How can human epidemiology data best support these 
procedures or models? 
3.4.2.5: Are their synergistic effects arising from other spaceflight factors (microgravity, stress, immune status, bone 
loss, etc.) that modify acute risks from space radiation including modifying thresholds for such effects? (post PPBE) 
3.4.2.6: Does long-term exposure to GCR modify acute doses from a SPE’s in relationship to acute radiation 
syndromes? 
3.4.2.7 Does immune depression from a high skin dose or loss of granulocytes in the GI-tract impact the risk of 
significant depletion of the blood system from a SPE?  
3.4.2.8: What are the most effective biomedical or dietary countermeasures to mitigate acute radiation risks? By what 
mechanisms are the countermeasures likely to work?  How can the effectiveness of countermeasures developed on 
Earth be estimated for exposure of astronauts to a large SPE in deep space, or the lunar or Mars surface?  
3.4.2.9: What are the optimal SPE alert and dosimetry technologies for EVAs?  
3.4.2.10: What are the most effective shielding approaches to mitigate acute radiation risks, how do we know, and 
implement? 
3.4.2.11:  What are the probabilities of hereditary, fertility, and sterility effects from space radiation? 
3.4.2.12: How can probabilities of acute space radiation events be improved? 
 
3.4.3  Description of Research Approach 
 
There are a variety of acute radiation syndromes of concern following a large SPE exposure. Through careful 
evaluation of SPE frequency and size probabilities, dose-rates, and likely shielding conditions, and dose 
distribution at specific organs, the SRPE Risk Assessment Project has determined that the likelihood of acute 
risks IVA is extremely small, however there are scenarios during lunar or trans-lunar or Mars EVA’s where 
acute radiation sickness may occur. Radiation sicknesses, i.e., the prodromal risks, include the risks of nausea, 
vomiting, diarrhea, and fatigue. These effects are manifested at about 4 to 24 hours post-exposure for exposures 
at sub-lethal doses with a latency time inversely correlated with dose.  Furthermore, albeit the possibility of 
acute death through the collapse of the blood forming organs (BFO) is negligible, there is a reasonable concern 
of a compromised immune system due to high skin doses from a SPE leading to burns, which could increase the 
risk to the BFO. 
In the long-term the SRPE will consider research on fertility, sterility, and hereditary risks from space radiation, 
and may request the NSBRI support these areas because of their unique nature from other risk areas (3.4.2.11).  
The Gantt charts in Appendix B describe research products and deliverables for Acute risk research that are 
listed in detail below.  
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3.4.3.1 Biological Mechanisms and Data 
Research on acute risks related to EVA conditions must factor in the role of dose-rate over an EVA time course, 
the additional exposure IVA for a terminated EVA, and other spaceflight factors that could modify expected 
dose response models for acute risks.  Animal and cell culture models appropriate for these acute risks will be 
used in the research to study protons effects at various doses, dose-rates, and proton energies including 
simulation of solar particle event spectra (Gaps 3.4.2.1 and 3.4.2.2) including mechanistic studies (Gap 3.4.2.3). 
A research emphasis on the role of the immune system and possible synergistic effects on acute risks are needed 
(Gaps 3.4.2.4, and 3.4.2.6). This area is under review by the NCRP. Because acute risks are manifested soon 
after exposure and there is an existing data based on gamma-ray induced risks, the research is expected to be 
completed in about a 5-year period by the NSBRI team. 
3.4.3.2 Risk Assessment 
The Risk Assessment Project has developed acute radiation risk models using a logistic scoring approach and is 
modifying these models to account for proton and secondary radiation biological effectiveness data. These 
models will be updated with results from the proposed NSBRI research team when available. A graphical user 
interface (GUI) of the resulting model will be developed and tested for use in an operational setting (Gap 
3.4.2.4). Probabilistic models of SPE are being developed by the Risk Assessment project and in coordination 
with new results from SMD (Gap 3.4.2.12) 
 
3.4.3.3  Shielding Physics & Dosimetry 
Optimization of radiation shielding, dosimetry, and alert approaches is supported with operational research in 
these areas by both SRPE (Design Tools and Risk Assessment Projects) and the NSBRI, and in collaboration 
with Space Mission Directorate (SMD) Living with the Star Program (Gap 3.4.2.9). The Design Tools project 
will develop tools to minimize shielding mass during vehicle design, and the Risk Assessment project will 
develop probabilistic models appropriate for acute risk protection for mission planning purposes. The 
development of reliable, lightweight EVA dosimetry is a goal of the research (Gap 3.4.2.10).  
 
3.4.3.4 Biological Countermeasures 
The important distinctions in the types of biological models, possible BCMs, and exposure conditions between 
acute, and the risks of cancer, CNS, and degenerative risks suggests a unique approach. Therefore, the SRPE has 
requested the NSBRI form a focus team in this area. This team will pursue research on the mechanisms of acute 
radiation risks and possible BCM development. Studies from radiation oncology of anti-nausea drugs will be 
considered as well as existing drugs used in spaceflight. The role of synergisms of radiation and other space 
related insults will be an important thrust of this research.  
 
3.4.4 Activity: 
− Peer-reviewed and directed research (in coordination with ops) 
− Integration of research results into Risk Assessment Tool  
 
3.4.5  Product/Deliverable/ Milestones:  
• PI annual/final reports and peer-reviewed journal articles 
• Updated R/A Model for lunar missions.  (Customer: RHO, SOMD)   Sept 2010  
– (will support both short and long mission trade studies prior to SRR) 
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• Updated Recommendations on Human System Standards and PELs for lunar radiation environment.  
(Customer OCHMO) Charter Feb 2011  
– (~approx. 1 year prior to LSAM SRR)  
• Provide scientific basis and recommendations on radiation protection requirements for short 
duration lunar missions (input to SRR). Customer: Constellation  Dec 2011 
– (~ 6 mos prior to LSAM SRR) 
o Updated Recommendations on Human System Standards and PELs  for lunar radiation environment. 
Sep 2014 (C)  
– (~approximately 1 year prior to LSH SRR) 
• Provide scientific basis and recommendations on radiation protection requirements for long duration 
lunar missions (input to SRR). Customer: Constellation  June 2014 
– (~ 6 mos prior to LSH SRR) 
• Updated Risk Assessment Model for long duration lunar stays (Customer: RHO, SOMD)  Sept 2015  
– ( ~12-18 mos. prior to LSH PDR) 
• Baseline enhanced computational design tools for vehicle design assessment. Charter March 2010  
– (will support both short and long mission trade studies prior to SRR) 
• Enhanced Phase C/D Simulation Tool source code and documentation  (Customer: SOMD)  
  CONTROLLED March 2012 (Supports mission ops SRR and PDR) 
• Countermeasure delivery (Customer SOMD)  ~2014 and subsequent years  
• Support delivery of Next Gen TEPC DTO Flight Unit for ISS ~ Jun 2010  
 
3.4.6 Required Platforms: 
• NASA Space Radiation Lab (NSRL); 
 
3.4.7 Project/Organization Responsible for Implementation of Activity: 
• SRPE & NSBRI 
– Via NRAs, NSCORs, NASA-DoE Collaborative Research 
 
4.0 Background 
NASA is concerned with the health risks for astronaut exposures to Galactic Cosmic Rays (GCR) and Solar 
Particle Events (SPE). GCR exposures occur at low fluence rates with each cell being traversed by a proton 
about every three days, helium nuclei once every few weeks, and high charge and energy (HZE) nuclei about 
once every few months. These fluence rates correspond to tissue doses or effective dose-rates of about 0.4-0.8 
mGy/d and 1-2.5 mSv/d, respectively. SPE’s are low to medium energy protons with smaller components of 
helium and heavy nuclei. SPE dose-rates are variable over the course of a SPE varying between 0-100 mGy/hr 
inside a vehicle and between 0-500 mGy/hr if an astronaut is exposed during extra-vehicular activity in deep 
space or on the surface of the moon. SPE dose-rates may also vary several-fold between tissue sites because of 
the variable energy spectra of the protons or other nuclei. 
For the particles composing space radiation, energy deposition is highly localized along the trajectory of each 
particle with lateral diffusion of energetic electrons (delta-rays) away from the nuclei’s path. Delta-rays from 
HZE nuclei and protons traverse each cell in space about once per day. This high rate of energy deposition per 
unit length of trajectory is the Linear Energy Transfer (LET). The unit generally used in radiobiology for LET is 
the kilo-electron volt per micrometer, or keV/μm. The LET of charged particles changes as a function of the 
particle velocity or kinetic energy. As the velocity (or the energy) of a particle increases, the LET decreases to a 
minimum near a velocity of approximately 95% of the speed of light; at higher energies the LET increases very 
slowly. High-energy charged particles lose energy when they traverse any material. As they slow down, the LET 
increases to a maximum and then very rapidly decreases to zero. The low energy maximum in LET occurs very 
97 
 HRP-47065 
close to the point where the charged particle loses its remaining energy and stops. Nuclear fragmentation and 
other nuclear interactions, including projectile fragmentation of the primary ion and target fragmentation of 
tissue constituents, occur as ions traverse tissue. For proton and HZE irradiation, target fragmentation, including 
secondary neutrons, introduces a high LET component into the radiation field. 
The understanding of the countermeasures (including shielding) to space radiation risks is hindered at this time 
because the large uncertainties in risk projection models indicate a lack of mechanistic understanding and data 
for assessing the need or effectiveness of countermeasures for specific space missions. GCR nuclei of average 
energy can penetrate a substantial thickness of materials, on the order of 10’s to 100’s of cm’s of water or 
aluminum. If they suffer nuclear interactions, the lighter secondary products will lose energy at a lower rate, and 
therefore will be able to penetrate even further. For this reason, it is not possible to provide sufficient material to 
fully absorb all types of radiation in space. In addition, the relative biological effectiveness (RBE) of radiation 
will change as a function of depth of penetration, because the composition of the particles changes and because 
the LET of each particle changes as it loses energy and slows down inside the material. Inaccuracies in risk 
assessment models prevent the proper evaluation of shielding material selection and reduce the ability of NASA 
to apply benefit analyses to shielding evaluations. Biological countermeasures including dietary antioxidants are 
expected to provide risk reduction for low LET radiation delivered at high dose and dose-rate; however their 
effectiveness at low dose-rates and for high LET radiation is less clear. Understanding the mechanisms of 
oxidative damage and its possible reduction through the use of anti-oxidants is a goal of space radiation 
research. Mechanistic studies of possible biochemical routes for countermeasure actions must be combined with 
approaches to extrapolate model system results to humans for such countermeasures to be used operationally by 
NASA. For these reasons, NASA’s current research program endeavors to establish the scientific basis for the 
model to human risk extrapolation problem in order to firmly establish the level of need for biological 
countermeasures and, if needed, to develop methods to properly assess the effectiveness of such 
countermeasures and their interactions with countermeasures developed for other non-radiation risk areas.  
Radiobiological studies have been conducted using x- or gamma-rays as standards of comparison because of the 
availability of human data for these radiation types. High-LET particles generally require a lower dose than 
gamma-rays to induce a given observable biological effect. The quantity used to describe this is the Relative 
Biological Effectiveness (RBE), which is equal to the ratio of the (generally higher) gamma-ray dose to the 
(generally lower) particle dose resulting in the same endpoint. For a multitude of radiation endpoints, the RBE 
varies significantly as a function of LET. The RBE peaks in the neighborhood of approximately 100 keV/μm, 
reflecting the optimal energy deposition in sensitive targets within cells or tissues. The RBE versus LET relation 
branches for ions with identical LET but distinct charge numbers (or velocity), and ions with smaller charge 
number have a higher value of RBE’s at a fixed value of LET. Above the RBE versus LET peak for a given 
charge number, the effectiveness for most endpoints again decreases, due to the fact that further energy 
deposition in the damaged sites is wasted once a particular endpoint has been achieved. 
The characterization of radiation quality in terms of RBE is widely used to describe biological response to 
radiation, but may ignore qualitative differences in biological effects between different types of radiation. RBE 
is also the basis for the regulatory approach that specifies Quality Factors patterned after the LET dependence of 
RBE. Nevertheless, it is limited to biological endpoints for which a significant response to gamma-rays can be 
obtained. When this is not the case, the ensuing very large values of RBE (“infinite RBE”) may be due to the 
lack of efficacy of gamma-rays rather than a particularly effective aspect of the high-LET radiation. For some 
endpoints in tissue, including carcinogenesis, Excess Relative Risk (ERR) or excess additive risk (EAR) may be 
used as the basis for comparing risks to spontaneous or gamma-ray risks, and additional information on the time 
dependence of these quantities may be obtained, which is valuable for risk assessment. For cancer risk 
projections, mortality or incidence rates are scaled to available human data for low LET radiation using RBE’s 
or excess relative risk or excess additive risk derived from experimental models. The mechanisms and biological 
effects associated with high-LET radiation also may be different from those attributable to gamma-rays for the 
same, or similar, macroscopic endpoints. For example, an observation of reduced latency of disease with 
increasing LET would not be described using RBE values. For these and other reasons, the description of 
radiation action is not complete without an understanding of the processes leading to an observed result. 
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Dose and Dose-rate Reduction Effectiveness Factors (DDREF’s) are used to reduce the risk coefficients derived 
from acute gamma-ray epidemiology data, largely based on the study of the atomic-bomb survivors, to low 
dose-rate exposure conditions. This approach introduces the uncertainties for gamma-ray exposures at low dose-
rates into risk estimates for protons and HZE nuclei. At the present time a universal DDREF value is applied to 
all solid cancers and a distinct approach used for leukemia’s. For large solar particle events intermediate dose-
rates are of concern (>50 mGy/hr). The use of the DDREF under these conditions is not warranted and an 
alternative approach is needed. For potential CNS and degenerative tissue risks, human epidemiology data are 
limited and new approaches to risk assessment will be needed to provide quantitative risk assessment. NASA is 
seeking information to determine risk limits for protons and HZE ion induced early or late CNS effects and is 
imposing conservative CNS limits for lunar missions because of concern for these risks. 
Research focus includes: Cancer Risk Estimation including understanding possible differences in the spectrum 
of tumors induced for low- vs. high-LET radiation and targeted studies on cancers of the GI Tract (colon, 
stomach); understanding the risk of non-cancer, non-CNS degenerative tissue disease; understanding the dose 
and dose rate effect for the identified risks; improved methods for extrapolation of cellular and animal 
mechanisms to human risk; and determining the importance of non-targeted effects especially on spacecraft 
shielding evaluations  The requirement is to develop an understanding of the mechanisms of radiation damage; 
increasing the dependency on biological mechanisms and individual genetics, thus reducing dependency on 
epidemiology data and ultimately reducing the uncertainty in risk projections.  
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5.0 Acronyms 
BCM Biological Countermeasure 
BFO Blood Forming Organs 
CHMO Chief Health And Medical Officer 
CNS Central Nervous System 
DDREF Dose and Dose-Rate Reduction Effectiveness Factor 
DoE Department of Energy 
EBIS Electron Beam Injector Source  
ERR Excess Relative Risk 
GCR Galactic Cosmic Rays 
HZE High Charge and Energy 
LAT Lunar Architecture Team 
LET Linear Energy Transfer 
MAT Mars Architecture Team 
NCRP National Council on Radiation Protection and Measurements 
NRA NASA Research Announcement 
NRC National Research Council 
NSCOR NASA Specialized Center of Research 
NSRL NASA Space Radiation Laboratory 
PDR Preliminary Design Review 
RBE Relative Biological Effectiveness 
SPE Solar Particle Event 
SRPE Space Radiation Program Element 
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Mars Exploration
Missions
by 2030
Lunar outpost 
Missions up to 
240 days
Lunar Sortie
Missions
by 2019
2006–2013 2014–2019 2020–2026
Contributions
to National
Priorities
Contribute to 
increased 
understanding of 
solar physics; 
Apply biomarker 
technologies to 
problems on Earth
Perform research on 
dose-rate effects of 
protons, develop 
shielding design 
tools; apply 
probabilistic risk 
assessment to lunar 
missions
Validate radiation 
environment and 
transport models 
using lunar data; 
Validate models of 
proton dose-rate 
effects
Develop and deploy 
operational strategies 
for managing SPE 
risks; Apply 
biomarker methods to 
samples from lunar 
crews
Use NSRL to 
simulate space 
radiation to 
understand their 
biological effects; 
Compete radiation 
transport codes and 
design tools
Continue NSRL 
research on risks; 
perform research on 
biological 
countermeasures; 
optimize shielding 
designs for Mars 
missions
New risk model that 
reduces uncertainties 
in projections to less 
than 2-fold; 
Determine if CNS 
and degenerative 
risks from GCR will 
occur 
Revised risk model 
with uncertainties in 
risk projections to 
less than 50%; lunar-
instruments to 
measure Mars surface 
environment at solar 
minimum
Finish NSRL research 
on countermeasures;
Develop diagnostics 
of radio-sensitivity 
and gene therapy for 
prevention and/or 
treatment of radiation 
damage
Design exploration 
missions; Apply new 
knowledge of 
radiation effects and  
NASA computational 
biology models to 
human diseases on 
Earth
Apply knowledge on 
individual risk 
assessments and 
biomarkers;  
integrate accurate 
long-term solar 
weather predictions 
for Mars assessments
Apply 
countermeasure 
knowledge to 
diagnosis, prevention 
and treatment of 
diseases on Earth
Agency
Mission
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3SRPE Research Plan
Deliverables
Gap 3.1.2.1: What are the probabilities for
increased carcinogenesis from space 
radiation as a function of NASA’s operational
parameters?
Gap 3.1.2.2: How can tissue specific risk
models be developed using human 3D cell
culture or animal models for the major 
cancer sites ? 
Gap 3.1.2.3: How can the roles of 
initiation, promotion and  progression in 
space radiation carcinogenesis best be
determined, and how do they influence the 
risk projection assumptions such as
linearity, additivity, scaling, RBE and 
DDREF?
Gap 3.1.2.4: How can the molecular
mechanisms of cancer risk be determined?
What surrogate endpoints result from this
research?
Risk of Carcinogenesis 
from Space Radiation
Biological Mechanisms & Data
2
SRPE 
NRA Risk Research 
Using NSRL
Is the Uncertainty in 
Cancer Risk 
Projections <2-fold?
Is the Uncertainty in Cancer Risk
Projections < ±50%?
YES
YES
Research focus  shifts 
to skin, bladder & brain
1,7 2,3,4 2,3,5,98
Ground Based Risk Research (NRA)  for Lung, 
Breast, Leukemia, Colorectal, 
Stomach, Esophagus and Liver Cancer
Ground Based Risk Research for 
Skin, Bladder and Brain
Continue Ground Based Risk 
Research for Lung, Breast, 
Leukemia, Colorectal, Stomach 
Esophagus and Liver
NO
Update recommendations on 
human systems stds (2) 
& PELs (3) for lunar environ.
Provide recommendations to Cx
on rad prot. for short (4) & long(5) 
Lunar missions
23
Update R/A model(1)
1 4
235
6,10
1
NO
Continue Risk Research
 
Graphics 
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3
SRPE Research Plan
DeliverablesRisk of Carcinogenesis 
from Space Radiation
Risk Assessment
Gap 3.1.2.5: How can the projections
of tissue specific cancer risk for
simulated SPE and GCR be validated
using NSRL's electron beam injector
system (EBIS) capability?
Gap 3.1.2.6: What quantitative
procedures or theoretical models 
are needed to extrapolate molecular,
cellular, or animal results to
determine the risks of specific
cancers in astronauts? How can
human epidemiology data best
support these procedures or models?
Gap 3.1.2.7: How can  systems biology
approaches be used to integrate
research on the molecular, cellular,
and tissue mechanisms of radiation
damage to improve the prediction of
the risk of cancer?
SRPE 
JSC Risk Assessment Project
Risk Assessment Project  Extrapolation of Cell and Animal 
Data to Humans; 
Integration of Ground Based and Epidemiologic Data 
Risk Assessment Project and NSCOR tasks in pathway description and integrative theoretical risk models
NSRL Validation using Lifespan Studies and 3D 
Cancer Risk Models for  GCR and SPE Simulations 
of Free Space
1,7 2,3,4 2,3,5,98 6,10
234 235
11
Update recommendations on 
human systems stds (2) 
& PELs (3) for lunar environ.
Provide recommendations to Cx
on rad prot. for short (4) & long(5) 
Lunar missions
23
6
Update R/A Model 
for long duration lunar (6)
2
4 5
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3
SRPE Research Plan
Deliverables
Ground Based NRA/NSCOR CM Research
Risk of Carcinogenesis 
from Space Radiation
Countermeasures
Gap 3.1.2.10: How can the mechanisms of
biomedical countermeasures for space
radiation be discovered? Would
countermeasures for low LET radiation 
have similar efficiency for high-LET
radiation?
Gap 3.1.2.11: How can 3D cell culture
models or animal models developed for
space radiation cancer risk determination
be used to validate biomedical or dietary 
countermeasure? What testing regime 
is required at NSRL?
Gap 3.1.2.12: What level of cancer risk
requires aggressive biomedical
countermeasures? And what projection
uncertainty in countermeasure
effectiveness is required for operational 
Use at NASA?
Gap 3.1.2.13 How can the Risk
Assessment Project’s system biology
models of cancer risk be used to project the
likely effectiveness of specific biological
countermeasures?
1,7 2,3,4 2,3,5,98 6,10
Risk < Limit;
Uncertainty <2-fold?
Risk > Limit; 
Uncertainty <±50%?
YES
CM Delivered to SOMD
CM Research
NO
10
Risk Assessment Project and NSCOR tasks in pathway 
description and integrative theoretical risk models
Continue CM research and continue with Gap 3.1.2.12 and 3.1.2.13
Risk Assessment Project, NCRP or NAS Study
3
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3
SRPE Research Plan
Deliverables
Gap 3.2.2.1:Is there a significant
probability that space radiation would
lead to acute functional changes in
the CNS due to a long term space
mission and if so what are the
mechanisms? Are there threshold
doses for effects? 
Gap 3.2.2.2: Is there a significant
probability that space radiation
exposures would lead to late
degenerative CNS risks, if so what
are the mechanisms? 
Gap 3.2.2.3: How does individual
susceptibility alter risk? Does
individual susceptibility modify
possible threshold doses for risks in a
significant way? 
Gap 3.2.2.7: Does chronic space
radiation or SPE exposure result in
increased cell death, and if so what
are mechanisms and consequences?
Risk of Acute or Late 
Central Nervous System 
Effects from Space Radiation
Biological Mechanisms and Data
2
SRPE NRAs, NSCORs 
NSRL
Is probability  for functional 
Acute &/or late rad. CNS effects 
significant?
Ground Based Risk Research 
NO
NSCOR Risk Research
YES       CM Research Gap 3.2.2.4 & Risk Research Gaps 3.2.2.11,3.2.2.12
Risk Research Gaps 3.2.2.11, 3.2.2.12 synergy with other space flight factors 
and individual susceptibility
Update Recommendations 
Human Health Standards (1); 
PELs (2) lunar radiation environment
1,2,3 1,2,4
Recommendations on radiation 
protection  requirements
for short (3) and long (4) duration lunar mission
5 6
4
1 2 3
1
2 4
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3
SRPE Research Plan
Deliverables
Gap 3.3.2.10: Are space validation 
experiments needed for verifying 
knowledge of CNS risks prior to long-
term deep space missions, and if so 
what experiments should be under-
taken? 
Gap 3.3.2.11: Are there significant CNS 
risks from combined space radiation 
and other physiological or space flight 
factors? 
Gap 3.2.2.12: How can the individual’s 
sensitivity to radiation induced CNS 
damage be estimated? 
Shielding Physics
Gap 3.2.2.9: What are the best 
shielding approaches to protect against 
CNS risks, and are shielding 
approaches for CNS and cancer risks 
synergistic? 
Risk of Acute or Late 
Central Nervous System 
Effects from Space Radiation
Risk Assessment
Risk Assessment Project Shielding Analysis
NCRP 
Commentary
YES
Flight Research
Flight Data input to R/A 
shielding analysis
Ground Based 
NRA Research
Continue research &
Input data to CM selection
Is there synergy of rad. & 
spaceflight factors for CNS risks?
YES
NO
NO
Ground Based
NRA Research
5
Update PELs
51,2,3 1,2,4 6
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3
SRPE Research Plan
Deliverables
Gap 3.3.2.5: How can the projections of
tissue specific degenerative risk for
simulated SPE and GCR be validated
using NSRL's EBIS capability? 
Gap 3.3.2.6: What quantitative
procedures or theoretical models
including systems biology approaches,
are needed to extrapolate molecular,
cellular, or animal results to predict
degenerative tissue risks in
astronauts? 
Countermeasures
Gap 3.3.2.7: What are the most
effective biomedical or dietary
countermeasures to degenerative
tissue risks? By what mechanisms
are the countermeasures likely to
work? (post PPBE)
Gap 3.3.2.8: Will countermeasures for
cancer, CNS, and degenerative
risks be additive, synergistic or
antagonistic to each risk? 
Risk of Degenerative
Tissue Effects
Risk Assessment
2
SRPE 
NRA Risk Research 
Using NSRL
NSRL Validation using lifespan studies and 
cell /tissue models 
Risk Assessment Project  Ground and Epidemiology Data Integration for 
Degenerative Risks
Results from 3.3.2.5 feed into RAP 3.3.2.6
R/A Model for Degenerative
Risks
CM & Biomarker Research, Selection & Testing
CM  Delivery to Cx (7)
6
2,3,52,3,41 6
6 6
(6)Updated RA Model Long Lunar Stay
7
7
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3
SRPE Research Plan
Deliverables
Biological Mechanisms & Data
Gap 3.4.2.1:  What are the probabilities
or RBE’s for various acute effects
from the GCR and SPE’s?
Gap 3.4.2.2: How can the dose-rate
modifying factors for acute risks be
determined from experimental model
systems? 
Gap 3.4.2.3: What are the molecular,
cellular and tissue mechanisms of
acute radiation damage? 
Gap 3.4.2.7: Does immune depression
from a high skin dose or GI-tract
effects impact risk of significant
depletion of the blood system from a
SPE?
Acute Risks from Space 
Radiation Exposure
2
NSBRI Acute Risk Team
SRPE NRAs
NSRL
Select Best CM
Risk & CM 
Projection Modules
Countermeasure Studies 
Countermeasures
Gap 3.4.2.8: What are the most effective 
CMs to mitigate acute radiation risks? 
What are mechanisms?  How can the 
effectiveness of CMs developed on 
Earth be estimated for exposure of 
astronauts to a large SPE in deep space, 
or on lunar or Mars surface? 
Ground Based Risk Studies 
NRAs and NSBRI focus on mechanisms of acute effects: 
oxidative damage, apoptosis/necrosis, 
cytokines, DNA damage processing etc
7
1,7,10 2,3,4 2,3,5,98 6
9
(9)CM Delivery to SOMD
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3
SRPE Research Plan
Deliverables
Gap 3.4.2.4: What quantitative
procedures or theoretical models are
needed to extrapolate molecular,
cellular,or animal results to
predict acute radiation risks in
astronauts?How can human
epidemiology data best
support these procedures or models? 
Gap 3.4.2.6:Does long-term exposure to
GCR modify acute doses from SPE’s in
relationship to acute radiation
syndromes? 
Gap 3.4.2.11: What are the probabilities
of hereditary, fertility and sterility  effects
from space radiation
Gap 3.4.2.12: How can probabilities of
acute space radiation events be
improved? 
JSC Risk Assessment Project
Acute Risks from Space 
Radiation Exposure
Risk Assessment
2
Prodromal 
Model & 
BRYNTRN
Track Models of 
RBE’s in Tissues
Couple Acute Risk Software 
& Real Time Alert Data
Cell Kinetics 
of Blood 
Systems & 
BRYNTRN
Coupled GI tract & 
Blood Systems
(2)Update 
Recommendations 
Human Health Standards; 
(3)PELs lunar radiation 
environment
Recommendations on radiation 
protection  requirements
for short (4) and long (5) duration lunar
(6)Updated R/A model for
long duration lunar
(1)Updated R/A model for 
lunar missions
Pass to Constellation
8
Design Tools
Pass to Cx
Ground Based Research 
Yes – CM Research
NO
Update Recommendations 
Human Health Stds
1,7,10 2,3,4 2,3,5,98 6
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.11, 4.1.12, 5.1.6, 
5.2.5, 5.3.5, 6.3
SRPE Research Plan
DeliverablesAcute Risks from 
Space Radiation Exposure
Synergy with Spaceflight Factors
Gap 3.4.2.5: Are there synergistic effects 
arising from other spaceflight factors that 
modify acute rad risks including modifying 
thresholds for such effects? (post PPBE)
NSBRI, SRPE/HRP
Shielding Physics & 
Dosimetry
Gap 3.4.2.9: What are the optimal SPE 
alert and dosimetry technologies for 
EVAs?
SMD-LWS, NSBRI, SRPE (SBIR)
Gap 3.4.2.10: What are the most effective 
shielding approaches to mitigate acute 
radiation risks, how do we know, and 
implement?
JSC Risk Assessment Project
LWS-EMM/REM SMD-LWS Stereo and other missions
Pass to CxEVA Dosimetry - NSBRI
Ground-based Analog Studies 
& NSRL
Synergisms with microgravity, stress, 
immune status, bone loss, etc?
YES – CM Research
NO
9
2,3,4 2,3,5,98 61,7,10
8
(8)Enhanced Phase C/D Simulation Tool
7 7
(7)Comutational Design Tools for Vehicle Design
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12.0 RISK OF COMPROMISED EVA PERFORMANCE AND CREW 
HEALTH DUE TO INADEQUATE EVA SUIT SYSTEMS -I X I 
Improperly designed EVA suits can result in the inability of the crew to perform as expected, and can cause 
mechanical and decompression injury.  Suit developers must fully understand the impact of the suit design on 
crew performance and health to ensure properly designed mobility, pressures, nutrition, life support, etc. 
 
Operational Relevance and Risk Context  
Constellation Missions to the Moon and Mars will include frequent EVAs involving exploration, science, 
construction and maintenance tasks.  The effectiveness and success of these missions is dependent on 
designing EVA systems and protocols which maximize human performance capabilities.  It is not be feasible 
to perform the Constellation EVAs using Apollo suit designs.  Limited mobility and dexterity, and high center 
of gravity and other features of the suit required significant crew compensation to accomplish mission 
objectives.  The Human Research Program has recommended that the EVA Physiology, Systems and 
Performance Project work with the Constellation EVA Systems Project to develop and execute an integrated 
human testing program across multiple environments to collect the objective data needed to make informed 
design decisions to create an EVA system that optimizes human health and performance.    
 
Priority 
Lunar Outpost Mission: Important to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission. 
 
Gaps 
 
EPSP1: What parameters of EVA suit design affect human performance and how can these designs be 
modified to increase efficiency in crew health and performance? 
M5: How will the suit limit the performance of tasks required for Lunar sortie, Lunar outpost and 
Mars missions? 
SM9: Idealize design of EVA suit for optimized surface ambulation characteristics 
 
Activity: 
Studies to Examine Factors that may Affect Human Performance While Working in an EVA Suit 
Parameters to be examined include: suit weight, mass, center of gravity (CG), pressure, 
biomechanics and mobility.  Studies will be performed in a number of analog environments.  Test 
activities will include characterizations of ambulation and exploration type activities, such as 
ambulation on level and inclined surfaces, ambulation while carrying a load, rock collection, 
shoveling, kneeling, recovery from a fall, and simple exploration and construction tasks using hand 
tools and power tools.  Data collected will include metabolic rates, subject anthropometrics, time 
series motion capture, ground reaction forces, subjective ratings of perceived exertion (RPE) and 
operator compensation using the modified Cooper-Harper rating scale.  Any conditions that result 
in suit-induced trauma will also be noted. 
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Data collected in these studies will be used to generate the “Suit Controllability Predictive 
Algorithm”, which is a model that can be used to predict metabolic cost and subjective ratings 
based on suit characteristics, subject anthropometrics, and operations concepts.  This will be used 
as a design tool to develop suits that increase efficiency in crew health and performance.  
 
Product/Deliverables: 
Recommendations to EVA Systems Project for suit design requirements (optimal suit weight, 
mass, CG, pressure, biomechanics, mobility, etc); Suit Controllability Predictive Algorithm; 
and defined set of standard measures to be used for evaluation of prototype suits 
Required Delivery Milestone: 
A majority of the studies will be completed by the end of FY09 in order to provide inputs to 
Suit Configuration 1 (initial capability: launch/abort/entry and microgravity EVA) Interim 
Design Review (FY09) and Suit Configuration 2 (lunar surface operations) Systems 
Requirements Review (FY10).  Follow-on studies will be conducted as needed to provide 
inputs to subsequent design reviews in FY11-FY15.  Where needed, preliminary data will be 
used for inputs to Suit Configuration 1 Preliminary Design Review (end of FY08).      
Studies to refine requirements for Mars suits will be performed during lunar operations 
(FY20 and beyond). 
Required Platforms: 
Lunar analogs such as Partial Gravity Simulator (Pogo), Neutral Buoyancy Laboratory 
(NBL), parabolic flight, and NASA Extreme Environment Mission Operations (NEEMO); 
lunar surface operations 
Project/Organization Responsible for Implementation of Activity: 
EVA Physiology Systems and Performance Project (EPSP) – via directed study; some studies 
will be in collaboration with Constellation EVA Systems Project Office 
 
Activity: 
Human Performance in Suit Prototypes, Qualification Units and Flight Suit Articles 
Prototype, qualification unit, and flight article suits will be evaluated per the same set of standard 
measures used in studies to determine optimal suit weight, mass, CG, pressure, biomechanics and 
mobility requirements (see above).  Evaluations of Suit Configuration 1 may include assessments 
of human performance during suited intravehicular activities and emergency egress.  Evaluations of 
Suit Configuration 2 will include short tests of individual exploration activities, similar to studies 
described above.  In addition, long-term testing of operational concepts will be conducted to 
determine how the suits affect human performance over the duration of a planned mission.  
Evaluation of the suit prototypes is expected to be an iterative process with results being used to 
provide recommendations for multiple subsequent design updates.   
Follow-on flight validation and optimization studies with flight suits will occur during lunar surface 
operations. 
 
Product/Deliverables: 
Evaluation of prototype, qualification unit and flight article suits per standard measures with 
inputs to design updates as needed.  
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Required Delivery Milestone: 
Suit Configuration 1 development and qualification testing will be complete by the System 
Acceptance Review in 2012.  Suit Configuration 2 development and qualification testing will 
be complete by the System Acceptance Review in 2017.  Evaluation of flight article suits will 
occur during lunar surface operations. 
Required Platforms: 
Lunar analogs such as Partial Gravity Simulator (Pogo) and parabolic flight; lunar surface 
operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Constellation EVA Systems Project Office – via directed study 
 
EPSP3: What are the metabolic costs and ground reaction force (GRF) doses associated with EVA 
tasks in Lunar sortie, Lunar outpost and Mars missions? 
M4: What are the physiological costs of tasks required for Lunar sortie, Lunar outpost and Mars 
missions? 
 
Activity: 
Determine Metabolic Costs and Ground Reaction Forces 
Conduct a series of studies to quantify metabolic load and ground reaction forces based on varying 
subject weight, suit inertial mass, suit pressure and location of center of gravity (CG).  Studies will 
be conducted in several analog environments.  Test activities will include a range of lunar surface 
EVA tasks:  ambulation on level and inclined surfaces, ambulation while carrying loads, and 
exploration type activities such as shoveling, collecting rock samples, and performing construction 
tasks.  Where possible, data will be collected during studies performed to address EPSP1 (see 
above).  Additional studies will be performed to collect 1G baseline data, such as determining the 
metabolic rates of geological tasks conducted in field studies and the metabolic rate during 10K 
walk-back over terrain. 
 
Product/Deliverables: 
Metabolic costs and ground reaction forces associated with EVA tasks 
Required Delivery Milestone: 
A majority of the studies will be complete by the end of FY09.  This is an internal milestone, 
since these studies provide data needed to address the following gaps: EPSP2, EPSP4, 
EPSP5, and B13.  
Required Platforms: 
Lunar analogs such as Partial Gravity Simulator (Pogo), Neutral Buoyancy Laboratory 
(NBL), Haughton Mars Project (HMP) and Desert Research and Technology Studies (D-
RATS) 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
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EPSP4: What are the quantities of consumables required to support EVA in Lunar sortie, Lunar 
outpost and Mars missions?  How can these consumables be managed best? 
 
Activities: 
Determine Mission Metabolic Profiles and Perform Evaluations to Optimize Consumable Usage 
Project metabolic loads and determine mission metabolic profiles based on operational concepts 
provided by Constellation Program and/or Lunar Architecture Team (LAT).  Profiles will be 
created for suited intravehicular operations and surface EVA tasks.  Metabolic data collected in 
EPSP1 and EPSP3 studies will be used, and studies will be performed as needed to collect 
additional metabolic data.  Metabolic profiles will be analyzed to determine consumables quantities 
needed to support mission operations. 
Studies and analyses will be performed to develop recommendations for suit design and operational 
concepts that will optimize consumable usage/management.  For example, an oronasal mask will be 
evaluated as a solution to minimize consumable usage.   
 
Product/Deliverables: 
Mission metabolic profiles; recommendations for consumables requirements; and 
recommendations for operational concepts regarding consumables usage and management 
Required Delivery Milestone: 
Preliminary studies and analyses will be completed in FY08 and FY09 to provide inputs to 
Orion Preliminary Design Review (FY08) and Suit Configuration 1 Preliminary Design 
Review (FY09).  Additional inputs will be provided to Surface Operations and Suit 
Configuration 2 Systems Requirements Reviews (FY10) and Preliminary Design Reviews 
(FY12).  Additional studies may be performed as operational concepts are updated.  
Validation studies will be performed during mission operations. 
Required Platforms: 
Modeling capability, such as MATLAB; lunar analogs such as Partial Gravity Simulator 
(Pogo), Neutral Buoyancy Laboratory (NBL), Rockpile, and Haughton Mars Project (HMP); 
and lunar surface operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
EPSP5: What are the energy/hydration requirements and associated waste management requirements 
of EVA, and what kind of integrated delivery/management systems can be supported in an EVA suit?  
N8: What are the energy/nutrient requirements of EVA?  What is the best delivery system for these 
nutrients? 
 
Activity: 
Determine Energy, Nutrient, Hydration and Waste Management Requirements 
 See Risk Factor of Inadequate Nutrition – Gaps N8 / EPSP5 
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Activity: 
Evaluate Concepts for Nutrient and Water Delivery System 
See Risk Factor of Inadequate Nutrition – Gaps N8 / EPSP5 
  
Activity: 
Evaluate Nutrient Delivery Systems and Waste Management Systems in Suit 
See Risk Factor of Inadequate Nutrition – Gaps N8 / EPSP5 
 
EPSP8: What are the biomedical monitoring requirements of an EVA suit for each phase of Lunar and 
Mars missions? 
 
Activity: 
Evaluate Candidate Biomedical Sensors 
Work with flight surgeons and biosensor technology experts to identify biomedical monitoring 
requirements for suited operations: launch/entry/abort, microgravity EVA, and surface EVA. 
 
Product/Deliverables: 
Recommendations for biomedical monitoring requirements 
Required Delivery Milestone: 
Inputs were provided during FY07 to Level II documentation (Human Systems Integration 
Requirements document) and EVA Systems Project documentation during the Level III and 
Level IV Systems Requirements Reviews.  Additional inputs will be provided as necessary 
during EVA Suit Configuration 1 and Configuration 2 Preliminary Design Reviews. 
Required Platforms: 
Workshops and face-to-face meetings 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
Activity: 
Evaluate Integrated Biosensor System 
Work with Exploration Medical Capability (ExMC) Project to evaluate candidate biomedical 
sensors and integrated sensor systems during suit tests at lunar analog environments, such as Partial 
Gravity Simulator (Pogo), Desert Research and Technology Studies (D-RATS), Haughton Mars 
Project (HMP) or parabolic flight.  Biomedical sensors to be evaluated include non-adhesive 
electrodes, heart rate sensors, temperature sensors, CO2 sensors and accelerometers.  
 
Product/Deliverables: 
Recommendations for integrated biomedical sensor system concept 
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Required Delivery Milestone: 
A majority of the studies will be completed by the end of FY09 in order to provide inputs to 
Suit Configuration 1 (initial capability: launch/abort/entry and microgravity EVA) Interim 
Design Review (FY09) and Suit Configuration 2 (lunar surface operations) Systems 
Requirements Review (FY10).  Follow-on studies will be conducted as needed to provide 
inputs to subsequent design reviews in FY11-FY15.  Where needed, preliminary data will be 
used for inputs to Suit Configuration 1 Preliminary Design Review (end of FY08).      
Required Platforms: 
Lunar analog testing environments 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Exploration Medical Capability (ExMC) – via directed study 
 
Activity: 
Bioadvisory Algorithm Laptop Demonstrator 
Develop bioadvisory algorithm laptop demonstrator that monitors biomedical and suit parameters, 
calculates metabolic rate, and uses voice recognition capability to interact with the crewmember.  
The algorithm will be evaluated using data collected during tests conducted for EPSP1 and EPSP3.  
Additional work will refine the algorithm equations and user notifications. 
 
Product/Deliverables: 
Bioadvisory algorithm laptop demonstrator, with equations and logic flowchart describing 
functions of the algorithm 
Required Delivery Milestone: 
Work will be completed by the end of FY09 in order to provide inputs to Suit Configuration 
2 Systems Requirements Review (FY10).  Follow-on studies will be conducted as needed to 
provide inputs to subsequent design reviews in FY11-FY15. 
Required Platforms: 
Statistical analysis, data collected during suit tests in EPSP 1, EPSP 3 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
Activity: 
Evaluate Integrated Biomedical Sensor System 
Evaluate integrated biomedical sensor system in prototype suits, qualification units and flight 
articles. Validation studies with flight suits will occur during lunar surface operations. 
 
Product/Deliverables: 
Evaluation of prototype, qualification unit and flight article suits per standard measures, with 
inputs to design updates as needed 
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Required Delivery Milestone: 
Suit Configuration 1 development and qualification testing will be complete by the System 
Acceptance Review in 2012. Suit Configuration 2 development and qualification testing will 
be complete by the System Acceptance Review in 2017.  Evaluation of flight article suits will 
occur during lunar surface operations. 
Required Platforms: 
Lunar analogs such as Partial Gravity Simulator (Pogo) and parabolic flight; and lunar 
surface operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Constellation EVA Systems Project Office – via directed study 
 
EPSP9: What suit-human biomechanical interaction aspects of the EVA suit design affect protection of 
crew health, and what design changes or countermeasures can be implemented to protect crew health? 
 
Activity: 
Suit-Induced Trauma Data Mining 
Perform retrospective study (data-mining) to identify suit-induced trauma that has occurred during 
NBL training and during flight activities. Create searchable database to track suit injury and 
populate with historical data. Continue to monitor suit-induced trauma in future Shuttle and ISS 
training and flight activities and enter cases in database.  
Identify suit-induced trauma that occurs during suit development/evaluation tests and concept of 
operation studies for Exploration missions.     
 
Product/Deliverables: 
Suit Injury Database 
Required Delivery Milestone: 
Phase I of the database will be complete in FY08; implementation of phase II is TBD. 
Required Platforms: 
Partial Gravity Simulator (Pogo), Neutral Buoyancy Laboratory (NBL), parabolic flight, 
Shuttle and ISS flights, CEV and Lunar operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Space Medicine and EVA Systems Project Office – via directed 
study 
 
Activity: 
Identify Mechanisms of Suit-Induced Injury 
Conduct a series of studies to identify mechanism of suit-induced injury.  Studies currently in 
progress include: EMU shoulder harness assessment to investigate shoulder injuries due to limited 
range of motion, studies to measure fingertip pressure and blood flow while working in suit gloves 
and to assess role of moisture in fingernail damage sustained while working in suit gloves, and 
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studies to determine the magnitude of oxidative stress in EVA crewmembers. Additional studies 
will be performed as necessary if new injuries are encountered during development of Constellation 
suits. 
 
Product/Deliverables: 
Recommendations for suit design to mitigate suit-induced trauma 
Required Delivery Milestone: 
A majority of the studies will be completed by FY10 in order to provide inputs to Suit 
Configuration 2 Systems Requirements Review. Follow-on studies will be conducted as 
needed to provide inputs to subsequent design reviews in FY11-FY15.   
Required Platforms: 
Lunar analogs, including Partial Gravity Simulator (Pogo), Neutral Buoyancy Laboratory 
(NBL), parabolic flight 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
Activity: 
Evaluate Suit/Seat Induced Trauma During CEV Landing 
Perform modeling to evaluate suit/seat induced trauma during CEV landing, based on data provided 
by Orion and on data collected in studies performed by EVA Systems Project. Develop concepts 
for occupant protection during landing. 
 
Product/Deliverables: 
Recommendations for suit/seat design to avoid suit-induced trauma 
Develop finite element models of bone and soft-tissue injury 
Required Delivery Milestone: 
Preliminary results will be complete in early FY08 to provide inputs prior to Orion 
Preliminary Design Review and Suit Configuration 1 Preliminary Design Review. Follow-on 
studies/analysis will be performed as needed through Suit Configuration 1 Critical Design 
Review (FY11).   
Required Platforms: 
Modeling capability 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Constellation EVA Systems Project Office and field technology 
experts in occupant protection – via directed study 
 
Activity: 
Evaluate Suit Trauma Countermeasure Garment Prototypes 
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Work with materials experts in Crew and Thermal Systems Division to develop concepts and 
prototype of suit trauma countermeasure garment. Candidate concepts include airbags, strain-
aligning material and crushable foam.  Garment will be evaluated in tests conducted by EVA 
Systems Project Office to simulate landing loads and during suit tests conducted at Lunar analogs. 
 
Product/Deliverables: 
Recommendations for design of countermeasures to mitigate suit-induced trauma 
Required Delivery Milestone: 
Development and testing of preliminary concept will be complete in FY08 prior to Suit 
Configuration 1 Preliminary Design Review. Subsequent studies will be performed to 
evaluate iterations of garment design.  
Required Platforms: 
Lunar analog testing environments 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Crew and Thermal Systems Division and Constellation EVA 
Systems Project Office – via directed study 
 
Activity: 
Evaluate Suit Trauma Countermeasure Garment 
Evaluate suit trauma countermeasures in prototype suits, qualification units and flight articles.  
Validation studies with flight suits will occur during Lunar surface operations. 
 
Product/Deliverables: 
Evaluation of prototype, qualification unit and flight article suits per standard measures, with 
inputs to design updates as needed 
Required Delivery Milestone: 
Suit Configuration 1 development and qualification testing will be complete by the System 
Acceptance Review in 2012.  Suit Configuration 2 development and qualification testing will 
be complete by the System Acceptance Review in 2017. Evaluation of flight article suits will 
occur during Lunar surface operations. 
Required Platforms: 
Lunar analogs such as Partial Gravity Simulator (Pogo) and parabolic flight; and Lunar 
surface operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Constellation EVA Systems Project Office – via directed study 
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EPSP10: What are the risks and risk definitions of decompression sickness (DCS)?  How can DSC risk 
be managed? 
 
Activity: 
DSC Risk Definition and Planning 
Define acceptable DCS risk for different phases of Lunar architecture (e.g. short-duration vs. long-
duration missions) based on concept of operations. This activity will include several meetings with 
external experts to discuss DCS policy and definitions of mission success as well as predictive 
modeling. 
 
Product/Deliverables: 
Inputs to Human Systems Integration Requirements document (CxP70024); Exploration DCS 
Risk and Contingency Plan 
Required Delivery Milestone: 
This work will be complete by the end of FY08 
Required Platforms: 
Statistical analysis and modeling 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
Activity: 
Develop Integrated DCS Predictive Model 
Develop Integrated DCS Predictive Model, which is a tissue gas bubble dynamics model. The 
model will incorporate parameters such as: pre-breathe conditions, suit pressure, breathing gas 
composition, depress/repress rates, and duration of exposure. Data used to develop this model will 
be provided by numerous EPSP studies. 
Utilize model to develop operations concepts to manage DCS risk and contingencies. Operational 
concepts will be validated during Lunar surface operations 
 
Product/Deliverables: 
Integrated DCS Predictive Model 
Operational concepts/protocols to manage DCS risk 
Required Delivery Milestone: 
Concepts of operations will be defined by FY13 to provide inputs to the Mission Operations 
System Requirements Review. Additional studies and analysis will be performed as needed 
to provide inputs to subsequent reviews.  
Required Platforms: 
Statistical analysis and modeling 
Lunar surface operations 
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Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
Activity: 
Develop a Pre-Breathe Protocol 
Conduct a series of tests to develop a pre-breathe protocol for Lunar surface operations that 
minimizes DCS risk while meeting WEI requirements. Initial studies will test accept criteria for 
worst-case scenario, and will involve a 36-hr saturation protocol. Subsequent studies will utilize an 
exercise-equivalent saturation protocol to evaluate intermittent recompression. Saturation procedure 
will be performed again to optimize the pre-breathe protocol and to validate procedures.  
Operational validation will also be performed during Lunar surface operations.   
 
Product/Deliverables: 
Validated pre-breathe protocol 
Required Delivery Milestone: 
Testing will begin in FY10 and will be complete by FY17 for the Suit Configuration 2 / 
Surface Ops System Acceptance Review 
Required Platforms: 
Hypobaric chambers 
Lunar surface operation 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
EPSP11: What is the best way to acclimate to slightly hypoxic LSAM and Lunar habitat 
environments? 
 
Activity: 
Evaluate Operational Concepts for Transition to Hypoxic Environment 
Conduct studies to evaluate operations concepts and determine how human performance is affected 
due to transition to hypoxic environment. Concepts will be validated during Lunar surface 
operations. 
 
Product/Deliverables: 
Recommendations for concept of operations to acclimate to LSAM and Lunar habitat 
environment 
Required Delivery Milestone: 
Work will be complete by FY17 for the Suit Configuration 2 / Surface Ops System 
Acceptance Review 
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Required Platforms: 
TBD 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
EPSP13:  How can heat rejection/suit cooling capability be improved to enhance contingency 
responses? 
 
Activity: 
Liquid Cooling Garment Studies 
Conduct studies to evaluate current US and Russian liquid cooling garments and prototype liquid 
cooling garments. Evaluations will be conducted during suit tests and in thermal chambers. 
 
Product/Deliverables: 
Recommendations for design of liquid cooling garment to improve heat rejection/cooling 
capability 
Required Delivery Milestone: 
Preliminary studies will be complete by the end of FY09 in order to provide inputs to Suit 
Configuration 1 Interim Design Review (FY09) and Suit Configuration 2 Systems 
Requirements Review (FY10). Follow-on studies will be conducted as needed to provide 
inputs to subsequent design reviews in FY11-FY15. Where needed, preliminary data will be 
used for inputs to Suit Configuration 1 Preliminary Design Review (end of FY08).      
Required Platforms: 
Partial Gravity Simulator (Pogo) and thermal chamber 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
Activity: 
Evaluate Liquid Cooling Garment in Prototype Suits, Qualification Units and Flight Articles 
Evaluate liquid cooling garment in prototype suits, qualification units and flight articles. Validation 
studies with flight suits will occur during Lunar surface operations. 
 
Product/Deliverables: 
Evaluation of prototype, qualification unit and flight article suits per standard measures, with 
inputs to design updates as needed 
Required Delivery Milestone: 
Suit Configuration 1 development and qualification testing will be complete by the System 
Acceptance Review in 2012. Suit Configuration 2 development and qualification testing will 
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be complete by the System Acceptance Review in 2017. Evaluation of flight article suits will 
occur during Lunar surface operations. 
Required Platforms: 
Lunar analogs such as Partial Gravity Simulator (Pogo) and parabolic flight; and Lunar 
surface operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Constellation EVA Systems Project Office – via directed study 
 
EPSP6: What work efficiency indices (WEI) metrics of EVA can be used to measure evolution of EVA 
systems? 
 
Activity: 
EVA Work and Task Efficiency 
Total EVA work efficiency index (WEI) is defined as: 
 
_________________________EVA Time_________________________ 
(Total suit, airlock prep + prebreathe + airlock depress, repress + post EVA 
 
Current NASA EVA Total WEI is 0.39 – 0.51.  Constellation EVA Systems Project documentation 
contains requirements stating that EVA WEI shall be 3.0.  Many factors contribute to WEI, 
including vehicle systems, suit systems, and operational protocols. EPSP will perform evaluations 
of WEI based on current knowledge and concepts of operations, and will make recommendations to 
improve WEI.  Studies will include the following: 1.) evaluation of suit components that may 
improve WEI, such as integrated biosensor systems that are quick don/doff and drink bags that 
require less preparation time; 2.) development of improved pre-breathe protocols; 3.) studies in 
Lunar analogs that will evaluate the efficiency of different operations concepts and will measure 
the trends in WEI over time; 4.) evaluation of suit prototypes and development of operational 
concepts to meet WEI requirements. 
 
Product/Deliverables: 
Recommendations for EVA WEI metrics and methods to improve WEI 
Required Delivery Milestone: 
Inputs were provided in FY07 to EVA Level III Systems Requirements Review based on 
studies performed during NASA Extreme Environment Mission Operations (NEEMO) 
missions.  Additional studies will continue through FY17, with inputs to Suit Configuration 2 
and Surface Operations design reviews.  Follow-on flight validation and optimization studies 
will occur during Lunar surface operations.   
Required Platforms: 
Lunar analog testing environments, such as Neutral Buoyancy Laboratory (NBL), NASA 
Extreme Environment Mission Operations (NEEMO), Desert Research and Technology 
Study (D-RATS), and Haughton Mars Project (HMP) 
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Lunar surface operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP in collaboration with Constellation EVA Systems Project Office – via directed study 
 
EPSP7: What surface ops concepts could maximize human performance of mission tasks as well as 
protect crew health? 
M3: What tasks will be required for Lunar sortie, Lunar outpost and Mars missions? 
 
Activity: 
Evaluate Operations Concepts 
Conduct studies in Lunar analog environments to evaluate surface operations concepts provided by 
Constellation and/or Lunar Architecture Team (LAT-2 and follow-on). Flight validation and 
optimization studies will occur during Lunar surface operations.   
 
Product/Deliverables: 
Recommendations for surface operations concepts that will maximize human performance of 
mission tasks and protect crew health 
Required Delivery Milestone: 
Studies will be performed through FY17, with inputs to Suit Configuration 2 and Surface 
Operations design reviews, including Systems Requirements Review (FY10), Preliminary 
Design Review (FY11), Critical Design Review (FY15), and System Acceptance Review 
(FY17).  Follow-on flight validation and optimization studies will occur during Lunar surface 
operations.   
Required Platforms: 
Lunar analog testing environments, such as NASA Extreme Environment Mission Operations 
(NEEMO), Desert Research and Technology Study (D-RATS), and Haughton Mars Project 
(HMP); and Lunar surface operations 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
SM8:  No functional requirements for lunar and Mars surface ambulation have been devised. 
 
Activity: 
Develop Fitness for Duty Standard for Surface EVA 
Identify recommended operations concept(s) from EPSP7.  Based on tasks included in concept(s), 
analyze metabolic cost data collected during Exploration Task studies and Lunar Concept of 
Operations Metabolic Profiles studies. Perform analysis to determine 75% VO2 peak and 75% 
strength and fitness requirements to create fitness for duty standard. 
 
 124
HRP-47065 
 125
Product/Deliverables: 
Recommendations to fitness for duty standard; and metrics for ability to meet standard 
Required Delivery Milestone: 
TBD 
Required Platforms: 
Statistical analysis and modeling capability 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
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13.0 RISK OF ADVERSE HEALTH EFFECTS FROM LUNAR 
DUST EXPOSURE -I X N/A 
It is clear that prolonged exposure to rock dust is harmful, but it is not clear if exposure to regolith 
dust is more or less harmful than terrestrial rock dust.  Research into this area may determine if 
exposure limits need be changed, and/or if additional medical treatment capability is required. 
 
Operational Relevance and Risk Context  
Lunar dust is characterized as fine, charged and reactive dust capable of entering habitats and 
vehicle compartments, where it can threaten crewmember health. Testing is critical for the 
determination of lunar dust toxicity in order to set a permissible exposure limit and risk criteria. 
Historically, previous lunar regolith studies were limited to gross geological analysis of samples 
greater than 20 microns and microbial analysis of the regolith. Since that time the science of dust 
toxicology has emerged (Khan-Mayberry, Noreen N. (JSC-SF) (NASA)) as well as major 
advances in microscopy, which enable the study of dust samples smaller than 20 microns. Current 
and future research areas should include identification of lunar dust size, shape and chemistry, the 
mode of activation and passivation of lunar dust particles, (Khan-Mayberry, Noreen N. (JSC-SF) 
(NASA))  in vivo and in vitro toxicity (Khan-Mayberry, Noreen N. (JSC-SF) (NASA)) studies of 
the respiratory system, ocular (Khan-Mayberry, Noreen N. (JSC-SF) (NASA)) toxicity 
(mechanical and chemical effects) , dermal toxicity (Khan-Mayberry, Noreen N. (JSC-SF) 
(NASA)) (mechanical and chemical effects) and cellular toxicity.  
Health effects from chronic exposure to lunar dust may include compromised pulmonary function 
and possible organ disease through relocation of toxic particulates through the bloodstream. 
Acute health effects include ocular abrasion which may impair crew vision and dermal abrasion 
which may compromise function while suited. 
The risk of lunar dust exposure was identified during the Apollo missions, when lunar dusts were 
introduced into the Lunar Lander and command module, resulting in direct exposure and 
occasional reports of respiratory, dermal and ocular irritation. Current plans for a return to the 
lunar surface entail an EVA schedule that is extensively more rigorous than that experienced 
during the Apollo era. Potential exposure of the crew to lunar dust requires that NASA set 
permissible exposure limits for respirable lunar dust including consideration of dermal and ocular 
abrasions that may occur during spaceflight.  Exposure of the crew to lunar dust can be controlled 
through operational procedures, such as post EVA clean-up in airlocks, use of temporary 
breathing apparatus during exposure periods, isolation of contaminated EVA suits and 
appropriate engineering and design. 
 
Priority 
Lunar Outpost Mission: Important to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Not Applicable 
 
Gaps 
 
AEH 1: What are the unique properties of lunar dust that effect physiology?   
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Lunar dust particles, unlike most terrestrial dusts, have a high surface area and very distinctive 
shape characteristics. The respirable fraction of lunar dust has not been characterized. 
Determining the properties of the respirable fraction is critical for setting health standards.  
 
Activity: 
Size, Shape, Chemistry Analysis and Lunar Activation Studies 
Perform studies to determine the size distribution, unique shape characteristics and 
chemical composition of lunar dust particulate. This will facilitate the management of 
lunar dust particles in the respirable size range. Lunar activation studies will attempt to 
replicate solar wind, micrometeorite bombardment and lunar processes that cause 
surface activation of lunar dust. Understanding the activation and passivation processes 
and their mode of action in the human system will determine potential health effects 
and exposure limits during mission related tasks.  
 
Product/Deliverables: 
These studies will provide activated dust particles for further toxicity testing. 
Determination of size distribution factor for calculation of permissible exposure 
limit.  
Required Delivery Milestone: 
Provide size distribution factor 2008, Final update 2010 
Required Platforms: 
The activity will be conducted in various ground laboratory studies 
Validation for planetary Ops is required in Lunar Return Timeframe on the Lunar 
surface. 
Project/Organization Responsible for Implementation of Activity: 
AEH, LADTAG – via directed study. 
 
AEH 2: What is the toxicity of respired lunar dust in the respiratory system? 
During the Apollo missions several crewmembers and at least one Apollo flight surgeon who 
came in contact with Lunar dust on EVA suits reported respiratory issues with lunar dust. The 
toxicity data are central in determining a permissible exposure limit and risk criteria for lunar 
dusts.  
 
Activity: 
Inhalation Toxicity testing and Intratracheal Instillation (ITI) Testing of Lunar Dust 
These studies will determine the distribution of inhaled and instilled dust particles 
throughout the lung and the overall toxicity in the lung tissue. Gross pathology will be 
performed as evidence of the degree of lunar dust toxicity.   
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Product/Deliverables: 
Data feeds the AEH5 Gap, and are ultimately used to produce an update to the 
Permissible Exposure Limit for Lunar Dust and subsequently flowed into 
spacecraft design requirements and operational controls to minimize crew exposure 
to dust if it is found to be highly toxic. 
Required Delivery Milestone: 
Provide initial species, dose and activation factors in 2008-09. Finalize factors in 
2010.   
Required Platforms: 
The activity will be conducted in various ground laboratory studies. 
Validation for planetary Ops in Lunar Return Timeframe. 
Project/Organization Responsible for Implementation of Activity: 
AEH, LADTAG – via directed study. 
 
AEH 3: What is the mode of action of lunar dust at the respiratory cellular level?  
Respirable particles are suspected to be present on the lunar surface (see AEH Gap 1). To 
appropriately set accurate exposure limits for crewmembers, it is important to understand the 
toxicity of lunar dust at the cellular level.  
 
Activity: 
Lunar Cell Culture Toxicity Testing 
Human lung cell culture will be tested to determine toxicity of lunar dust particles. The 
generation of reactive oxygen species (ROS) will be one marker of potential toxicity. 
Active vs. non-active dust will be tested to determine the differences in toxicity due to 
chemical activation.  
 
Product/Deliverables: 
Data will contribute to the determination of both dose and activation factors, and 
are ultimately integrated and used in gap AEH5 to produce an update to the 
Permissible Exposure Limit for Lunar Dust and subsequently flowed into 
spacecraft design requirements and operational controls to minimize crew exposure 
to dust if it is found to be highly toxic. 
Required Delivery Milestone: 
Provide required data mid 2008, Final Update 2010. 
Required Platforms: 
The activity will be conducted in various ground laboratory studies.  
Validation for planetary Ops in Lunar Return Timeframe. 
Project/Organization Responsible for Implementation of Activity: 
AEH, LADTAG – via directed study. 
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AEH 4: What is the dermal and ocular toxicity of lunar dust? 
During Apollo missions several crewmembers reported dermal and ocular issues with lunar dust 
exposure. Other than these anecdotal reports, there is no objective scientific data to support the 
dermal and ocular toxicity of lunar dusts. The determination of the dermal and ocular hazards is 
necessary to predict and prevent any visual decrement and vapor barrier loss during lunar 
operations.   
 
Activity: 
Dermal Toxicity Studies 
Dermal abrasion studies will be performed to determine the degree of dermal toxicity 
from acute and chronic exposure to lunar dust particles.  
 
Product/Deliverables: 
Research data indicating the degree of dermal toxicity of lunar dusts; based upon 
these results a follow on, recommended countermeasures, design and operational 
controls.  
Required Delivery Milestone: 
Provide required data in 2009; final recommendations in 2010  
Required Platforms: 
The activity will be conducted in various ground laboratory studies.  
Project/Organization Responsible for Implementation of Activity: 
AEH, LADTAG – via directed study. 
 
Activity: 
Ocular Toxicity Studies 
Ocular exposure studies will be performed to determine the degree of ocular toxicity 
from acute and chronic exposure to lunar dust particles.  
 
Product/Deliverables 
Research data indicating the degree of ocular toxicity of lunar dusts. Based upon 
these results a follow on could include an ocular exposure standards, recommended 
countermeasures, design and operational controls.  
Required Delivery Milestone: 
Provide required data in 2009. Final recommendations in 2010.  
Required Platforms: 
The activity will be conducted in various ground laboratory studies.  
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Project/Organization Responsible for Implementation of Activity: 
AEH, LADTAG – via directed study 
 
AEH 5: What should be the permissible exposure limits for inhalation of lunar dust? 
 
Activity: 
LADTAG final recommendations of Lunar Dust Health Standards  
 
Product/Deliverables: 
Reconciliation of extrapolation factors (species, exposure time, activation, size 
distribution) resulting in recommendations for setting time based (acute and 
chronic) permissible exposure limits for fresh and aged lunar dust, and subsequent 
guidelines or requirements for mission planners. 
Required Delivery Milestone: 
Final recommendations in 2010  
Required Platforms: 
The activity will be conducted in various ground laboratory studies.  
Project/Organization Responsible for Implementation of Activity: 
AEH, LADTAG – via directed study. 
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14.0 RISK OF ACCELERATED OSTEOPOROSIS -D X I 
 
Bone mineral loss occurs in microgravity due to unloading of the skeletal system, with average loss rates of 
approximately 1% per month.  It is unclear whether this bone mineral density will stabilize at a lower level, or 
continue to diminish. It is unknown if fractional gravity, present on the moon and Mars, would mitigate the 
loss; crewmembers could be at greater risk of osteoporosis-related fractures in later life. Greater 
understanding of the mechanisms of bone demineralization in microgravity is necessary to frame this risk, as 
well as to understand how current and future osteoporosis treatments may be employed. 
 
Operational Relevance and Risk Context  
It is not currently possible to track the course of changes in bone mineral density and bone quality during long 
duration missions, or to predict what bone losses will occur during a Mars Mission, or what the risk of 
fracture will be upon return to Earth after a Mars mission.  However, even after 6-month missions there are 
indications that bone quality/strength does not recover as quickly as bone mineral density.  This may 
represent a long term health effect (accelerated age related osteoporosis or osteopenia and elevated fracture 
risk) related to this discordant recovery dynamic.  This information is required to assess long term health risks 
to returning crew. 
 
Priorities: 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
B10: What is the time course of bone demineralization during flights >90 days on ISS and during 
Lunar Outpost missions? 
B1: Is bone strength completely recovered with recovery of BMD? 
 
Activity:  
Bone Recovery Studies – TBD  
Current 2007 NRA solicitation (NNJ07ZSA002N) is requesting research to address the risk of 
long-term effects on crew health regarding bone loss. There are preliminary indications that overall 
bone quality/strength does not recover at the same rate that bone mineral density recovers after 
spaceflight. It is not known if there is a long term health effect related to this discordant recovery 
dynamic. Research proposals are solicited that directly address this relationship. The specific topic 
solicited is: novel research that defines the precise relationship between long term recovery of bone 
mineral density and bone strength/quality, including the effects of multiple spaceflights.  It is 
anticipated that research addressing this topic will require a ground-based or bed rest definition as 
well as a flight component. 
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Product/Deliverables: 
Space normal data will be gathered to define long term recovery of bone mineral density.  In 
addition, data will be used to validate and/or update the current SFHSS bone standard. 
Required Delivery Milestone: 
Concurrent flight and ground studies will be performed in 2008-2012 and the results will be 
utilized to validate and/or update the existing bone health standards in 2013. If results 
determine that a bone recovery countermeasure is needed, ground-based studies for 
countermeasure development and follow-on ISS flight validation studies will be solicited.  A 
bone recovery countermeasure will be delivered to mission operations in 2020. These 
activities are designed to mitigate a risk for long-duration Mars missions and are conducted 
on board ISS prior to the loss of the ISS as a Mars transit analog. Follow-on validation and 
optimization studies for Mars missions will occur during lunar ops. 
Required Platforms: 
ISS is required to gather the space normal data.  If the data indicate bone recovery 
countermeasures are required, follow-on ground-based studies will then be required.  The ISS 
will be required to validate any potential countermeasures.  Further validation of the 
countermeasure for planetary ops will occur in the lunar surface operations timeframe. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
 
Activity:  
Expanded Analysis of Bone Turnover – study TBD 
Current 2007 NRA solicitation (NNJ07ZSA002N) requesting novel technologies that provide for 
real-time, in-flight monitoring of bone turnover during long-duration spaceflight. It is anticipated 
that research addressing this topic will require a ground-based or bed rest definition proposal. 
 
Product/Deliverables: 
A validated method to analyze bone turnover for use in spaceflight applications is the product 
to be delivered. If initial studies successfully validate the analysis method(s), follow-on 
countermeasure development studies may also be performed. 
Required Delivery Milestone: 
Ground-based studies performed in 2008-2011; flight studies performed in 2011-2014; 
together with results of technology development, informing mission operations of space 
normal bone loss rates and updating the SFHSS bone standard in 2015. If all methods and 
technology results determine that a countermeasure is needed, ground-based studies for 
countermeasure development and follow-on ISS flight validation studies will be solicited.  
From these add-on studies, a countermeasure to mitigate the risk will be delivered to mission 
operations in 2021. These activities are designed to mitigate a risk for long-duration Mars 
missions and are conducted on board ISS prior to the loss of the ISS as a Mars transit analog.   
Required Platforms: 
Initially the platform will be ground-based technology development. The ISS may be 
required to ensure that the instrument or analysis method is appropriate for spaceflight 
environment.   
 140
HRP-47065 
Project/Organization Responsible for Implementation of Activity: 
Non-Exercise Physiological Countermeasures Project (NxPCM) – via NRA  
 
Activity:  
Technology to Monitor Bone Quality Changes – study TBD 
Current 2007 NRA solicitation (NNJ07ZSA002N) is requesting novel technologies that provide for 
real-time, in-flight monitoring and/or diagnosis of 1) bone turnover; 2) bone structure; and 3) bone 
fracture. It is anticipated that research addressing this topic will require a ground-based or bed rest 
definition proposal. 
 
Product/Deliverables: 
A validated method to monitor changes in bone quality for use in spaceflight applications is 
the product to be delivered. If initial studies successfully validate the analysis method(s), 
follow-on countermeasure development studies may also be performed. 
Required Delivery Milestone: 
Ground-based studies performed in 2008-2011; flight studies performed in 2011-2014; 
together with results of technology development, informing mission operations of space 
normal bone loss rates and updating the SFHSS bone standard in 2015. If all methods and 
technology results determine that a countermeasure is needed, ground-based studies for 
countermeasure development and follow-on ISS flight validation studies will be solicited.  
From these add-on studies, a countermeasure to mitigate the risk will be delivered to mission 
operations in 2021. These activities are designed to mitigate a risk for long-duration Mars 
missions and are conducted on board ISS prior to the loss of the ISS as a Mars transit analog.   
Required Platforms: 
Initially the platform will be ground-based technology development. The ISS is required to 
ensure that the instrument is appropriate for spaceflight environment. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
 
N5: Can a single test monitor net bone calcium changes? 
 
Activity: 
Calcium Isotope Study – TBD  
Current 2007 NRA solicitation (NNJ07ZSA002N) requests innovative means to measure and 
monitor net bone calcium loss during long-duration space flight. It is anticipated that methods for 
addressing this risk will be among selected proposals.   
 
Product/Deliverables: 
A validated method to analyze calcium loss from bone for use in spaceflight applications is 
the product to be delivered. If initial studies successfully validate the analysis method(s), 
follow-on countermeasure development studies may also be performed. 
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Required Delivery Milestone: 
Ground-based studies performed in 2008-2011; flight studies performed in 2011-2014; 
together with results of technology development, informing mission operations of space 
normal bone loss rates and updating the SFHSS bone standard in 2015. If all methods and 
technology results determine that a countermeasure is needed, ground-based studies for 
countermeasure development and follow-on ISS flight validation studies will be solicited.  
From these add-on studies, a countermeasure to mitigate the risk will be delivered to mission 
operations in 2021. These activities are designed to mitigate a risk for long-duration Mars 
missions and are conducted on board ISS prior to the loss of the ISS as a Mars transit analog.   
Required Platforms: 
Initially the platform will be ground-based technology development. The ISS may be 
required to ensure that the instrument or analysis method is appropriate for spaceflight 
environment.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA  
 
B3: What pharmaceuticals against bone loss are best used and how? 
MO5: Determine how can osteoporosis treatments be employed? 
 
Activity: 
Bisphosphonates as a Countermeasure to Spaceflight-Induced Bone Loss, SMO-021 
The purpose of this SMO is to determine whether bisphosphonates, in conjunction with the routine 
in-flight exercise program, will protect ISS crewmembers from the regional decreases in bone 
mineral density documented on previous ISS flights. Two dosing regimens will be used:  (1) an oral 
dose of 70 mg of alendronate taken weekly during flight or (2) an I.V. dose of zoledronic acid 4 
mg, administered just once approximately 45 days before flight. Secondary goals will be to 
document the return to normal bone remodeling post-flight in crewmembers who took 
bisphosphonates. If shown to be an effective countermeasure to spaceflight-induced bone loss, 
bisphosphonates could prevent or ameliorate several potential bone-related problems. This study is 
being conducted in conjunction with the Japan Space Agency. 
 
Product/Deliverables: 
A product will be an effective pharmaceutical countermeasure to mitigate the risk of bone 
loss. 
Required Delivery Milestone: 
The countermeasure will be delivered in 2012. 
Required Platforms: 
The ISS is required to validate the countermeasure. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
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B18:  Is vibration a good countermeasure? 
 
Activity: 
A Low Intensity Mechanical Countermeasure to Prohibit Osteoporosis in Astronauts During Long-
Term Spaceflight; referred to as VIBE (Vibrational Inhibition of Bone Erosion; ISS/HRF 
Experiment 01-E079). 
This study is currently in bed rest trials with projected completion in FY08. This study is currently 
on hold as a flight experiment on ISS pending the outcome of the ground-based study, having 
completed an Experimental Requirements Review.  
Using 90d of bed rest as a ground-based model of the loss of bone density, reduction in bone 
strength, and deterioration of postural stability, the principal objectives of this proposal are to 
establish the ability extremely low-level mechanical vibrations to serve as a countermeasure to curb 
this loss. Male subjects, between the ages of 25-55, will be recruited for the bed rest study. The bed 
rest subjects to bear weight in a single leg stance for ten minute periods each day, while subjected 
to the low level stimulus (30 Hz, 0.3g; n=12), allowing the contralateral limb to serve as an intra-
subject control.  This will be compared to subjects in single-legged stance who stand on a placebo 
device (n=12).  Evaluation of bone (DXA, QCT and ultrasound), muscle strength, and postural 
stability will be performed pre- and post bed rest.  This work represents a critical step (CRL Level 
7) in establishing a physiologically based, non-pharmacologic, non-invasive countermeasure to 
curb deterioration of the musculoskeletal system, for use on earth or in space.   
 
Product/Deliverables: 
Efficacy will be determined as based on the ability of the signal to inhibit bone loss, prevent 
loss of muscle power and loss of postural stability. Given the ground-based evidence, we 
anticipate that treated crewmembers will retain bone density and muscle strength regardless 
of the deleterious consequences of the absence of gravity. Further, it is anticipated that bone 
loss in the axial skeleton (spine) will be reduced through exposure to the low-level 
mechanical signal.   
Data from these studies is the initial deliverable, and a validated microgravity 
countermeasure is the product of the ISS study.  The ISS flight validation study will inform 
future lunar bed rest studies using this countermeasure. 
Required Delivery Milestone: 
Effectiveness of countermeasure in bed rest determined in 2008; delivery of validated 
microgravity countermeasure in 2014; inform lunar bed rest studies starting in 2020. 
Required Platforms: 
The bed rest ground analog is required for the demonstration of microgravity countermeasure 
efficacy, and later for lunar countermeasure efficacy studies.  ISS is required as the Mars 
transit analog for countermeasure validation.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
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Activity 
A Low Intensity Mechanical Countermeasure to Prohibit Osteoporosis in Astronauts During Long-
Term Spaceflight; referred to as VIBE (Vibrational Inhibition of Bone Erosion; ISS/HRF 
Experiment 01-E079).  
 
This study is currently on hold as an ISS flight experiment pending the outcome of the ground-
based study. The study has completed the Experiment Requirements Review.  
If ground-based testing shows positive protection against bone loss, then the subsequent flight 
study will proceed. During extended missions ISS crewmembers will receive daily doses of high 
frequency (30Hz), low magnitude mechanical accelerations as tested in ground-based studies.  
Assays will evaluate bone density, trabecular and cortical bone density, cortical thickness, apparent 
bone quality, and bone mineral density by comparing post-flight DEXA, QCT and ultrasound 
measurements to pre-flight baseline measurements. Pre- and post-mission muscle strength and 
postural stability will also be evaluated. Differences from the baseline will be examined in terms of 
the ability of extremely low-level mechanical stimulation to inhibit the loss of bone quality and 
quantity. The preservation of muscle strength and postural stability, as based on these mechanical 
signals will provide a key to the regulatory stimulus in the maintenance of the musculoskeletal 
system.  
 
Product/Deliverables:  
Efficacy will be determined based on the ability of the mechanical signal to inhibit bone 
loss, prevent loss of muscle power and loss of postural stability.  
If the ground-based study results indicate protection from bone loss, a validated microgravity 
countermeasure is the product of the ISS study. The ISS flight validation study, if performed, 
will inform future lunar bed rest studies using this countermeasure.  
Required Delivery Milestone:  
If a countermeasure is determined in the ground-based testing then delivery of validated 
microgravity countermeasure in 2014; inform lunar bed rest studies starting in 2020.  
Required Platforms:  
ISS is required for countermeasure validation if bed rest ground analog is validated. If ISS 
countermeasures are validated and become operational then the bed rest ground analog is 
required for lunar countermeasure efficacy studies. 
Project/Organization Responsible for Implementation of Activity:  
   NxPCM – via NRA 
 
N14: What nutritional countermeasures can be used to mitigate bone loss? 
 
Activity: 
Nutrition Countermeasures for Bone – study TBD 
Current 2007 NRA solicitation (NNJ07ZSA002N) requests effective nutritional countermeasures 
that will assist in maintenance of bone structure and strength during long-duration spaceflight. It is 
anticipated that research addressing this topic will require bed rest studies.  
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Product/Deliverables: 
Ground-based studies to test proposed countermeasure(s) and ISS studies to validate best 
countermeasures during in-flight operations. Follow-on validation studies for Mars missions 
to occur in Lunar ops. 
Required Delivery Milestone: 
Ground-based studies in 2008-2013; selection of best countermeasures in 2013; flight 
validation studies in 2013-2016; countermeasure delivery to mission operations by 2016.  
Required Platforms: 
Ground-based analogs will initially be utilized to develop countermeasures. ISS is required to 
validate the countermeasures. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
 
N7: What are the K+, Mg+, and P+ changes in relation to cardiovascular issues and bone loss? 
 
Activity: 
Nutrition Status Assessment – SMO O16E: Nutrition SMO  
This is a directed study that seeks to expand the Medical Requirement 016L testing in three ways:  
1) include in-flight blood and urine collection, 2) expand nominal testing to include makers of 
normative markers of nutritional assessment, and 3) add an R+30 session to allow evaluation of 
post flight nutrition and implications for rehabilitation.  Additional markers of bone metabolism 
(helical peptide, OPG, RANKL, IGF-1) will be measured to better monitor bone health and 
countermeasure efficacy.  New markers of oxidative damage will be measured (8-iso-prostaglandin 
F2a, protein carbonyls, oxidized and reduced glutathione) to better assess the type of oxidative 
insults during space flight.  The array of nutritional assessment parameters will be expanded to 
include serum folate, plasma pyridoxal 5'-phosphate, and homocysteine to better understand 
changes in folate, vitamin B6 status, and related cardiovascular risk factors during and after flight.  
Additionally, stress hormones and hormones that affect bone and muscle metabolism will be also 
measured (DHEA, DHEA-S, cortisol, testosterone, estradiol). This additional assessment would 
allow for better health monitoring, and allow for more accurate recommendations to be made for 
crew rehabilitation.  These additional parameters were added due to the recommendation of an 
extramural panel that met to define nutritional standards and requirements in 2005.  If data indicate 
countermeasures are necessary for cardiovascular issues and/or bone loss, additional ground-based 
studies will be initiated. These countermeasures will be validated on board the ISS. 
 
Product/Deliverables: 
The SFHSS nutrition standard will be validated/updated and if required, a countermeasure to 
mitigate the risk of accelerated osteoporosis will be delivered to mission operations. 
Required Delivery Milestone: 
The SFHSS nutrition standard will be validated/updated in 2011 and countermeasure delivery 
in 2019. 
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Required Platforms: 
ISS is required to ensure that the data represents space normal and for validation of potential 
countermeasures.  The bed rest ground analog (6° head down tilt) is required for ground 
studies for countermeasure development. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
Activity: 
Lunar Analog Bed Rest Development 
This study is for the development of a lunar analog. These lunar mission simulations may or may 
not include (~3 day) transit phases between Earth and Moon. While it may be useful to simulate 
some impacts of (7-14 day) sortie missions, the primary focus will be on longer, outpost missions; 
thus, simulation durations will generally range up to 90 days. 
 
Product/Deliverables: 
Lunar analog  
Required Delivery Milestone: 
The pilot study will occur during 2008 and the completed development of the analog will be 
completed in 2011. 
Required Platforms: 
This effort is ground-based analog development, developing a lunar analog model.  The 
model will not be validated until lunar surface mission ops begin the in the 2020 timeframe. 
Project/Organization Responsible for Implementation of Activity: 
Flight Analogs Project (FAP) – via Directed Study 
 
B14: How does 1/6-g and 3/8-g influence countermeasures? 
B17: Can partial gravity be simulated on Earth? 
 
Activity: 
Lunar Analog Bed Rest Development 
This study is for the development of a bed rest lunar analog. These lunar mission simulations may 
or may not include (~3 day) transit phases between Earth and Moon. While it may be useful to 
simulate some impacts of (7-14 day) lunar sortie missions, the primary focus will be on longer, 
outpost missions; thus, simulation durations will generally range up to 90 days. The timeline for 
this analog development will be as follows: initially external experts will be consulted to generate 
ideas for lunar analog development; the pilot study will take place in the spring of FY08; a 
workshop including external experts will be held post-pilot study; finally a decision on the lunar 
analog will be made to determine if the analog will be useful. 
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Product/Deliverables: 
Lunar analog  
Required Delivery Milestone: 
The pilot study will occur during 2008 and the completed development of the analog 
complete with standard measures data will be completed in 2011. Lunar surface operations 
will determine if microgravity countermeasures are sufficient for lunar gravity. If additional 
countermeasures are required, they will be delivered in 2023. 
Required Platforms: 
This effort is ground-based analog development, developing a lunar analog model.  The 
model will not be validated until lunar surface mission operations beginning in the 2020 
timeframe. 
Project/Organization Responsible for Implementation of Activity: 
Flight Analogs Project (FAP) – via directed study AP 
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15.0 RISK OF ORTHOSTATIC INTOLERANCE DURING RE-EXPOSURE 
TO GRAVITY -D X I  
 
Post-flight orthostatic intolerance, the inability to maintain blood pressure while in an upright position, is an 
established, space-related medical problem. Countermeasures have been successfully identified and 
implemented (fluid loading, compression garments) or being evaluated (Midodrine & others). Completion of 
these efforts will be useful in determining what preventive measures should be used to combat orthostatic 
intolerance during future mission profiles. 
 
Operational Relevance and Risk Context  
Twenty percent of Shuttle crewmembers and up to 83% of returning ISS crewmembers suffer hypotension 
and presyncope or syncope during 10 minutes of upright tilt on landing day.  This may constitute a risk when 
crewmembers experience Earth's gravity after exposure to microgravity. Currently available countermeasures 
are not effective in all crewmembers; in particular, women are more susceptible than men. While it is well 
known that crewmembers can be incapacitated by orthostatic intolerance after six-month missions when they 
return to Earth’s gravity, it is not known the degree to which this may be ameliorated in the gravity 
environment on the Martian surface.  Early surface operations may require astronauts to be upright and active 
soon after landing on Mars. A combination of countermeasures, both physical and pharmaceutical, should be 
pursued for this risk.  It is not known if exposure to 1/6 g and 3/8 g will cause orthostatic intolerance or will 
have mitigating effects on orthostatic intolerance upon return to 1 g.    
    
Priorities: 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
CV3: Orthostatic intolerance is a potential hazard. 
 
Activity: 
Midodrine SMO: Test of Midodrine as a Countermeasure against Postflight Orthostatic 
Hypotension, SMO-006 
To date, available countermeasures (e.g., G-suit, fluid load) have not sufficiently reduced post-
flight orthostatic hypotension.  This study is designed to evaluate a new pharmacological 
countermeasure for protection from post-flight orthostatic hypotension.  This project will measure 
the efficacy of Midodrine in reducing the incidence and/or severity of orthostatic hypotension in 
returning astronauts.  Efficacy will be evaluated with an expanded operational tilt test.  The tilt test 
is used to assess the effects of prolonged weightlessness on orthostatic tolerance during upright 
posture, as measured by supine and standing heart rate, blood pressure, stroke volume, cardiac 
output and total peripheral resistance.  
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Product/Deliverables: 
Recommendation to Flight Medicine for orthostatic intolerance medication prescriptions 
Required Delivery Milestone: 
Countermeasure delivery in 2009; countermeasure delivery required to support mission 
operations by FY13 
Required Platforms: 
ISS and Shuttle are required for flight validation of the countermeasure. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
Activity: 
Hypovolemia Studies 
A hypovolemia model that reproduces the plasma volume loss seen on landing day has been 
developed utilizing a regimen of a single dose of IV furosemide, followed by 36 hours of a very 
low salt diet.  In the astronauts, this dehydration regimen reproduces the landing day incidence of 
orthostatic hypotension and presyncope during tilt tests with 100% fidelity.  Future work will 
include testing the utility of this ground-based model by expanding the measurements to include 
specific hemodynamic and vascular responses, and compare/contrast them with measurements from 
bed rest studies.  Additional activities include validating the Jobst stocking as a method to mitigate 
orthostatic intolerance on landing day, and examining alternate pressure garments if the Jobst 
stocking is not validated as a valid countermeasure.  In addition, alternate medications to mitigate 
orthostatic intolerance (i.e., octreotide) will be examined using the hypovolemic model.  Follow on 
studies could include validating octreotide in the 6° head-down tilt bed rest model and flight 
validation of octreotide on ISS.  VO2max measurements will also be taken using the hypovolemia 
model.  These data will be combined with the VO2 max SMO occurring on-board the ISS. 
 
Product/Deliverables: 
Inform mission operations regarding data gathered from Jobst stocking studies.  If additional 
pressure garments require evaluation, mission operations will be informed of those results.  
Data from the pressure garments studies and from the VO2max studies will be combined to 
update the SFHSS cardiovascular standard.  If the octreotide pharmaceutical is successful, it 
will be delivered to mission operations as a validated countermeasure against orthostatic 
intolerance. 
Required Delivery Milestone: 
Information on the pressure garments activities will be delivered to mission operations in 
2008 and 2010; delivery required in FY08 to support G-suit design requirements.  The 
SFHSS cardiovascular standard will be updated in 2010; delivery required in FY08 to 
support G-suit design requirements. A validated pharmaceutical countermeasure will be 
delivered in 2016; delivery required in FY13 to support mission operations requirements.  
Required Platforms: 
These activities utilize the ground-based hypovolemia model.  Future countermeasure 
evaluation studies will utilize the bed rest analog and countermeasure validation will utilize 
ISS to ensure proper use in the spaceflight environment. 
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Project/Organization Responsible for Implementation of Activity: 
NxPCM – directed study 
 
Activity: 
Gender Differences in Bed Rest:  Autonomic and Neuroendocrine Changes and Vascular 
Responses in Lower and Upper Extremities 
Although the reasons are undefined, female astronauts are more susceptible to post-flight 
orthostatic hypotension and presyncope than male astronauts. Due to the lack of cardiovascular bed 
rest studies that have female participation, many conclusions about the effects of simulated 
microgravity on humans may be flawed, in that they fail to describe physiologic mechanisms in 
women. This study focuses on how differences in strategies of arterial pressure control in men and 
women affect orthostatic tolerance before and after bed rest. Endothelium-dependent, endothelium-
independent and adrenergic receptor responses in both arteries and veins will be evaluated, before 
and after bed rest. In addition, plasma volumes, and hemodynamic and neuroendocrine responses to 
arterial and cardiopulmonary baroreceptor inputs will be measured in women versus men, before 
and after bed rest. Studies have indicated a differential response of different vascular beds in animal 
studies where hindlimb-suspended rats show hypertrophic remodeling of the vessels in their 
forelimbs and atrophic remodeling in the vessels of their hindlimbs. This is thought to occur 
because changes in transmural pressures and shear forces with hindlimb suspension occur in 
opposite directions in the upper and lower extremities. These studies have not been repeated in 
female rats, and nothing like this has been performed in humans of either gender. Since humans are 
bipedal, bed rest would greatly reduce transmural pressures and shear forces in the legs, but not the 
arms. If vessel remodeling follows the patterns in humans as in the rats, large changes could occur; 
this might contribute to orthostatic hypotension after bed rest. Accordingly, the study will repeat 
the vascular measurements mentioned above in both upper and lower extremities before and after 
bed rest and relate the findings to the occurrence of orthostatic hypotension. 
 
Product/Deliverables: 
The initial product is space normal data on gender differences with regards to orthostatic 
intolerance.  If the results indicate that a gender-specific countermeasure is needed, ground-
based countermeasure studies will be solicited. When the development is complete the 
countermeasure will be validated on the ISS.  Data gathered from all activities will be fed 
into lunar surface studies. 
Required Delivery Milestone: 
Bed rest study completion in 2012; updates to the cardiovascular standard 2012; ground-
based countermeasure studies solicited and performed in 2012-2016; informing mission 
operations in 2015; flight validation studies in 2016-2019; delivery of validated 
countermeasure(s) in 2019.  All products are needed by FY13 to support mission operations 
requirements. 
Required Platforms: 
Initially this study requires the bed rest ground analog to microgravity.  If a gender-based 
countermeasure is indicated, the countermeasure will be evaluated in the bed rest 
microgravity analog and the countermeasure will be validated for flight using the ISS.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – NRA  
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Activity: 
Vestibular-Cerebrovascular Interaction and their Contribution to Post-Spaceflight Orthostatic 
Intolerance 
The goal of this research is to examine the role of vestibular inputs in cerebral blood flow 
regulation and the effect of these inputs on orthostatic tolerance. The general hypothesis is that 
otolith mediated vestibular inputs act as a feed forward mechanism causing cerebral vasodilation to 
compensate for the decrease in cerebral perfusion pressure during the upright posture. The results 
of these studies will provide direct evidence on the role of vestibular inputs in cerebrovascular 
regulation. This work may lead to new methods to diagnose and treat post-spaceflight orthostatic 
intolerance and may have ground based applications as well. 
 
Product/Deliverables: 
Study completion, final report of findings 
Required Delivery Milestone: 
Study completion and final report by 2009 
Required Platforms: 
Ground-based work 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – NRA 
 
Activity: 
Lunar Analog Bed Rest Development 
This study is for the development of a lunar analog. These lunar mission simulations may or may 
not include (~3 day) transit phases between Earth and Moon. While it may be useful to simulate 
some impacts of (7-14 day) sortie missions, the primary focus will be on longer, outpost missions; 
thus, simulation durations will generally range up to 90 days. 
 
Product/Deliverables: 
Lunar analog  
Required Delivery Milestone: 
The pilot study will occur during 2008 and the completed development of the analog will be 
completed in 2011. 
Required Platforms: 
This effort is ground-based analog development, developing a lunar analog model. The 
model will not be validated until lunar surface mission ops begin the in the 2020 timeframe. 
Project/Organization Responsible for Implementation of Activity: 
FAP – via Directed Study 
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CV4: Is 1/6-g exposure protective of 1-g orthostatic tolerance? 
 
Activity: 
Lunar Analog Bed Rest Development 
This study is for the development of a lunar analog. These lunar mission simulations may or may 
not include (~3 day) transit phases between Earth and Moon. While it may be useful to simulate 
some impacts of (7-14 day) sortie missions, the primary focus will be on longer, outpost missions; 
thus, simulation durations will generally range up to 90 days. 
 
Product/Deliverables: 
Lunar analog 
Required Delivery Milestone: 
The pilot study will occur during 2008 and the completed development of the analog will be 
completed in 2011. 
Required Platforms: 
This effort is ground-based analog development, developing a lunar analog model. The 
model will not be validated until lunar surface mission ops begin the in the 2020 timeframe. 
Project/Organization Responsible for Implementation of Activity: 
Flight Analogs Project (FAP) – via Directed Study 
 
Activity: 
Lunar Analog Study TBD 
This study will utilize the lunar analog to determine if lunar gravity has any protective effects on 
orthostatic intolerance. Using the analog, it will be determined if countermeasures to protect against 
orthostatic intolerance are required for the lunar surface. If countermeasures are required, follow-on 
countermeasure development studies will be initiated. These countermeasures will be validated on 
the lunar surface. 
 
Product/Deliverables: 
The deliverable will be updates to the SFHSS cardiovascular standard and a validated lunar 
countermeasure to orthostatic intolerance. 
Required Delivery Milestone: 
This study requires development of the lunar analog and will occur 2011-2014 with updates 
to the cardiovascular standard occurring in 2014. These updates are needed by FY13 to 
support mission operations requirements.  If lunar countermeasures are required, those 
studies will take place in the 2014-2020 timeframe. A lunar surface validated countermeasure 
will be delivered to mission operations on 2023. The lunar countermeasures are needed by 
FY14 for lunar mission operations implementation. 
Required Platforms: 
This effort requires the lunar analog model. Countermeasure validation requires the lunar 
surface. 
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Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
Note that some studies resulting from the Lunar Analog study may be conducted by the 
NSBRI. 
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16.0 RISK OF IMPAIRED PERFORMANCE DUE TO REDUCED 
MUSCLE MASS, STRENGTH AND ENDURANCE -D X I  
 
There is a growing research database which suggests that skeletal muscles, particularly postural 
muscles of the lower limb, undergo atrophy and structural and metabolic alterations during space 
flight.  However, the relationships between in-flight exercise, muscle changes and performance 
levels are not well understood. Efforts should be made to try to understand the current status of 
in-flight and post-flight exercise performance capability and what the goals/target areas for 
protection are with the current in-flight exercise program.    
 
Operational Relevance and Risk Context  
Successful lunar outpost and mars missions will require an adequate level of physical fitness. 
Mission tasks may range from simple intra-vehicular activities, to ambulation on a planetary 
surface, to construction of outpost habitats. The decrements that occur to skeletal muscle strength 
and endurance in response to reduced gravitational forces may make associated tasks more 
difficult to perform. Thus, impaired muscle performance may impact crew performance and 
mission success. It is important to identify Critical Mission Tasks, evaluate the muscle 
performance costs of these tasks (as related to provided tools and equipment), quantify the 
expected muscle performance decrements during lunar and mars missions, and design effective 
exercise countermeasures (hardware and prescriptions) that allow for mission success and safety 
with minimal time cost to additional mission operations. Will work closely with the engineering 
community to ensure that the EVA suit, tools and tasks will be designed to reduce the strength 
and endurance burden on the crewmember as much as possible. 
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
M1: What is the current state of knowledge regarding exercise performance? 
 
Activity: 
Knowledge compilation  
The current state of knowledge of exercise in the development and maintenance of 
muscle mass, strength and endurance will be assessed. Published and unpublished data 
will be analyzed from ambulatory studies, bed rest studies and space flight. 
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Product/Deliverables: 
State of Knowledge NASA technical manual 
Information from this activity will guide Prescription Optimization Studies. 
Findings will be used as input for the Digital Astronaut Program (DAP). 
Required Delivery Milestone: 
This work will occur during 2008. 
Required Platforms: 
Ground based analysis of existing data. 
Project/Organization Responsible for Implementation of Activity: 
Exercise Countermeasure Project (ECP) – via directed study 
 
M7: Can the current in-flight performance be maintained with reduced exercise volume? 
M8: What is the minimum exercise regimen needed to maintain fitness levels for tasks? 
M9: What is the minimum set to equipment needed to maintain those (M8) fitness levels? 
 
Activity: 
Bed Rest Exercise Countermeasures Optimization 
This study will develop minimal exercise countermeasures requirements will allow 
additional crewmember time to be dedicated to other tasks required for mission 
success. The minimal exercise volume, time and hardware required to maintain 
adequate muscle mass, strength and endurance will be determined. Optimized exercise 
countermeasures routines will be tested in subjects following prolonged bed rest with 
follow-up flight validation as needed. 
 
Product/Deliverables: 
Results from the Prescription Optimization Studies will determine if bed rest 
exercise countermeasure prescriptions have been optimized. The initial results 
will determine if follow-on flight validation studies to further optimize the 
prescription are required. 
Required Delivery Milestone: 
The initial milestone will be to inform mission operations in FY13 that the 
exercise prescription is optimized. If the data indicate the protocol cannot be 
optimized, then further flight studies will be initiated; countermeasure delivery to 
occur in FY20 and updates to the Health Standards to occur in FY20. All 
products are required by FY13 to support mission operations requirements 
development. 
 161
HRP-47065 
Required Platforms: 
The bed rest ground analog (6° head down tilt) is required for ground studies for 
countermeasure optimization. ISS will be required to validate any optimized 
countermeasures. 
Project/Organization Responsible for Implementation of Activity: 
ECP – via NRA or NSBRI solicitation 
 
Activity: 
ISS ARED Muscle Function Study 
The Advanced Resistive Exercise Device (ARED) is gravity-independent exercise 
hardware that will be used for strength training aboard ISS. ARED will accommodate 
greater resistance loads than what is currently available to ISS crewmembers. ARED is 
instrumented to allow for measurement of muscle strength, power and endurance and 
will be used to monitor changes in muscle performance during flight. Results may 
determine if improved countermeasures and flight validation of countermeasures are 
needed. 
 
Product/Deliverables: 
Data that will guide decision of whether current countermeasures need only 
optimization (e.g., reduced volume, time) or if improved countermeasures and 
flight validation studies are needed. 
Required Delivery Milestone: 
The initial milestone will be to inform mission operations in FY13 that the 
exercise prescription is optimized.  If the data indicate the protocol cannot be 
optimized, then further studies will be initiated with countermeasure delivery 
occurring in FY20 and updates to the Health Standards occurring in FY20.  All 
products are required by FY13 to support mission operations requirements 
development. 
Required Platforms: 
ISS is required for instrumentation validation; if improved countermeasures are 
required the ground-based flight analog bed rest will be needed 
Project/Organization Responsible for Implementation of Activity: 
ECP – via directed study 
 
Activity: 
Center for Space Medicine (CSM) harness SDTO 
Treadmill use in microgravity requires the use of a harness and a system to provide a 
subject load to keep the crewmember in contact with the treadmill belt. A common 
complaint from returning ISS crewmembers is that the current harness is 
uncomfortable. The pain and chafing that occurs with the use of the current harness 
contributes to sub-optimal subject loading (approximately 65% of body weight). A new 
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harness design will be tested to determine if it is more comfortable that the current 
harness and will allow for greater loading which is expected to result in better 
maintenance of muscle mass and bone density of the lower extremities 
 
Product/Deliverables: 
Decision to change to newer CSM harness or continue with current harness 
during treadmill activities 
Required Delivery Milestone: 
N/A 
Required Platforms: 
ISS 
Project/Organization Responsible for Implementation of Activity: 
Glenn Research Center ECL/ECP – via directed study 
 
M10: What is the correct set of ground-based studies (bed rest and others) to optimize 
exercise prescriptions for Lunar Outpost and Mars? 
 
Activity: 
Lunar Analog Bed Rest Studies – TBD  
A lunar bed rest model with simulated EVA tasks will be used to determine if lunar 
gravity combined with EVA activities are protective of muscle mass, strength and 
endurance or if additional resistance training will be required for mission success and 
safety. 
 
Product/Deliverables: 
Determination if lunar EVA is protective of muscle performance. Results will be 
used along with the Critical Mission Task Assessment (below) to determine if 
Lunar Bed Rest Countermeasures Studies are needed. 
Required Delivery Milestone: 
Potential lunar countermeasure information will be delivered to mission 
operations in FY20. This is required by FY13 to support mission operations 
requirements development.  Potential lunar countermeasures will be validated on 
the lunar surface and the validated countermeasures will be delivered in FY23 to 
meet long-duration lunar mission requirements.  
Required Platforms: 
Lunar analog bed rest (9.5° head up tilt) 
Project/Organization Responsible for Implementation of Activity: 
ECP – via directed study 
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Activity: 
An integrated musculoskeletal countermeasure battery for long-duration lunar missions 
 
Product/Deliverables: 
Required Delivery Milestone: 
N/A 
Required Platforms: 
Lunar analog bed rest (9.5° head up tilt) 
Project/Organization Responsible for Implementation of Activity: 
NSBRI 
 
M3: What tasks will be required for Lunar Sortie, Lunar Outpost and Mars missions? 
M4: What are the physiologic costs of those (M3) tasks? 
M6:  Need to develop a standardized performance measure of readiness for the (M3) tasks.  
 
Activity: 
Critical Mission Task (CMT) Assessment 
The human performance tasks that will be required in order to assure mission success 
and safety will be identified (e.g., post landing egress, suited 10 kilometer walk-back, 
and emergency crewmember rescue). The muscle performance requirements to perform 
these tasks will then be determined by biomechanical and metabolic analyses obtained 
during performance of these tasks. 
 
Product/Deliverables: 
Results from this study will drive requirements for exploration exercise hardware 
development. 
Results from this study along with Lunar Bed Rest (above) will help to determine 
if Lunar EVA is protective for successful performance of critical mission tasks or 
if lunar mission analog bed rest studies are required prior to lunar validation 
studies. 
Required Delivery Milestone: 
Mission operations will be informed of hardware development in FY12; this 
information is required by FY13 to support mission operations requirements 
development. 
Data will also be provided to develop potential lunar countermeasures that will 
be validated on the lunar surface and the validated countermeasures will be 
delivered in FY23 to meet long-duration lunar mission requirements.  
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Required Platforms: 
Ground based studies utilizing the partial gravity simulator (POGO) and the 
Neutral Buoyancy Lab.  Bed rest facilities including the lunar analog will be 
utilized if required.  Validation of the tasks will require lunar surface operations. 
Project/Organization Responsible for Implementation of Activity: 
ECP – via directed study; collaborators include Constellation Program Ground 
and Mission Ops SIG and Constellation Program working groups (e.g., 
CEV Cockpit Working Group, etc.).  
 
Activity: 
Factors of Influence Studies (for CMT) 
The effects of specific human factors such as gender, initial fitness level and hydration 
status on the ability to perform critical mission tasks will be assessed as supplemental 
studies to Critical Mission Task Assessment. 
 
Product/Deliverables: 
Data will feed CMT model. 
Required Delivery Milestone: 
Data will feed into critical mission task assessments FY09-FY12. 
Data will also be provided to develop potential lunar countermeasures that will 
be validated on the lunar surface and the validated countermeasures will be 
delivered in FY23 to meet long-duration lunar mission requirements. 
Required Platforms: 
Ground based studies utilizing the partial gravity simulator (POGO) and the 
Neutral Buoyancy Lab.  Bed rest facilities including the lunar analog will be 
utilized if required.   
Project/Organization Responsible for Implementation of Activity: 
ECP – via directed study 
 
SM7: Need for an integrated post-flight functional task performance test to be used on 
returning ISS crewmembers. Develop and validate operational tests to define the linkage 
between functional capabilities and physiological changes. This task should include 
planetary EVA-like activities 
 
Activity: 
STS/ISS Functional Task Test  
During space flight astronauts experience alterations in multiple physiological systems. 
These physiological changes include sensorimotor disturbances, cardiovascular 
deconditioning, and loss of muscle mass and strength. These changes lead to disruption 
in the ability to ambulate and perform functional tasks during the initial reintroduction 
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to a gravitational environment and may cause significant impairments in performance 
of operational tasks immediately following landing on a planetary surface. To date 
changes in functional performance that result from physiological changes have not 
been systematically documented. Therefore, the goal of this study is to develop and 
evaluate an integrated set of functional and physiological tests and then use these tests 
to determine how postflight changes in sensorimotor, cardiovascular and muscle 
physiology impact postflight functional performance. These tests will be performed pre 
and postflight on astronauts exposed to short and long-duration space flight. The 
STS/ISS Functional Task Test will assess operational relevance of these changes by 
measuring the performance of specific exploration tasks (e.g., simulated seat egress, 
ladder climb, hatch opening, etc.). Additionally changes in functional performance will 
be mapped standard muscular, neurological, and cardiovascular measures. Data 
obtained from this study will facilitate the design of countermeasures that specifically 
target the physiological systems responsible for impaired functional performance.   
 
Product/Deliverables: 
Crew performance space normal data and physiological systems that require 
countermeasures in order to preserve performance of functional tasks will be 
identified. 
Required Delivery Milestone: 
Data obtained with this study will deliver information on performance of crew 
after spaceflight. The updates on crew performance will be continual with no 
definitive product delivered. If an established countermeasure is developed, it 
will be delivered in FY20. 
Required Platforms: 
STS (short term flights) 
ISS (long term flights) 
Project/Organization Responsible for Implementation of Activity: 
ECP – via directed study 
 
Activity: 
Bed Rest Functional Task Test 
A battery of functional tasks (see STS/ISS Functional Task Test above) will be 
assessed before and after bed rest (simulated micro/partial gravity). The ability of 
targeted countermeasures to maintain performance of functional tasks will be 
examined. 
 
Product/Deliverables: 
Countermeasures that will preserve performance of functional tasks 
Required Delivery Milestone: 
Data obtained with this study will deliver information on performance of crew 
after bed rest. The updates on crew performance will be continual with no 
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definitive product delivered. If an established countermeasure is developed, it 
will be delivered in FY20. 
Required Platforms: 
The bed rest ground analog (6° head down tilt) is required for ground studies.   
Project/Organization Responsible for Implementation of Activity: 
ECP – via directed study 
 
Activity: 
Factors of Influence Studies (for Bed Rest Functional Task Test) 
The effects of specific human factors such as gender, initial fitness level and hydration 
status on the ability to perform functional mission tasks will be assessed as 
supplemental studies to the Bed Rest Functional Task Test. 
 
Product/Deliverables: 
Results from factors of influence will determine if tailored countermeasures are 
need for specific groups or individuals. 
Required Delivery Milestone: 
N/A 
Required Platforms: 
The bed rest ground analog (6° head down tilt) is required for ground studies.   
Project/Organization Responsible for Implementation of Activity: 
ECP – via directed study 
 
M3: What tasks will be required for lunar sortie, lunar outpost and Mars missions? 
EPSP7: What surface ops concepts could maximize human performance of mission tasks as 
well as protect crew health? 
 
Activity: 
Evaluate Operations Concepts for Lunar Analogs 
See Risk of Compromised Eva Performance and Crew Health due to Inadequate Eva 
Suit Systems – Gaps EPSP7 / M3
 
M4: Identify physiological cost of tasks required for lunar sortie, lunar outpost and Mars 
missions 
EPSP3: What are the metabolic costs and ground reaction force (GRF) doses associated 
with EVA tasks in lunar sortie, lunar outpost and Mars missions? 
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Activity: 
Determine Metabolic Costs and Ground Reaction Forces for EVA Tasks 
See Risk of Compromised Eva Performance and Crew Health due to Inadequate Eva 
Suit Systems – Gaps EPSP3 / M4
 
M5: How will suit limit performance of lunar sortie, lunar outpost and Mars tasks? 
EPSP1: What parameters of EVA suit design affect human performance and how can these 
designs be modified to increase efficiency in crew health and performance? 
 
Activity: 
Studies to Examine Factors that may Affect Human Performance While Working in an 
EVA Suit 
See Risk of Compromised Eva Performance and Crew Health due to Inadequate Eva 
Suit Systems – Gaps EPSP1 / M5 / SM9
Activity: 
Human Performance in Suit Prototypes, Qualification Units and Flight Suit Articles 
See Risk of Compromised Eva Performance and Crew Health due to Inadequate Eva 
Suit Systems – Gaps EPSP1 / M5 / SM9
 
EPSP2: How much cardiovascular and resistive exercise and ground reaction force (GRF) 
dose does EVA provide in lunar sortie, lunar outpost and Mars mission? 
 
Activity: 
Calculate Cardiovascular and Resistive Exercises 
Analyze physiologic data collected during Exploration Task studies and Lunar Concept 
of Operations Metabolic Profiles studies in multiple analog environments (EPSP1, 
EPSP3, EPSP4, and EPSP7). Calculate cardiovascular exercise, resistive exercise and 
ground reaction forces based on surface operations concepts.   
 
Product/Deliverables: 
Quantified cardiovascular exercise, resistive exercise and ground reaction forces 
due to extravehicular activity 
Required Delivery Milestone: 
TBD 
Required Platforms: 
Statistical analysis and modeling capability 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
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EPSP12: What will suited human performance be upon arrival at the lunar surface? 
 
Activity: 
Analyze Functional Task Test data 
Collaborate with Investigators conducting the Functional Task Test to determine 
human performance degradation due to short-duration space flight. Analyze data 
collected in EPSP1 to determine human performance degradation due to the suit.  
Combine analyses and apply to the recommended operations concepts from EPSP7 to 
determine estimate for suited human performance upon arrival at the lunar surface.   
 
Product/Deliverables: 
Inputs to muscle fitness for duty standard 
Required Delivery Milestone: 
TBD 
Required Platforms: 
Lunar analog environment 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
HRP-47065 
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17.0 RISK OF REDUCED PHYSICAL PERFORMANCE 
CAPABILITIES DUE TO REDUCED AEROBIC CAPACITY -D X I  
Astronauts’ physical performance during a mission, including activity in microgravity and 
fractional gravity, is critical to mission success   Setting minimum fitness standards and 
measuring whether crew can maintain these standards will document the effectiveness of 
maintenance regimens.   
 
Operational Relevance and Risk Context  
In addition to reduced skeletal muscle strength and endurance, reduced aerobic capacity may put 
mission success at risk. Evidence demonstrates that aerobic capacity is markedly reduced in 
response to space-flight and space-flight analogs. Sustained sub-maximal activities (walking on a 
planetary surface) could become difficult to perform if there are large enough decrements in 
aerobic capacity, though to date, astronauts have been able to perform strenuous mission 
activities. It will be important to identify Critical Mission Tasks and associated aerobic costs in 
order to design and validate effective exercise countermeasures for mission success.  Current 
collaborative efforts with ESA are obtaining in-flight measurements of VO2max aboard ISS.  
These measurements can be used as a baseline for future research to “optimize” or reduce the 
amount of in-flight exercise necessary to maintain performance.   
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
M1: What is the current state of knowledge regarding exercise performance? 
 
Activity: 
Knowledge Compilation 
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gap M1 
 
M7: Can the current in-flight performance be maintained with reduced exercise volume? 
M8: What is the minimum exercise regimen needed to maintain fitness levels for tasks? 
M9: What is the minimum set to equipment needed to maintain those (M8) fitness levels? 
 
Activity: 
Prescription Optimization Studies 
 173
HRP-47065 
Developing minimal exercise countermeasures requirements will allow crewmember 
time to be dedicated to other mission tasks. The minimal exercise volume, time and 
hardware required to maintain aerobic capacity will be determined during bed rest with 
follow-up flight validation studies as required. 
 
Product/Deliverables: 
Results will be used for a go forward decision regarding implementing an ISS 
Exercise Optimization Validation study. 
Required Delivery Milestone: 
The initial milestone will be to inform mission operations in FY13 that the 
exercise prescription is optimized. If the data indicate the protocol cannot be 
optimized, then further studies will be initiated with countermeasure delivery 
occurring in FY20 and updates to the Health Standards occurring in FY20. All 
products are required by FY13 to support mission operations requirements 
development. 
Required Platforms: 
Ground based studies utilizing the partial gravity simulator (POGO) and the 
Neutral Buoyancy Lab. Bed rest facilities including the lunar analog will be 
utilized if required.   
Project/Organization Responsible for Implementation of Activity: 
ECP – via NRA or NSBRI solicitation 
 
M10: What is the correct set of ground-based studies (bed rest and others) to optimize 
exercise prescriptions for Lunar Outpost and Mars? 
 
Activity: 
Lunar Analog Bed Rest Studies – TBD  
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gap M10 
Activity: 
An Integrated Musculoskeletal Countermeasure Battery for Long-Duration Lunar 
Missions 
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gap M10 
 
CV2: Unknown in-flight and immediate post-flight VO2max
M2: What is the current status of in-flight and post-flight exercise performance capability?  
What are the goals/targets for protection with the current in-flight exercise program? 
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Activity: 
ISS/VO2max Study 
See Risk of Unnecessary Operational Limitations Due to Inaccurate Assessment if 
Cardiovascular Performance – Gap CV2 
 
Activity: 
Hypovolemia VO2max Studies 
Loss of plasma volume is hypothesized to be a major contributing factor to reduced 
aerobic capacity in response to space flight. An established ground-based model of 
microgravity-induced hypovolemia will be used to determine the effect of reduced 
plasma volume on VO2max. 
 
Product/Deliverables: 
Results from this study will aid Prescription Optimization Studies 
Required Delivery Milestone: 
Study will be conducted during the 2008-2010 timeframe and will feed data into 
the Bed Rest Prescription Optimization studies 
Required Platforms: 
Ground-based hypovolemia model 
Project/Organization Responsible for Implementation of Activity: 
NxPCM/ECP 
 
M3: What tasks will be required for lunar sortie, lunar outpost and Mars missions? 
M4: What are the physiologic costs of those (M3) tasks? 
 
Activity: 
Critical Mission Task Assessment 
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gaps M3, 4, 6 
Activity: 
Factors of Influence Studies (for CMT) 
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gaps M3, 4, 6 
HRP-47065 
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18.0 RISK OF THERAPUTIC FAILURE DUE TO 
INEFFECTIVENESS OF MEDICATION -D X I  
 
Based on subjective reports, drugs are effective during space flight.  Better record keeping of 
medication use, efficacy and side effects will be instituted and those records will provide 
evidence for or against this risk.  If medications are found to be ineffective, research will be 
performed to determine if drug metabolism is affected by space flight.  Studies to determine if 
space flight affects drug stability are currently underway. 
 
Operational Relevance and Risk Context  
Better recordkeeping of medication use, efficacy and side effects should be instituted.  It is 
particularly important to know what pharmaceuticals are taken prior to in-flight tasks. This will 
provide evidence for or and should be a precursor to a formal assessment of PK/PD on orbit.  It is 
thought that the reduction in gastrointestinal (GI) motility and function, offered as the first piece 
of evidence for this gap, is not an issue after the first few days of flight. In general, oral 
medications are not prescribed during this period of the mission. It is not known to what extent 
different volumes of distribution might be a factor in flight. Drugs selected for the PK/PD studies 
should be commonly used, have few side effects, and different metabolic pathways.  External 
consultants should be used to determine which drugs to test and to design testing protocols.   
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
PH6: Develop standard procedure for prospective analyses of drugs to be considered for 
flight and periodic analyses of drugs that are used for flight. 
PH10: What are the performance effects of in-flight drugs on exercise, orthostatic tolerance, 
motor control, cognitive function, etc.? 
CV6: Influence of in-flight medication use on physical and cognitive performance is not 
systematically documented. 
 
Activity: 
Terrestrial Drug Database Review – Data Mining TBD 
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Product/Deliverables: 
Two items will be delivered: a final report of findings and a proposed standard 
procedure for prospective analyses of drugs to be considered for flight.  Periodic 
analyses of drugs that are used for flight.   
Required Delivery Milestone: 
Data obtained by the completion of database review will inform procedure 
development and ultimately inform Flight Medicine by 2010. 
Required Platforms: 
Access to necessary pharmacological and Space Medicine databases is required. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
PH7: What are the effects of spaceflight on Pharmacokinetics/Pharmacodynamics? 
 
Activity: 
Bioavailability and Performance Effects of Promethazine (PMZ) During Spaceflight   
Promethazine is currently given to treat motion sickness during space flight.  The side 
effects associated with PMZ include dizziness, drowsiness, sedation, and impaired 
psychomotor performance. Anecdotal reports from crewmembers indicate that these 
central nervous system side effects of PMZ are absent or greatly attenuated in 
microgravity.  Recent reviews of medical debriefs indicate that, at least in some 
crewmembers, there are significant central nervous system depressant effects. In 
addition, the pharmacokinetics and bioavailability of medications administered in 
microgravity may be different than on Earth which could significantly alter drug 
efficacy, as well as, the severity of side effects for a given dosage. This study will 
systematically evaluate PMZ bioavailability, effects on performance, side effects, and 
efficacy in the treatment of motion sickness to determine optimal dosage and best route 
of administration of PMZ in flight.  
 
Product/Deliverables: 
Complete study and report findings. 
Required Delivery Milestone: 
Study completion in 2009, final report of findings in 2010. 
Required Platforms: 
Space Shuttle is required for assessing spaceflight effects of PMZ. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
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Activity: 
Drug Efficacy Studies [data mining activity (proposal in-work)] 
This study will review the available pharmacokinetic/pharmacodynamic and efficacy 
data from previous missions to develop and understanding of the bioavailability and 
uptake of pharmaceuticals in a microgravity environment. If results indicate drugs are 
ineffective, flight studies will be initiated to examine PK/PD. 
 
Product/Deliverables: 
Initial product is a final report of findings.  If results indicate that drug 
effectiveness is diminished in flight, ISS pharmaceutical PK/PD studies will be 
solicited and performed. Follow-on studies to assess any necessary 
countermeasures will also be performed if necessary. 
Required Delivery Milestone: 
Ground-based data mining completion and report by 2009.  Any required 
validated countermeasures will be delivered to mission operations in FY19. The 
potential countermeasures are required as soon as possible for current crew as 
well as for lunar mission operations requirements development. 
Required Platforms: 
Access to Flight Medicine, JSC Biomedical Research Laboratory data, and 
LSDA databases is necessary for the data mining study. ISS is required as the 
Mars transit analog for in-flight PK/PD studies and for countermeasure 
validation.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
PH9:  What is the effect of long-term spaceflight on drug stability and what measures can 
be employed to extend the duration of drug efficacy? 
 
Activity: 
Stability of Pharmacotherapeutic and Nutritional Compounds: Stability SMO (Flight) 
This protocol involves investigative physical/chemical analyses of both medications 
and food items returned from STS and ISS along with corresponding lot-matched 
controls stored on ground in a controlled environment. This experiment has 2 sub-
payloads attached to it.  See the Risk of Inadequate Nutrition for the nutrition sub-
payload information. The Pharmacology Sub-Payload will identify pharmaceutical 
preparations at risk for degradation; characterize degradation profiles of the unstable 
formulations after exposure to ISS environment; and compare and contrast stability of 
ISS flown medications to their matching controls from the same lot and commercial 
packing conditions. This study will provide critical information about the susceptibility 
of medications and vitamins in the space food system to adverse environmental factors 
encountered during space missions. 
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Product/Deliverables: 
Any new requirements or proposed new medications for flight will be submitted 
to mission operations. Data will be supplied to in-flight PK/PD studies. 
Required Delivery Milestone: 
Flight Medicine will be informed of any operational changes in FY09. This 
information is required by Flight Medicine as soon as possible. 
Required Platforms: 
ISS required for proper radiation doses on pharmaceutical samples. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
Activity: 
Assessment of Pharmaceutical Stability in Analog Environments of Space Missions:  
Stability SMO (Ground) 
Previous reports suggest that the space flight environment may compromise chemical 
and physical stability of pharmaceuticals contained in the Space Shuttle and ISS 
medical kits. The Pharmacotherapeutics laboratory has demonstrated that exposure to 
gamma radiation on the ground can reduce the shelf life of certain pharmaceutical 
formulations. The objectives of this proposal are to systematically evaluate the 
following effects of spacecraft environmental factors using ground based analog 
environments: 1) cyclic temperature/humidity fluctuations, 2) vibrational stress, and 3) 
synchrotron light and radiation sources, on the chemical and physical stability of 
pharmaceutical formulations.  This study uses radiation exposure to test the stability of 
various pharmaceutical components and will be compared to on-going flight data that is 
being collected.  
 
Product/Deliverables: 
The initial product is a series of radiation studies using ground-based radiation 
sources (Brookhaven, university or hospital facilities).   
Required Delivery Milestone: 
Data from the ground Stability study will feed into the flight Stability SMO. 
Required Platforms: 
Ground-based radiation sources (Brookhaven, university or hospital facilities)   
required for assessment of radiation doses on pharmaceuticals, and ground-based 
platforms may be required for follow-on studies. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
PH1:  Inadequate tracking of medication use, indication, efficacy and side effects. 
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PH3:  What training methods and reference documents should be employed for training the 
crew and medical team to identify and mitigate side effects and interactions of commonly 
used medications? 
 
Activity: 
The HHC shall negotiate with SD to investigate methods to improve tracking of 
medication use, indication, efficacy and side effects during flight and to determine 
what training methods and reference documents should be employed for training the 
crew and medical team to identify and mitigate side effects and interactions of 
commonly used medications. 
 
Product/Deliverables: 
Required Delivery Milestone: 
Required Platforms: 
Project/Organization Responsible for Implementation of Activity: 
SD 
HRP-47065 
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19.0 RISK OF ERROR DUE TO INADEQUATE INFORMATION -D X I  
 
Operator errors are common in all work environments. Task errors during human spaceflight 
missions could have drastic consequences. Errors can be due to lack of information which in turn 
may be due to any of the following: (a) lack of situational awareness, which can be due to poorly 
designed interfaces, poorly designed tasks, or cognitive decrements due to, e.g., fatigue or 
exposure to toxic environments; (b) forgetting, which can be due to inadequate training, poorly 
designed procedures, or to cognitive decrements due to, e.g., fatigue or exposure to toxic 
environment; (c) inability to access appropriate data and procedures due to poorly designed 
interfaces, poorly designed tasks, or to cognitive decrements due to, e.g., fatigue or exposure to 
toxic environments; or (d) failure of judgment due to incorrectly perceived or interpreted cues, 
inappropriately estimated results of decisions, or inadequate data. The risk is currently based on 
extensive data from commercial aviation, from nuclear power plant operations, and from other 
activities with high dependence on technology under sustained operations. The HRP must provide 
standards for reducing operator errors in spaceflight through adequate understanding of causes 
and mitigations of operator errors. 
 
Operational Relevance and Risk Context  
One of the most critical components for human presence in space has been ensuring that there are 
human systems standards in place that will provide for crew health as well as standards for 
habitability, environmental, and human factors. The Space Flight Human System Standards - 
SFHSS - (and the companion Human Integration Design Handbook – HIDH) require that each 
human spaceflight program derive program-specific, verifiable requirements to comply with the 
standards, and require that each human spaceflight program establish a human factors process 
involving health and human factors experts. This is to ensure that there will be identification of 
any standards in the SFHSS that are not applicable (or altered) and the rationale for non-
applicability; that all program level health and human factors requirements are based on the 
HIDH, cited empirical evidence, or known best practices; and that end-items are in compliance 
with SFHSS, and agency and program level requirements and specifications. 
The activities cited reflect the need to work toward the mitigation of identified SHFE risks by 
continuing to inform the standards, by engagement in the development of the requirements that 
will implement the standards based upon the resulting products, as well as providing content to 
the HIDH that will serve as the implementation guide. In addition, products resulting from these 
activities may provide valuable information to spaceflight programs that can inform the requests 
for trade studies. 
To ensure operational relevance of the deliverables from the tasks, all tasks leaders will identify 
stakeholders who will work with them in framing the questions and approach. The stakeholders 
will participate by identifying specific issues requiring research or technology development, by 
reviewing progress, and by suggesting operational evaluations. Depending on the specific tasks, 
stakeholders may include engineers or operations personnel. 
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
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Gaps 
 
SHFE1:  New Display and control designs are required to meet the new environments of the 
Constellation system 
 
Activity:  
Display Development 
This is a requirements development activity, supplemented by some research or 
validation activities on the ground. Produce requirements for display information density 
consistent with the smaller cockpit environments of the Orion CEV, the lander, and the 
Rover. 
 
Product/Deliverables 
Display and control design solutions for human computer interfaces for the Orion 
PDR and CDR. 
Caution and warning and display requirements for the Lunar Lander SRR 
Caution and warning and display design solutions for the Lunar Lander 
Guidelines for EVA interfaces with suit, spacecraft, rover, and tool displays and 
controls. 
Required Delivery Milestone 
Orion PDR design solutions required FY-08 
Orion CDR design solutions required FY09 
Lander SRR Requirements required FY-12 
Lander PDR design solutions required FY-13 
Required Platforms 
Laboratory Testbeds 
Mockups 
EVA Suit Development Facility, DESERT RATS 
Project/Organization Responsible for Implementation of Activity 
SHFE Directed Research Project. 
Partnership with NSBRI teams for Human Performance Factors, Sleep and 
Chronobiology, Sensorimotor Adaptation, Smart Medical Systems, and 
Technology Development. 
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Activity:   
Cursor Control 
This is a technology survey and testing effort to determine the best solutions for 
crewmembers to make computer inputs under various vibratory environments and in 
gloved suits. These are intrinsic to commanding spacecraft and its subsystems. 
Product/Deliverables 
Cursor control design solutions for human computer interfaces for the Orion PDR and 
CDR. 
Cursor control requirements for the Lunar Lander SRR 
Cursor control design solutions for the Lunar Lander 
Required Delivery Milestone 
Orion PDR design solutions required FY-08 
Orion CDR design solutions required FY09 
Lander SRR Requirements required FY-12 
Lander PDR design solutions required FY-13 
Required Platforms 
Laboratory Testbeds 
Mockups 
EVA Suit Development Facility, DESERT RATS 
Project/Organization Responsible for Implementation of Activity 
SHFE Directed Research Project. 
 
Activity: 
Caution and Warning System Displays and Electronic Procedures 
This is a technology survey and testing effort to evaluate advanced concepts for 
annunciation of events and display and paging of electronic procedures during a time 
critical event. It integrates procedural knowledge and knowledge bases with sensory data. 
 
Product/Deliverables 
Caution and Warning design solutions for the Orion PDR and CDR. 
Caution and Warning requirements for the Lunar Lander SRR 
Caution and Warning design solutions for the Lunar Lander 
Required Delivery Milestone 
Orion PDR design solutions required FY-08 
Orion CDR design solutions required FY09 
Lander SRR Requirements required FY-12 
Lander PDR design solutions required FY-13 
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Required Platforms 
Laboratory Testbeds 
Mockups 
EVA Suit Development Facility, DESERT RATS 
Project/Organization Responsible for Implementation of Activity 
SHFE Directed Research Project. 
Partnership with NSBRI teams for Human Performance Factors, Sleep and 
Chronobiology, Sensorimotor Adaptation, Smart Medical Systems, and Technology 
Development. 
 
Activity: 
Information Presentation for EVA 
This is a requirements development activity, supplemented by some research or 
validation activities on the ground. Produce requirements for presentation and navigation 
of displays of procedures, suit status sensors, navigation, and other information consistent 
with the unique environment of EVA suits. 
 
Product/Deliverables 
Guidelines for EVA interfaces with suit, spacecraft, rover, and tool displays and 
controls. 
Required Delivery Milestone 
Interfaces and approaches for Suit-1 PDR FY-09 
Requirements for Suit-2 SRR FY-11 
Interfaces and approaches for Suit-2 PDR FY-12 
Required Platforms 
Laboratory Testbeds 
Mockups 
EVA Suit Development Facility, DESERT RATS 
Project/Organization Responsible for Implementation of Activity 
SHFE Directed Research Project. 
Partnership with NSBRI teams for Human Performance Factors, Sleep and 
Chronobiology, Sensorimotor Adaptation, Smart Medical Systems, and Technology 
Development. 
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SHFE2: Need for objective measures for proficiency in training; minimal time available for 
crew medical training. 
 
Activity:  
Medical Proficiency Training 
Provide guidelines for the most efficient methods of training, and guidelines for the best 
media for presenting refresher training and just-in-time (JIT) training in flight. 
Development of a concept demonstration, in collaboration with Exploration Medicine 
team, using medical training as a test bed. This is not a research effort per-se. Rather; it is 
a review of training procedures and checklists to optimize to make emergency procedures 
and response more effective and timely.  
Address method of delivery, duration, and timing of training for pre-flight and in-flight 
activities. Pre-flight training includes familiarization, core knowledge, and hands-on 
training in preparation for a space mission. In-flight training includes JIT training and 
refresher training.  
 
Product/Deliverables: 
Initial training materials integrated for ISS use: 
o Draft requirements for optimal training type, duration and timing (with 
respect to anticipated task performance). 
o Sample training module for use in ground personnel training. 
Complete Training Materials and Medical Procedures Library for use in lunar 
exploration missions 
Required Delivery Milestone: 
FY10 Initial training materials and medical procedures integrated (Required as soon 
as practically available for ISS) 
FY14 Training materials integrated into Lunar operations and medical procedures 
library available for Lunar surface PDR   
Required Platforms: 
Ground Studies 
Project/Organization Responsible for Implementation of Activity: 
SHFE Directed Research Project. 
Partnership with NSBRI teams for Human Performance Factors, Sleep and 
Chronobiology, Sensorimotor Adaptation, Smart Medical Systems, and Technology 
Development. 
 
Activity: 
Spaceflight Resource Management Training 
Work with MOD to incorporate training on roles responsibilities and communications 
during intensive flight activities, similar to cockpit resource management concepts that 
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are employed in the aviation industry.  These materials are not specific training materials 
themselves, but are designed to incorporate the concepts of cockpit resource management 
into all MOD training materials. This is not research per-se, but rather an organizational 
effort to update the training materials and requires coordination with MOD training. 
 
Product/Deliverables: 
New modules of training materials incorporating Spaceflight Resource Management 
concepts (3 examples) 
Complete training library with Spaceflight Resource Management concepts 
incorporated. 
Required Delivery Milestone: 
FY14 Training materials integrated into Lunar operations training library available for 
Lunar surface PDR   
Required Platforms: 
Ground Studies 
Project/Organization Responsible for Implementation of Activity: 
SHFE Directed Research Project. 
 
SHFE3: Need for on-board crew to semi-autonomously plan and dynamically replan their 
schedules and activities.  Scheduling, rescheduling and real-time changes are done manually 
and are labor intensive.   
 
Activity: 
Science Planning Interface to Engineering (SPIFe) – Scheduling Tool 
Future mission concepts will require a significantly more efficient planning process and 
tools. The ultimate goal of this effort is to allow an on-board crew to semi-autonomously 
plan and dynamically replan their activity.  Based on a firm understanding of ground-
based replanning in several domains, the activity will be well-positioned to understand 
and develop tools for on-board use. The SPIFe tool considers a wide range of the 
dynamic resources constraining schedule and allows the crewmember to schedule tasks 
and check that the resources required to execute the task will be available, and that there 
are no unintended consequences of scheduling the task at a particular time (such as not 
being able to execute another required task at a later time). Development of this tool is 
almost complete, and then a decision will be made regarding its utility for spacecraft 
operations planning and if required, the tool will be validated in an operationally-
intensive ground analog (e.g. NEEMO). A functional prototype could be run alongside 
existing tools to collect valuable data on the tool and its capability to optimize a schedule. 
 
Product/Deliverables: 
Planning tool, validated in a ground analog available for use on the ISS 
Planning tool, validated in a ground analog available for use for Lunar Outpost 
Operations 
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Required Delivery Milestone: 
FY-12 SPIFe, could be integrated into crew operations as soon as available in ground-
validated form 
~FY22 SPIFe needed to support Lunar Outpost long-duration operations (Note: SPIFe 
is not envisioned to support lunar sorties because of the short duration and schedule-
intensive advanced planning that must occur for these missions.) 
Required Platforms: 
Ground or analog studies 
Project/Organization Responsible for Implementation of Activity: 
SHFE Directed Research Project
HRP-47065 
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20.0 RISK ASSOCIATED WITH POOR TASK DESIGN -D X I  
 
Errors are often related to poor task design. Critical tasks must be designed to minimize operator 
error. Automation, feedback and other task design elements may be used in these cases. Multiple 
actors, including robots, present a unique risk. 
 
Operational Relevance and Risk Context  
One of the most critical components for human presence in space has been ensuring that there are 
human systems standards in place that will provide for crew health as well as standards for 
habitability, environmental, and human factors.  The Space Flight Human System Standards - 
SFHSS - (and the companion Human Integration Design Handbook – HIDH) require that each 
human spaceflight program derive program-specific, verifiable requirements to comply with the 
standards, and require that each human spaceflight program establish a human factors process 
involving health and human factors experts.  This is to ensure that there will be identification of 
any standards in the SFHSS that are not applicable (or altered) and the rationale for non-
applicability; that all program level health and human factors requirements are based on the 
HIDH, cited empirical evidence, or known best practices; and that end-items are in compliance 
with SFHSS, and agency and program level requirements and specifications. 
The activities cited reflect the need to work toward the mitigation of identified SHFE risks by 
continuing to inform the standards, by engagement in the development of the requirements that 
will implement the standards based upon the resulting products, as well as providing content to 
the HIDH that will serve as the implementation guide.    In addition, products resulting from these 
activities may provide valuable information to spaceflight programs that can inform the requests 
for trade studies. 
To ensure operational relevance of the deliverables from the tasks, all tasks leaders will identify 
stakeholders who will work with them in framing the questions and approach. The stakeholders 
will participate by identifying specific issues requiring research or technology development, by 
reviewing progress, and by suggesting operational evaluations.  Depending on the specific tasks, 
stakeholders may include engineers or operations personnel. 
 
Priority  
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
SHFE4:  Guidelines are needed for appropriate task automation as well as for effective 
allocation of tasks between humans and automation to increase performance, efficiency, 
and safety.   
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Activity: 
Automation Interface Design Tools Development 
The task will focus on the development of methods and tools to help with the challenge 
of optimally distributing functions between automation and human operators in space and 
on the ground, during both the mission architecture definition and hardware/software 
design processes, based on analyses of integrated human-system performance.  
Tools to assist designers when they are designing automated modes, the various modes of 
operation and communicating those various modes and to ensure that all modes are 
identified and properly reviewed and addressed by the designer. 
 
Product/Deliverables 
Automation Evaluation Methods and Tools 
Required Delivery Milestone 
Insert into ISS Mission Ops (Attitude Controllers) FY08 
Demonstrate Task Decomposition Tool, Performance Modeling Tool and Interface 
Prototyping Tool to support EVA Suit 2 SRR, FY11. 
Demonstrate Task Decomposition Tool, Performance Modeling Tool and Interface 
Prototyping Tool, Required for Lander PDR FY13. 
Required Platforms 
Ground or analog studies 
Project/Organization Responsible for Implementation of Activity 
SHFE Directed Research Project 
HRP-47065 
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21.0 RISK OF REDUCED SAFETY AND EFFICIENCY DUE TO POOR 
HUMAN FACTORS DESIGN -D X I  
 
Inadequate human factors design in the physical work environments (e.g. vehicles, tools and tasks) will result 
in reduced human performance and increase the likelihood of errors. Research is needed to provide 
spaceflight human factors design data and design tools in microgravity and partial gravity. 
 
Operational Relevance and Risk Context  
One of the most critical components for human presence in space has been ensuring that there are human 
systems standards in place that will provide for crew health as well as standards for habitability, 
environmental, and human factors.  The Space Flight Human System Standards - SFHSS - (and the 
companion Human Integration Design Handbook – HIDH) require that each human spaceflight program 
derive program-specific, verifiable requirements to comply with the standards, and require that each human 
spaceflight program establish a human factors process involving health and human factors experts.  This is to 
ensure that there will be identification of any standards in the SFHSS that are not applicable (or altered) and 
the rationale for non-applicability; that all program level health and human factors requirements are based on 
the HIDH, cited empirical evidence, or known best practices; and that end-items are in compliance with 
SFHSS, and agency and program level requirements and specifications. 
The activities cited reflect the need to work toward the mitigation of identified SHFE risks by continuing to 
inform the standards, by engagement in the development of the requirements that will implement the 
standards based upon the resulting products, as well as providing content to the HIDH that will serve as the 
implementation guide.    In addition, products resulting from these activities may provide valuable 
information to spaceflight programs that can inform the requests for trade studies. 
To ensure operational relevance of the deliverables from the tasks, all tasks leaders will identify stakeholders 
who will work with them in framing the questions and approach. The stakeholders will participate by 
identifying specific issues requiring research or technology development, by reviewing progress, and by 
suggesting operational evaluations.  Depending on the specific tasks, stakeholders may include engineers or 
operations personnel. 
 
Priority  
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission. 
 
Gaps 
 
SHFE5:  ISS Noise levels exceed levels specified in requirements; tools and models are not currently 
available for Constellation vehicle design verification.   
 
Activity: 
Develop and Validate Models That Can be Used for Verification in CDR Design of Constellation 
Vehicle Systems 
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This activity will enhance the capability of existing models and modify them for application to the 
Constellation designs. These models will be assessed for adequate parameter complexity and 
accuracy. 
Product/Deliverables 
Verification model for Constellation Orion vehicle 
Required Delivery Milestone 
FY08 for Orion PDR 
FY09 for Orion CDR 
Required Platforms 
Ground development 
Project/Organization Responsible for Implementation of Activity 
SHFE Directed Research Project
HRP-47065 
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22.0 RISK OF PERFORMANCE ERRORS DUE TO POOR TEAM 
COHESION AND PERFORMANCE, INADEQUATE SELECTION/TEAM 
COMPOSITION, INADEQUATE TRAINING, AND POOR PSYCHOSOCIAL 
ADAPTATION -D X I  
Human performance errors may occur due to problems associated with working in the space environment and 
incidents of failure of crews to cooperate and work effectively with each other or with flight controllers have 
been observed.  Interpersonal conflict, misunderstanding and impaired communication will impact 
performance and mission success.  The history of spaceflight crews regarding team cohesion, training and 
performance has not been systematically documented.  Tools, training and support methods should be 
provided to reduce the likelihood of this risk and improve crew performance. 
 
Operational Relevance and Risk Context  
While little empirical data have been collected regarding the impact of interpersonal and intrapersonal factors 
on spaceflight performance, it is possible that crew conflict could jeopardize a long duration Exploration 
Missions. Reports from MIR reveal that several missions may have been terminated earlier than planned due 
to interpersonal frictions between crewmembers, and some veteran NASA astronauts have reported crew 
conflict during previous space travels. Understanding the potential negative impacts of interpersonal and 
intrapersonal issues on spaceflight and analog environments is critical for identifying actions required to help 
crewmembers succeed during new types of missions (e.g., Mars Missions). Few individuals have spent one 
year or longer in isolated and confined environments, and a Mars Mission could be as long as three to five 
years in duration. Observations and “lessons learned” from previous space missions and from analog 
environments are critical sources of information required to inform these efforts. In preparation for 
Exploration Missions, BHP research focuses on preventing and mitigating the risk of performance errors due 
to inadequate Team Cohesion and Performance, Inadequate Selection/Team Composition, Inadequate 
Training, and Poor Psychosocial Adaptation. Monitoring tools, countermeasures, training requirements, and 
selection recommendations are needed to aid flight crews and ground support teams.  
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission. 
 
Gaps 
 
BHP 2.1.4 What is the experience of spaceflight crews regarding team cohesion, psychosocial 
adaptation, and training? (Priority 1) 
The behavioral health experience of crews has not been systematically documented. This approach will 
inform the development of strategies for improving crew cohesion and communication, as well as adapting 
tools or measures to help monitor, detect, and prevent potential problems.  
 
Activity: 
Systematic Procedure: Crew History Report 
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Review of existing crew information and literature from analogs to examine small groups in extreme 
environments; debrief questionnaire development and analysis of current and future long-duration 
crews regarding their experiences, emphasizing interpersonal factors. This is largely a clinical activity 
until data from a sufficient number of subjects are collected.  
 
Product/Deliverables: 
1) Crew History Report - provides recommendations based on existing spaceflight and analog 
experience of crews, including training, in-flight, and post-flight events.  
2) Systematic procedure for collecting behavioral health data regarding interpersonal 
relations and crew dynamics from returning long duration astronauts. 
3) Updates to Standards, if applicable. 
Required Delivery Milestone: 
Crew History Report based on current anecdotal evidence and analog evidence delivered in 
2008. Systematic procedure delivered to Med Ops in 2008. Updates to recommendations 
made once thirty subjects have been evaluated, with subsequent updates following every four 
years. Recommendations required by 2013 for Mission Ops Requirements Definition and 
2023 for Lunar Habitat Mission Ops. Standards update in 2012. 
Required Platforms:  
Ground based research. 
Project/Organization Responsible for Implementation of Activity: 
Directed Study, in collaboration with CB and SD 
 
BHP Gap 2.2.1 What are the most effective methods for maintaining crew cohesion and ground 
communication, to manage and resolve conflict in space? (Priority 1) 
Given the extended duration and confinement of Exploration Missions, strategies to promote crew cohesion 
and effective communication will be needed. Development of strategies and countermeasures, including 
development of training protocols, and new monitoring methods and tools may address this gap. 
 
Activity: 
Optimal Communication and Conflict Management 
Lab studies that examine the impact of environmental stressors, incentives, and crew configuration 
changes on communication and performance within simulated space crews and between simulated 
space and ground crews. 
Obtain and analyze data on crew cohesion and optimal communication methods during spaceflight, 
including communications between space and ground crews, in order to develop recommendations 
for improved communication strategies related to performance of mission objectives.  
Ground tests to validate and optimize existing conflict management technologies to support crew 
cohesion and ground communication.  
If flight data collected reveals that additional countermeasures are needed to address cohesion and 
communication, additional studies will be developed to help design and test new strategies. 
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Product/Deliverables: 
1) Recommendations for optimal communication strategies 
2) Technologies that provide conflict management support and guidance for crewmembers, 
particularly for autonomous operations. 
3) Updates to Standards, if applicable. 
Required Delivery Milestone: 
In-flight validation to begin in 2012, and Mission Ops to be informed by 2013 with 
Recommendations in preparation for Lunar Mission Design. Conflict Management 
Technology to be delivered by 2014. Updates to Recommendations made in 2015, upon 
completion of flight validation. Standards update in 2012. 
Recommendations due by 2013, and technologies due by 2014.  
Required Platforms: 
Flight data for past and future flights can be collected pre and post flight. Conflict 
management technology to be evaluated in analogs, including NEEMO, Haughton-Mars and 
the Antarctic.  Flight validation of technology and Recommendations to occur on ISS.  
Project/Organization Responsible for Implementation of Activity: 
 TBD 
 
Gap 2.3.1 What are the best methods for training crews for maintaining cohesion and optimal 
performance during exploration missions (TBR-11)? (Priority 1) 
Crews on ISS are multicultural, and this diversity will most likely continue for Exploration Missions.  Finding 
adequate time for crews to train together continues to remain a challenge.  These factors make it essential to 
determine what acceptable alternatives to traditional team training methods (i.e. virtual team training) exist. 
In addition, the type of team training activities (role playing, etc.) and the duration of the training are 
important factors in designing the most efficient and effective training model. It is critical to capture what 
type, dose, style and length of training can most adequately cover multiple competencies to ensure efficiency 
of the astronauts’ time while ensuring mastery of the required competencies.  
 
Activity: 
Training Studies 
Lab simulations to evaluate relationships between types of training, and their effects on cohesion and 
performance. These lab simulations allow for control of the type of training each team goes through, 
so that an accurate assessment of team training style on cohesion and performance can be determined.  
Analog studies to validate optimal training methods; further validation to occur during NASA 
training with astronauts and flight controllers. Evaluate Training Requirements during spaceflight to 
determine if Training Requirements are adequate.  
If further Training Requirements are needed, ground based studies will commence and will be 
followed by a phase of in-flight validation and lunar studies. 
 
Product/Deliverables:  
1) Requirements, crew training for team cohesion and optimal performance. 
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2) Update to Standards, if applicable. 
Required Delivery Milestone: 
Delivered by 2012 for Mission Operations; Update Standards in 2012. Required by 2013 for 
Mission Operations 
Required Platforms 
This effort, at this time, is primarily lab studies, analogs (NEEMO, HMP, Antarctic), and 
data mining; validation to require ISS. 
Project/Organization Responsible for Implementation of Activity: 
ITA with ARC  
 
BHP 2.1.1 What methods and technologies can be developed to monitor individual and crew coping 
with the behavioral conditions of spaceflight? (Priority 2)  
During Exploration Missions, and especially during a Mars Mission, real time communication between the 
crew and flight surgeons will not be available as it is now on ISS. Flight surgeons have stated the need for 
unobtrusive monitoring tools that are transparent to crews, require minimal crew time or effort, and that help 
detect if crews are having difficulties coping with the spaceflight environment.  
The aim of the current Requirements is to develop a tool that detects changes in crew cohesion that may be 
precursors of crew dysfunction and poor performance. Such a tool would evaluate, as a measure of crew 
cohesion, changes in  communication patterns (e.g., ratio of positive affect to total communication for given 
period). The tool would enable in real-time, an objective evaluation of crew dynamics and scheduling of risk 
mitigation countermeasures, as needed. 
Monitoring tools identified in the Risk of Behavioral and Psychiatric Conditions may also provide an 
assessment of team cohesion. These tools (e.g., voice acoustics and facial expression recognition) will be 
validated in ground studies through 2010, and validated in flight through 2012 (more information can be 
found in Gap 3.1.1). 
 
Activity: 
Develop Requirements for Crew Communications Technology 
Activities include evaluating various existing techniques for assessing team cohesion through crew 
communication, validating these techniques in analog environments and during astronaut training, 
and validating on ISS.  
Preferred techniques will be developed into Requirements for an automated, unobtrusive tool to be 
utilized during Exploration Missions. 
If after undergoing flight validation, these techniques are found to be not effective, additional 
research to occur on ground and on ISS. New Requirements will then be delivered by 2023 for 
informing Mission Ops and Input to Mars Ops Development. 
 
Product/Deliverables: 
1) Requirements for Crew Communications Technology (unobtrusive, passive measures that 
assesses changes in crew communication patterns as a measure of modified cohesion). 
2) Updates to Standards (if applicable). 
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Required Delivery Milestone: 
Delivered for Mission Operations by 2013. Standards updates by 2012. 
Techniques are required to inform Mission Ops by 2013. 
Required Platforms: 
Ground studies to adapt technology for spaceflight; analogs include NEEMO, Haughton 
Mars Project (HMP), and other Isolated, Confined and Extreme (ICE) Environments. 
Validate on ISS, as the ISS will emulate the transit environment to Mars.   
Project/Organization Responsible for Implementation of Activity: 
NASA ITA with Ames  
 
BHP 2.1.3 Does increased autonomy impact crew cohesion and performance? (Priority 2) 
As crews begin operations for long duration missions beyond low Earth orbit, they will need to exercise 
increasing command and control of their daily activities. The distance for Mars Missions will result in loss of 
capability for real-time communication, downlink, and commanding. Likewise, the crew will have to 
augment and adapt their schedules based on real time changes in their schedules. Medical Operations has 
requested a study of crew autonomy while we are still in low Earth orbit, to identify (if any) the impact of 
increased autonomy on crew dynamics and performance.  
 
Activity: 
Autonomy Studies 
Studies in analog environments (including NEEMO) evaluating the impact of increased autonomy on 
crew dynamics and performance. Workshop to examine preliminary results from analog studies and 
further define role of autonomy in Mars exploration and its effects on crew performance and crew 
dynamics. Studies on ISS to observe crew performance and cohesion, working under a low autonomy 
condition versus a high autonomy condition. 
If evidence exists that increased autonomy impacts crew dynamics and performance, the need for 
countermeasures in addition to what BHP has developed/is developing, will be considered. 
 
Product/Deliverables: 
1) Recommendations based on the impact (if any) of increased autonomy in analogs and 
spaceflight. 
2) Input for ISS as needed. 
3) Updates to Standards, if applicable. 
Required Delivery Milestone: 
ISS data collection to be completed by 2015; Mission Ops for Lunar Habitat missions to be 
informed in 2015 
Recommendations to Mission Ops for Lunar Habitat missions are due by 2023. 
Required Platforms: 
Requires analogs (NEEMO) and ISS 
Project/Organization Responsible for Implementation of Activity: 
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NRA 
 
BHP Gap 2.2.2 What are the most effective countermeasures for mitigating stress and deteriorated 
morale in order to optimize performance? (Priority 2) 
 
Activity: 
 TBD 
 
Product/Deliverables:  
TBD 
Required Delivery Milestone: 
TBD 
Required Platforms: 
TBD 
Project/Organization Responsible for Implementation of Activity: 
TBD 
 
Gap 2.3.2 What are the best methods and tools for selecting and composing crews for optimal team 
performance during Exploration Missions (TBR-12)? (Priority 3) 
Group cohesion plays an important role in team performance: cohesive teams perform higher than less 
cohesive teams. Research demonstrates team selection factors influence team cohesion; thus, it is important to 
examine and implement practices to secure the best crew composition for Exploration Missions. Therefore, 
BHP’s third priority within the Team Risk addresses recommendations for astronaut selection and team 
composition for Exploration Missions.   
 
Activity: 
Crew Composition Studies 
Lab simulations allow for teams to be tasked with strenuous endeavors that simulate planetary surface 
activities (i.e. searching for moon rocks, water), with manipulation of variables within a controlled 
environment to examine cause and effect. Thus, the impact of personality factors and other various 
individual on differences on performance and cohesion can be observed. Lab simulations provide an 
efficient and cost effective way to build a knowledge base prior to going to an analog environment 
and then to spaceflight.  
Following lab simulations, a review research from analogs to determine optimal selection criteria for 
crew cohesion and performance will be conducted. Assess factors of ISS crew and how those are 
related to measures of cohesion and performance. Develop composition and selection 
recommendations for Exploration Missions.   
   
Product/Deliverables:  
1) Recommendations, composition and selection. 
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2) Update Standards. 
Required Delivery Milestone:  
Inform Mission Ops for Lunar Habitat missions in 2015.  Recommendations required by 
2023. 
Required Platforms: 
This effort is primarily ground studies and data mining effort. 
Project/Organization Responsible for Implementation of Activity: 
ITA with ARC/ NSBRI 
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23.0 RISK OF CARDIAC RHYTHM PROBLEMS -D X I  
 
Heart rhythm disturbances have been seen among astronauts.  Most of these have been related to 
cardiovascular disease, but it is not clear whether this was due to pre-existing conditions or 
effects of space flight.  It is hoped that advanced screening for coronary disease has greatly 
mitigated this risk.  Other heart rhythm problems, such as atrial fibrillation, can develop over 
time, necessitating periodic screening of crewmembers’ heart rhythms.  Beyond these terrestrial 
heart risks, some concern exists that prolonged exposure to microgravity may lead to heart 
rhythm disturbances.  Although this has not been observed to date, further surveillance is 
warranted. 
 
Operational Relevance and Risk Context  
Missions may be impacted by the occurrence of a clinically-significant dysrhythmia.  It is 
important document whether or not space flight results in clinically significant arrhythmias in 
astronauts who do not have heart disease. 
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission. . 
 
Gaps 
 
CV1: Unknown in-flight alterations in cardiac structure and function 
CV8: Inability to predict manifestation of sub-clinical or environmentally-induced 
cardiovascular diseases during spaceflight 
 
Activity:  
Integrated Cardiovascular Study 
This is a comprehensive study of cardiac function. Data will be obtained pre-flight, 
inflight (2 weeks, 4 weeks, q 1-2 months), and postflight.  Inflight testing will include 
holter monitoring, 2-d echocardiography, and ambulatory blood pressure monitoring.  
After completion of this study, the clinical expression of cardiac atrophy during long 
duration spaceflight will be defined, and its significance for cardiac systolic and diastolic 
function at rest and during gravitational transitions will be determined.  In addition, 
preliminary information will be obtained regarding ventricular conduction and 
repolarization that may provide clinical reassurance, or pathophysiologic insight into the 
risk for cardiac arrhythmias.   
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Product/Deliverables: 
The initial products are quantification of the extent, time course, and clinical 
significance of spaceflight-related cardiac atrophy and identification of its 
mechanisms and functional consequences. If the results indicate that a 
countermeasure is needed to protect cardiac function, ground-based 
countermeasures will be evaluated.  
Required Delivery Milestone: 
The SFHSS cardiovascular standard will be validated / updated in 2013 (needed 
by FY13 to support mission operations requirements); deliver countermeasure, if 
necessary, in 2020 (needed as soon as possible to mitigate the risk).  Data will 
feed into lunar validation studies on the lunar surface and a lunar countermeasure 
will be delivered in 2023 which is required in FY23 for long-duration mission 
operations. 
Required Platforms: 
ISS is required for characterization of spaceflight-induced cardiac changes.  The 
bed rest analog may be used for ground-based countermeasure development and 
efficacy studies prior to validation study using ISS.  Further counter-measure 
development for partial gravity environments may require lunar bed rest analog 
studies. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
N7: What are the K+, Mg+ and P+ changes in relation to cardiovascular issues and bone 
loss?  
 
Activity 
Nutrition Status Assessment – SMO O16E: Nutrition SMO 
See Risk of Accelerated Osteoporosis – Gap N7 
HRP-47065 
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24.0 RISK OF INVERTEBRAL DISC DAMAGE -D X I  
 
Extended exposures to microgravity (and possibly fractional gravity) may lead to an increased 
risk of spinal nerve compression and back pain. 
 
Operational Relevance and Risk Context  
Clinical data indicates that astronauts have a higher incidence of intervertebral disc damage 
(Postflight?  Related to flight?)  than the general population.  Data should be collected to better 
define the extent of this problem and to guide design of re-entry and postflight protocols.  
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
B4:  What is the incidence of intervertebral disc damage following spaceflight? 
 
Activity: 
Data Mining for Intervertebral Disc Damage 
Additional should be to be collected to establish whether the lengthening of the spine 
during space flight exacerbates the risk for IVD damage with loading.  The risk for 
injury may be greater during the performance of mission tasks in hypogravity, with 
accelerated g forces from piloting spacecrafts, or with return to gravitational loading on 
Earth.   
 
Product/Deliverables: 
Report of findings, and if the results indicate that a countermeasure is needed to 
protect against IVD damage, ground-based countermeasure studies may be 
solicited.   
This countermeasure will then inform lunar bed rest studies to determine if 
microgravity IVD damage countermeasures are adequate for fractional gravity. 
Required Delivery Milestones: 
Mission operations needs to be informed of data as soon as possible to make any 
modifications to Orion regarding loads on crew.  Validation / updates to the 
health standard will occur in FY11.  If countermeasure development studies are 
required, a validated countermeasure will be delivered in FY14; which is 
required as soon as possible to mitigate the risk.  Data will feed into lunar 
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validation studies on the lunar surface and a lunar countermeasure will be 
delivered in 2023 which is required in FY23 for long-duration mission 
operations. 
Required Platforms: 
Retrospective flight data collection and prospective flight data collection plan.   
If the data indicate there is damage, the bed rest ground analog is required for the 
demonstration of microgravity countermeasure efficacy, and ISS is required for 
countermeasure validation.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – directed study 
 
Activity: 
Lunar Analog Bed Rest Development 
This study is for the development of a lunar analog.  These lunar mission simulations 
may or may not include (~3 day) transit phases between Earth and Moon. While it may 
be useful to simulate some impacts of (7-14 day) sortie missions, the primary focus will 
be on longer, outpost missions; thus, simulation durations will generally range up to 90 
days. 
 
Product/Deliverables: 
Validated lunar analog model 
Required Delivery Milestone: 
Required Platforms: 
This effort is ground-based analog development, developing a lunar analog 
model.  The model will not be validated until lunar surface mission ops begin the 
in the 2020 timeframe. 
Project/Organization Responsible for Implementation of Activity: 
Flight Analogs Project (FAP) – via Directed Study 
 
Activity: 
Pre/post MRIs for Intervertebral Disc Damage 
Additional evidence will be gathered in order to document IVD damage post flight.   
 
Product/Deliverables: 
Report of findings, and if the results indicate that a countermeasure is needed to 
protect against IVD damage, ground-based countermeasure studies may be 
solicited.   
This countermeasure will then inform lunar bed rest studies to determine if 
microgravity IVD damage countermeasures are adequate for fractional gravity.. 
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Required Delivery Milestone: 
Mission operations needs to be informed of data as soon as possible to make any 
modifications to Orion regarding loads on crew.  Validation / updates to the 
health standard will occur in FY11.  If countermeasure development studies are 
required, a validated countermeasure will be delivered in FY14; which is 
required as soon as possible to mitigate the risk.  Data will feed into lunar 
validation studies on the lunar surface and a lunar countermeasure will be 
delivered in 2023 which is required in FY23 for long-duration mission 
operations. 
Required Platforms: 
ISS crewmember participation is required 
The bed rest ground analog is required for the demonstration of microgravity 
countermeasure efficacy, and later for lunar countermeasure efficacy studies.  
ISS is required as the Mars transit analog for countermeasure validation.   
Project/Organization Responsible for Implementation of Activity: 
Space Medicine
HRP-47065 
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25.0 RISK OF CREW ADVERSE HEALTH EVENT DUE TO 
ALTERED IMMUNE RESPONSE -D X I  
 
Human immune function is altered in- and post-flight, but it is unclear if this change leads to an 
increased susceptibility to disease.  Reactivation of latent viruses has been documented in 
crewmembers, though this reactivation has not been directly correlated with the immune changes 
or with observed disease.  Further research may elucidate whether microgravity exposure impairs 
the immune system, and whether this change represents a health risk to crews. 
 
 
Operational Relevance and Risk Context  
While there is post-flight evidence to support this risk, in-flight evidence should also be obtained.  
In-flight immune function data and any clinical correlations should be documented before further 
research plans are developed.  Ground-based work should be conducted using the Antarctic 
station space flight analog (best available analog for immunity during >6 months. flight) so that 
ground control data of an appropriate sample size may be obtained.  Validation of an analog 
directly to flight data would be useful for future countermeasures validation.  The laboratory 
findings are to be correlated to clinical findings and follow-up studies are performed to document 
any latent, long-term effects. 
 
Priority 
 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
IM1:  Lack of in-flight immune data, which is required to determine risk. 
IM2:  Need formulation of an improved immunology standard for exploration spaceflight. 
IM5:  Need investigation of individual records of in-flight illness for clarification of time-
course and etiology. 
 
Activities: 
1) Flight-Induced Changes in Immune Defenses: ‘Immune Function,’ DSO 498/SDBI 
1498 
Shuttle-based study investigating the effects of space flight on 1) neutrophil and 
monocyte functions (phagocytosis, degranulation, oxidative burst capacity, and 
expression of surface molecules) and 2) natural-killer cell and lymphokine-activated 
killer cell cytotoxicity against target cells, and cytokine production 
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2) Incidence of Latent Virus Shedding During Space Flight: ‘Latent Virus,’ DSO 
493/SDBI 1493 
Shuttle-based study investigating the frequency of latent virus reactivation, latent virus 
shedding, and clinical disease after exposure to the physical, physiological, and 
psychological stressors associated with space flight 
3) Space Flight-Induced Reactivation of Latent Epstein-Barr Virus: ‘Epstein-Barr,’ on 
Shuttle as DSO 493/SDBI 1493 and ISS as E129 
Shuttle- and ISS-based study investigates the magnitude of immunosuppression as a 
result of space flight by 1) analysis of stress hormones, 2) quantitative analysis of EBV 
replication using molecular and serological methods, and 3) determining virus-specific 
T-cell immune function. 
 
Product/Deliverables: 
Final report of findings will be delivered in 2009. Data from these Shuttle-based 
immune studies will be combined with the ISS-based Integrated Immune SMO to 
inform and update health standards. If these studies together indicate that a 
countermeasure is needed, ground-based countermeasure studies will be 
solicited, then these countermeasures will be validated on ISS. 
Required Delivery Milestone: 
Final report of findings will be delivered in 2009. Together with Integrated 
Immune SMO, update health standards in 2011. Validated countermeasures, if 
required, will be delivered in 2019. All products are required as soon as possible 
to mitigate this risk. 
Required Platforms: 
ISS is required to validate the risk (Integrated Immune SMO), to ensure that the 
data represents space normal and for validation of potential countermeasures. A 
ground analog (Antarctica, NEEMO, and/or Haughton-Mars) is required for 
ground studies for countermeasure development. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
 
Activity: 
Validation of Procedures for Monitoring Crewmember Immune Function: ‘Integrated 
Immune SMO,’ SMO 015/SDBI 1900 
The objective of this SMO is to develop and validate an immune monitoring strategy 
consistent with operational flight requirements and constraints. There are no procedures 
currently in place to monitor immune function or its effect on crew health.  Immune 
dysregulation has been demonstrated to occur during spaceflight, yet little in-flight 
immune data has been generated to assess whether or not this may be a clinical 
problem. This SMO will assess the clinical risks resulting from the adverse effects of 
space flight on the human immune system and will validate a flight-compatible 
immune monitoring strategy. The correlation between in-flight immunity, physiological 
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stress and a measurable clinical outcome (viral reactivation) will be determined for 
long- vs. short-duration space flight. 
 
Product/Deliverables: 
Data from this study will be combined with the Shuttle-based immune studies to 
inform and update health standards. If results indicate that a countermeasure is 
needed, ground-based countermeasure studies will be solicited and performed.  
Then these countermeasures will be validated on ISS. 
Required Delivery Milestone: 
Together with previously mentioned Shuttle-based immune study results, the 
health standards will be updated in FY11. Validated countermeasures, if 
required, will be delivered in 2019. All products are required as soon as possible 
to mitigate this risk. 
Required Platforms: 
ISS is required to validate the risk (Integrated Immune SMO), to ensure that the 
data represents space normal and for validation of potential countermeasures. A 
ground analog (Antarctica, NEEMO, and/or Haughton-Mars) may be used to 
provide additional data. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
IM3:  Lack of ground analog studies, however suitable analogs for immune dysregulation 
have been identified.  Forward work may be expedited using these opportunities. 
 
Activity: 
NEEMO Rapid Operational Investigation (ROI):  Immune function changes during a 
spaceflight-analog 10-day undersea mission 
This study measures immune functional changes, physiological stress, viral reactivation 
and viral specific immunity during the NEEMO mission. NEEMO represents a good 
analog for some aspects of short-duration spaceflight on immunity. This study will 
provide data to compare this ground-based spaceflight-analog to actual flight data. If 
immune dysregulation is observed in the NEEMO crews that is similar to that observed 
in flight crews during/following spaceflight, this analog will be validated for some 
aspects of spaceflight-associated immune dysregulation. This analog will not supersede 
the program goal to validate a ground analog for long-duration spaceflight and 
immunity.  
 
Product/Deliverables: 
Initial product is completion of the NEEMO study and final report of findings 
whether the analog is valid for assessing immune responses. If the analog is not 
valid, additional studies will be solicited to determine a more suitable analog.  
Results will be combined with other immune studies and if these studies together 
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indicate that a countermeasure is needed, ground-based countermeasure studies 
will be solicited and performed. Any countermeasures will be validated on ISS. 
Required Delivery Milestone: 
Data will feed into knowledge gathered by the Integrated Immune SMO. 
Required Platforms: 
NEEMO undersea environment is required to assess the validity of the short-
duration space analog. Other analog facilities may be required for follow-on 
studies.  A ground analog (Antarctica, NEEMO, and/or Haughton-Mars) is 
required for development of any needed microgravity countermeasures and ISS is 
required for their validation. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
Activity: 
3D Tissue Analogs for the Study of Varicella-Zoster Virulence and Infectivity 
This study is concerned with determining if: VZV is alive, active and has the potential 
to spread.  VZV may assume increased virulence and/or live virus numbers in 
microgravity.  This study will demonstrate the sensitivity of the model and provide an 
operational deliverable in the form of a reliable test for live quantifiable virus.  
 
Product/Deliverables: 
Initial product is completion of the ground-based study and final report of 
findings. Results will be combined with other immune studies and if these studies 
together indicate that a countermeasure is needed, ground-based countermeasure 
studies will be solicited and performed.  Any countermeasures will be validated 
on ISS. 
Required Delivery Milestone: 
Study completion by 2008. Data will feed into knowledge gathered by the 
Integrated Immune SMO. 
Required Platforms: 
Ground-based laboratory is required.  
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
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26.0 RISK OF IMPAIRED ABILITY TO MAINTAIN CONTROL OF 
VEHICLES AND OTHER COMPLEX SYSTEMS -D X I  
It has been shown that long-duration Spaceflight alters sensorimotor function which manifests as 
changes in locomotion, gaze control, dynamic visual acuity, and perception. These changes have 
not specifically been correlated with real time performance decrements. The possible alterations 
in sensorimotor performance are of interest for Mars missions due to the prolonged microgravity 
exposure during transit followed by landing tasks. This risk must be better documented and NS 
changes must be better correlated with performance issues. 
 
Operational Relevance and Risk Context  
New evidence regarding landing performance indicates that research into these types of issues is 
not a high priority for Shuttle or ISS. However, since Mars operational scenarios are still TBD, it 
is agreed that the ISS should be utilized to gather the data required to define the research that 
might be needed to enable future Mars mission operations. Therefore, this risk is considered to 
have a higher priority than the others within the sensorimotor discipline. Spaceflight data should 
be collected (RMS, SSRMS, docking, glove box ops, Soyuz landings, etc.). In addition, 
performance related to neurosensory dysfunction should be used to determine the need for further 
research and countermeasure development.   
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Important to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
SM1: Relationship between the mode of in-flight exercise and post-flight sensorimotor 
performance 
 
Activity: 
Sensorimotor Performance Data Mining 
It is proposed that the type and amount of in-flight exercise performed by 
crewmembers may influence post-flight disturbance in balance and locomotion.    
Exercise logs for both US and Russian crewmembers will be evaluated to determine the 
relationship between the types of in-flight exercise performed and post-flight 
sensorimotor performance.   
 
Product/Deliverables: 
Initial product is space normal data from a data review activity.  If results 
indicate that a microgravity countermeasure can improve sensorimotor 
performance, ground based studies may be solicited and performed, and the best 
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countermeasures validated using ISS flight studies.  Data from the 
countermeasure flight validation studies will feed into lunar surface studies. 
Required Delivery Milestones: 
Report of findings will be delivered in 2009 and the SFHSS sensori-motor 
standard will also be validated / updated at that time; if necessary a 
countermeasure will be delivered in FY17.  Both products are required in FY13 
to support mission operations requirements development.  
Required Platforms: 
Access to Flight Medicine, JSC Biomedical Research Laboratory data, and 
LSDA databases is necessary for the data review. 
A ground analog is required for the demonstration of microgravity 
countermeasure efficacy, and ISS is required for potential countermeasure 
validation.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
SM2: What is the time course of recovery of sensorimotor function after long-duration 
space flight? 
 
Activity: 
Sensorimotor Performance Recovery Data Mining 
After long -space flights, astronauts require time to return to pre-flight sensorimotor 
performance.  This study will compile the recovery data from previous long-duration 
astronauts to determine the average amount of time that is required for sensorimotor 
function recovery. 
 
Product/Deliverables: 
Initial product is space normal data from a data mining activity.  Results will be 
provided to mission operations. 
Required Delivery Milestone: 
Mission operations will be informed of the results and updated health standard 
will be delivered in 2009.  Both products are required in FY13 to support mission 
operations requirements development. 
Required Platforms: 
Access to Flight Medicine, JSC Biomedical Research Laboratory data, and 
LSDA databases is necessary for the data mining study. 
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
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SM4: Correlate previous performance data with clinical observations 
 
Activity: 
Performance Data Mining 
This study will compile data recorded from previous missions regarding ISS EVAs.  
The purpose of this data mining activity is to gain additional operational data. Lessons 
learned from this analysis can be applied to the Constellation Program to ensure that 
the evidence for sensorimotor changes in crew performance as a result of space flight is 
thoroughly assessed.   
 
Product/Deliverables: 
Initial product is space normal data from a data mining activity.  If results 
indicate that a microgravity countermeasure is needed for sensorimotor 
performance, ground-based studies will be solicited and performed, and the best 
countermeasures validated using ISS flight studies. 
Required Delivery Milestone: 
Report of findings will be delivered in 2009 and the SFHSS sensori-motor 
standard will also be validated / updated at that time; if necessary a 
countermeasure will be delivered in FY17.  The countermeasure is required as 
soon as possible to mitigate the risk for current crew and the standard update is 
required in FY13 to support mission operations requirements development.  
Required Platforms: 
Access to Flight Medicine, JSC Biomedical Research Laboratory data, and 
LSDA databases is necessary for the data mining study. 
A ground analog may be required for the demonstration of microgravity 
countermeasure efficacy.  ISS is required as the Mars transit analog for 
countermeasure validation.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
SM5: What are the effects of disorientation and inter-individual differences on supervisory 
control, docking, RMS, etc? 
 
Activity: 
Performance Data Mining 
This study will compile data recorded from previous missions regarding manual control 
and landing.  The purpose of this review is to gain additional operational data and 
insight regarding Shuttle landings to determine the multi-factorial causes that led to the 
landing outcomes. Lessons learned from this analysis can be applied to the 
Constellation Program to ensure that the evidence for sensorimotor changes in crew 
performance as a result of space flight is thoroughly assessed.  Data will also be 
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gathered from available data from RMS operations, EVAs and Shuttle/Soyuz docking 
operations relevant to manual control. 
 
Product/Deliverables: 
Initial product is space normal data from a data mining activity.  If results 
indicate that a microgravity countermeasure is needed for sensorimotor 
performance, ground-based studies will be solicited and performed, and the best 
countermeasures validated using ISS flight studies. 
Required Delivery Milestone: 
Report of findings will be delivered in 2009 and the SFHSS sensori-motor 
standard will also be validated / updated at that time; if necessary a 
countermeasure will be delivered in FY17.  The countermeasure is required as 
soon as possible to mitigate the risk for current crew and the standard update is 
required in FY13 to support mission operations requirements development.  
Required Platforms: 
Access to Flight Medicine, JSC Biomedical Research Laboratory data, and 
LSDA databases is necessary for the data mining study. 
A ground analog may be required for the demonstration of microgravity 
countermeasure efficacy.  ISS is required for countermeasure validation.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
SM6: Need to perform a seated Manual/Visual performance assessment after long-duration 
spaceflight. 
 
Activity: 
Head-eye Coordination during Simulated Orbiter Landings  
The aim of this study is to obtain basic data on the characteristics of head and eye 
movements during simulated Orbiter landings. This information will be used to 
determine landing tasks that may induce spatial disorientation. In addition, two 
paradigms will be used to model spatial disorientation due to microgravity exposure: 1) 
long-duration hyper-gravity exposure in a centrifuge, and 2) galvanic vestibular 
stimulation (GVS). Preliminary results suggest that post-centrifuge disorientation, and 
per-GVS exposure, generate symptoms of spatial disorientation comparable to space 
flight. Simulated landings in the VMS will be performed both post-centrifugation and 
with GVS, to test the hypothesis that spatial disorientation diminishes head-eye 
coordination and landing performance. This may serve as a model for the deterioration 
in pilot performance during reentry, and provide a training regimen to allow 
commanders and pilots to experience spatial disorientation in a simulator. 
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Product/Deliverables: 
Initial product is completion of ground-based study and a validated model of 
spatial disorientation (SD) due to microgravity exposure that can be used to 
familiarize shuttle pilots with SD symptoms during simulated landings, as well as 
a training tool to improve landing performance after space flight. 
Required Delivery Milestone: 
Complete study by 2009  
Required Platforms: 
Ground based study  
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
 
Activity: 
Manual/Visual Control Study (Phase I & II) – TBD 
This study in preparation will be conducted as a pre- and post-flight study using long-
duration ISS crewmembers. 
 
Product/Deliverables: 
Initial product will be completion of an ISS pre- and post-flight study to 
determine seated manual/visual control performance (i.e., landing a spacecraft).  
If study results determine that a countermeasure is necessary, ground-based 
studies will be solicited and performed. The best countermeasures will be 
selected and validated on ISS. 
This countermeasure will then inform lunar bed rest studies to determine if 
microgravity manual/visual control performance countermeasures are adequate 
for fractional gravity. 
Required Delivery Milestone: 
Complete study and report findings will be delivered by FY13. If 
countermeasures are needed, validated countermeasure(s) will be delivered to 
mission operations by FY20.  This potential countermeasure is required as soon 
as possible to mitigate the risk. 
Data will feed into lunar countermeasure validation studies with delivery of lunar 
countermeasure in FY23 which are required for long-duration lunar missions. 
Required Platforms: 
ISS is required for countermeasure validation.  The bed rest ground analog is 
required for the demonstration of microgravity countermeasure efficacy.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
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SM3: What is the appropriate rehabilitation protocol for sensorimotor function? 
 
Activity: 
The HHC Element will collaborate with the Space Medicine Division (SD), specifically 
the Astronaut Strength, Conditioning and Rehabilitation (ASCR) group to identify the 
appropriate rehabilitation protocol for sensorimotor function. 
 
Product/Deliverables: 
Required Delivery Milestone: 
Required Platforms: 
Project/Organization Responsible for Implementation of Activity: 
HHC and ASCRs 
 
SM10: There are no stated acceptable ranges of cognitive and psychomotor performance. 
 
Activity: 
The HHC Element will negotiate with the Behavioral Health and Performance (BHP) 
Program Element to develop a multi-factorial cognitive risk assessment. 
 
Product/Deliverables: 
Required Delivery Milestone: 
Required Platforms: 
Project/Organization Responsible for Implementation of Activity: 
BHP 
 
SM13: Incorporate vestibular assessments within the in-flight periodic exams. 
SM15:  Need to adopt a multi-disciplinary approach to identify crewmembers at greatest 
risk of falls; also need to implement and track directed rehabilitation 
SM16:  Need to insure that astronauts at risk of falls are accompanied until the risk 
diminishes to acceptable levels. 
SM17:  Require an astronaut post-flight fall risk assessment that should be a coordinated 
effort between crew surgeons, ASCRs and discipline researchers. 
  
Activity: 
The HHC shall negotiate with SD to: determine whether vestibular assessment should 
be incorporated into in-flight periodic exams; develop a multi-disciplinary approach to 
identifying crewmembers at greatest risk of falls, and to implement and track directed 
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rehabilitation; insure that astronauts at risk of falls are accompanied until risk 
diminishes to acceptable levels; and develop an astronaut post-flight fall risk 
assessment that should be a coordinated effort between crew surgeons, ASCRs and 
discipline researchers. 
 
Product/Deliverables: 
Required Delivery Milestone: 
Required Platforms: 
Project/Organization Responsible for Implementation of Activity: 
SD 
 
SM11: Need to provide alternate sources for spatial orientation. 
 
Activity: 
Advanced Displays for Efficient Training and Operation of Robotic Systems 
 
Product/Deliverables: 
Required Delivery Milestone: 
Required Platforms: 
Project/Organization Responsible for Implementation of Activity: 
SHFH – NSBRI NRA 
 
Activity: 
Modeling and Mitigating Spatial Disorientation in Low-Gravity Environments 
 
Product/Deliverables: 
Required Delivery Milestone: 
Required Platforms: 
Project/Organization Responsible for Implementation of Activity: 
SHFH – NSBRI NRA 
 
SM12: Need to develop standards for spaceflight cockpit control displays and inputs. 
 
Activity: 
This work needs to be completed by the Human Environmental Factors Division 
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Product/Deliverables: 
Required Delivery Milestone: 
Required Platforms: 
Project/Organization Responsible for Implementation of Activity: 
SHFH-SHFE
HRP-47065 
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27.0 RISK OF PERFORMANCE ERRORS DUE TO SLEEP LOSS, 
CIRCADIAN DESYNCHRONIZATION, FATIGUE, AND WORK 
OVERLOAD -D X D 
Fatigue occurs during spaceflight and will jeopardize health and performance.  This risk may be influenced 
by artificial and transmitted light exposure, individual vulnerability to sleep loss and circadian dynamics, and 
work/sleep schedules.  Efforts are needed to improve sleep hygiene, and to identify and improve conditions 
that interfere with sleep quality.  Research areas may include: development of a self-assessment tool for 
cognitive function and fatigue, light therapy for phase shifting, alertness and mood disorders, and other means 
to improve sleep quality and reduce fatigue. 
Operational Relevance and Risk Context  
Research demonstrates that aspects of the spaceflight environment may disrupt circadian rhythms and reduce 
sleep; anecdotal evidence from spaceflight reveals that fatigue and work overload can also occur. Ground 
studies illustrate that lack of adequate amounts of good quality sleep, as well as performance operations 
during times of fatigue or circadian desynchronization, can adversely affect performance capability and 
safety.  
Lunar surface activities will be both strenuous and fatiguing, and will likely involve some shift work. 
Furthermore, fatigue is a risk factor for the other two Behavioral Health and Performance Risks (Risk of 
Performance Errors Due to inadequate Team Cohesion and Performance, Inadequate Selection/Team 
Composition, Inadequate Training, and Poor Psychosocial Adaptation; Risk of Behavioral and Psychiatric 
Conditions.) It is therefore essential to develop countermeasures for issues related to sleep loss, fatigue, 
circadian desynchronization and work overload. BHP research activity aims to assess this risk as well as 
provide adequate standards and countermeasures for Exploration Missions.  
  
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Desirable to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
BHP 1.1.1 What are the best measures and tools to use for assessing decrements in cognitive function 
due to fatigue and other aspects of spaceflight? (Priority 1) 
A correlation between fatigue and performance in spaceflight has not been documented.  A means to 
objectively assess cognitive decrements and provide information during mission operations to the crew 
surgeon and astronaut may be helpful.  
 
 Activity: 
 Refine and Validate Three Minute Performance Vigilance Task (PVT) 
Validate in analogs (NEEMO, HMP, PML); field test on STS; validate for spaceflight on ISS. 
Concurrently enhance tool so it serves as a self-assessment measure for the Astronaut and provides 
feedback to flight surgeons during autonomous missions.  
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Product/Deliverables: 
1) PVT/Cognitive Assessment Tool 
2) Update Standards (if applicable) 
Required Delivery Milestone: 
Field test on STS in 2009; Deliver in 2013; Required by 2014 for Missions Ops 
implementation 
Required Platforms: 
Analogs include: NEEMO, Phoenix Mars Lander (PML), Haughton Mars Project (HMP), 
Russian Chamber Study (105-day) 
Data gathered on NEEMO to provide normative data for spaceflight 
Field testing and initial validation anticipated on STS. In-flight validation of tool to continue 
on ISS. Requires spaceflight because of sleep loss and fatigue issues related to microgravity 
and other spaceflight environmental factors, and to ensure the test is appropriate for the 
spaceflight environment.  
Project/Organization Responsible for Implementation of Activity: 
Directed Study, with NSBRI 
 
Activity: 
Refine and Validate Fatigue Meter  
A physical meter that measures environmental (e.g., light exposure, noise) and physiological signals 
(e.g., sleep wake activity) to determine individual fatigue levels and provide the user (e.g., 
astronaut/flight surgeon, MOD/ground support) with feedback about potential decrements in 
performance ability. Such a measure will also provide information on circadian phase to indicate 
levels of potential risk due to fatigue. 
 
Product/Deliverables:  
1) Validated meter for use in spaceflight  
2) Update to Standards, if applicable 
Required Delivery Milestone: 
  Delivered by 2013; Required by 2014 for Mission Ops implementation 
Required Platforms: 
Identify tools being used in military operations. Validate in analogs including:  Phoenix Mars 
Lander (PML), Haughton Mars Project (HMP) and Russian Chamber Study (RC) – 105-day. 
Requires the ISS because of sleep-related issues associated with microgravity, and to ensure 
the instrument is appropriate/feasible for spaceflight environment; Involves collaboration 
with EPSP. 
Project/Organization Responsible for Implementation of Activity: 
Directed Studies (PML, HMP) with NSBRI and possible NRA 
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BHP 1.1.5 How is performance in spaceflight affected by sleep loss, circadian desynchronization, 
fatigue and work overload? (Priority 1) 
Data needs to be collected so that cognitive performance in the spaceflight environment can be assessed, and 
appropriate countermeasures developed, as necessary, and/or policies/standards enforced. 
 
Activity: 
Cognitive Performance Studies 
Collect performance data using PVT (a hand-held instrument that uses a three-minute psychomotor 
vigilance test of speed and accuracy), augmented with self-assessment interface that provides real-
time feedback to users regarding cognitive performance. 
Collect data during field test of PVT on STS, and validate PVT on ISS. If data collected in-flight 
reveals that additional measures are needed to address cognitive function, beyond those already 
developed/being developed, ground based studies will commence and be followed by a phase of in-
flight validation and lunar studies. 
 
Product/Deliverables: 
1) Recommendations to Mission Ops regarding fatigue and cognitive performance, based on 
evidence gathered using the PVT  
2) Update to Standards 
Required Delivery Milestone 
Data collection to begin on STS in 2009; Recommendations delivered in 2013. 
Recommendations required by 2013 for Mission Ops Requirements Definition.  
Required Platforms: 
Data collection to begin during field testing of instrument on STS; Data collection to then 
continue on ISS; Requires the ISS because aim of the study is to characterize cognitive 
performance as a result of the spaceflight environment, including the sleep-related issues 
associated with microgravity. This effort involves collaboration with HHC and SHFH, with 
BHP serving as lead.  
Project/Organization Responsible for Implementation of Activity: 
Directed Study with NSBRI 
 
BHP 1.3.1: How can physical and cognitive workloads be optimally managed in space relative to 
fatigue and recovery? (Priority 2)  
BHP 1.3.3: What duration of physiological sleep is needed to recover from chronic partial sleep loss, 
slam shifting, or high tempo sustained operations? (Priority 2) 
While the evidence is largely anecdotal, strict adherence to timelines has been reported to be fatiguing and 
stressful for astronauts. Furthermore, individuals on analog missions where there are unusual light cues (i.e. 
twenty four hour sunlight in the Arctic) have reported that they continue to work for hours on end without 
feeling a need for sleep, a potential concern since lack of sleep and fatigue can affect performance. In future 
space missions to the Moon or Mars, crewmembers will be given more autonomy to plan and carry out their 
activities due to the long distances involved and the tasks that will be needed to explore a planetary surface, 
and they will also be exposed to light cues unlike those on Earth. Recommended optimal work rest schedules 
need to be provided so that crews can make informed decisions around work and rest.    
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Activity:  
Develop Optimal Work Rest Schedules  
Refine mathematical models to optimize schedules and target countermeasures for sleep strategies, 
and to identify the best countermeasure application and timing. Ground based studies to investigate 
sleep dose recovery requirements. Data mining/collection of performance in flight, in conjunction 
with subjective assessment of sleep/recovery/work schedules, and actigraphy data. Evaluation of 
preferred work-rest schedules during the high- and low- autonomy conditions identified in Autonomy 
Study (Team Risk, Gap 2.1.3) 
 
Product/Deliverables:  
1) Optimal work-rest schedules to prevent mental and physical fatigue during any operational 
tempo. 
2) Recommendations to be incorporated into Spaceflight Human Systems Standards.  
3) Input for developing an integrated mathematical model to optimize schedules, 
countermeasures, and performance (see Gap 1.1.3). The models are based on overall risk for 
the crew as well as performance risk tailored for individual astronauts. Recommendation for 
crew scheduling controls to mission designers.  
Required Delivery Milestone: 
Update Standard 2012. Requirements for Mission Ops due by 2013. Study completed 2014 
(status provided in 2013 with subsequent updates.)  
Required Platforms:  
Ground studies include analogs:  NEEMO, PML, HMP, and MOD flight controllers.  Data 
collection requires BHP/MOD/CB/SD/SHFH collaboration.  Requires the ISS because of 
sleep-related issues associated with microgravity, and to accurately emulate the spaceflight 
high-tempo, remotely scheduled and controlled environment. The ISS will emulate the transit 
environment to Mars.   
Project/Organization Responsible for Implementation of Activity: 
NRA 
 
BHP 1.3.2: How can sleep loss be administratively controlled? (Priority 2) 
 
Despite medication use, sleep loss does occur during spaceflight, with some crewmembers reporting minimal 
amounts of sleep, particularly prior to conducing critical mission tasks. Many factors can affect sleep quality 
and quantity in the spaceflight mission environment including high noise levels, shifting schedules, high 
tempo workloads, thermal temperature changes, microgravity adjustment, and close proximity to others. 
Flight surgeons have requested information that can aid individual astronauts on improving their sleep quality 
and quantity during spaceflight. Given the complexity of spaceflight missions, and the effects of sleep loss on 
fatigue and performance, such information will be instrumental for not only crewmembers, but also their 
families, ground support teams, and other medical personnel regarding strategies to improve sleep quantity 
and quality. Information will help inform current standards as well as those for future missions. 
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Activity: 
Sleep Quality Questionnaire 
Data collection from crews returning from flight regarding their sleep quality on-orbit, and in 
comparison to their terrestrial sleep and during various training activities. This questionnaire is 
designed to assess what factors effect sleep quality and quantity and seeks suggestions regarding 
strategies for improving sleep on-orbit for future flyers. 
 
Product/Deliverables: 
1) Educational materials for astronauts, management and ground support on strategies for 
improving sleep quality and quantity during human spaceflight missions.  
2) Recommendation for standard to protect sleep, minimize fatigue, and maintain 
performance. 
Required Delivery Milestone: 
Standards update required by 2012. Recommendations for policies to be delivered by 2013 
for Lunar Operations Mission Design. Requirements for Lunar Habitat due by 2023, 
delivered by 2013.  
Required Platforms: 
Primarily ground effort. Once policy changes are implemented, data collection to assess and 
evaluate effectiveness of changes.  This includes a data mining effort in collaboration with 
CB and Med Ops. 
Project/Organization Responsible for Implementation of Activity: 
Directed Study 
 
BHP 1.2.2 What are the performance risk/benefits of specific sleep/wake medication during sleep in-
flight? (Priority 2) 
Flight surgeons have requested an electronic database that will make information regarding the effects of 
sleep-wake medications readily available to them. 
 
Activity: 
Develop Electronic Sleep Wake Medication Database 
Literature review regarding the effects of sleep medication, including performance, safety, and 
potential side effects. Literature should also indicate potential effects if user is awakened shortly after 
consuming sleep medication.  
 
Product/Deliverables: 
Electronic Sleep Medication Database 
Required Delivery Milestone: 
Database to be delivered in 2008, with subsequent updates every four years; Database due by 
2013 for Mission Ops Requirements Definition 
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Required Platforms: 
This effort, at this time, is primarily data mining and building the database. Results from the 
planned Crew Quarters Sleep/Wake medications study (see Gap 1.2.3) will provide additional 
information on performance effects following medication use.  Involves collaboration with 
HHC/ Pharmacology and ExMC.  
Project/Organization Responsible for Implementation of Activity: 
BHP Directed study  
 
BHP 1.2.3 What are the best individual dosing requirements/protocols for sleep and alertness 
medications during spaceflight? (Priority 2) 
 
Activity: 
Crew Quarters Sleep Medication Study 
 The “Crew Quarters Study” is a ground based study to test commonly used sleep/wake medications 
on the presence, magnitude and time course of cognitive performance deficits in astronauts prior to 
spaceflight missions. The study will determine also if there are sedating carry over effects on 
neurobehavioral functions upon abrupt premature termination of sleep in order to simulate an 
emergency situation. Astronauts sleep overnight in the Crew Quarters facility at Johnson Space 
Center after consuming their choice/dose of sleep medication. Performance and safety effects will be 
evaluated at different times following the consumption of the medication.  
 
Product/Deliverables: 
1) Requirements for best operational approach for utilizing sleep/wake medications during 
training/flight. 
2) Individualized Recommendations for Sleep/Wake Medications. 
Required Delivery Milestone: 
Ground study completed in 2010; Requirements and Recommendations validated in flight and 
delivered to Mission Ops by 2013; Due for Mission Ops Requirements Definition by 2013 
Required Platforms: 
This effort is primarily ground studies using astronauts.  Requires validation on ISS, with CEV 
and surface operations validation on moon.  Involves collaboration with HHC/Pharmacology 
and ExMC as well as SD and CB. 
Project/Organization Responsible for Implementation of Activity: 
Space Medicine – BHP Directed study  
 
BHP 1.1.2 Does sleep loss continue on long duration missions or is there adaptation? (Priority 3) 
Previous spaceflight studies have revealed that space crews are at times not sleeping for the duration of their 
scheduled sleep period. Crewmembers experience frequent shifts in their sleep/wake schedules, and in 
addition, various environmental factors affect sleep quality and quantity. Studies have shown that self-report 
of just how much sleep one is actually getting can be inaccurate. Therefore, in order to accurately assess to 
what degree sleep is disrupted on-orbit, an unobtrusive, objective measure of sleep-wake activity is needed. 
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Objective sleep data during the course of a mission provides important operational feedback for the astronaut 
as well as the flight surgeon, particularly prior to performing critical mission tasks. 
 
Activity: 
Sleep/Wake Activity Study 
Collect inflight data using an Actigraph watch to objectively document sleep and wake times, and a 
sleep log for subjective information on countermeasure use, and factors related to sleep loss during 
spaceflight. Data are collected during shuttle and ISS missions to quantify spaceflight and light-
exposure-related sleep disturbances, examine sleep shift schedules on sleep, and use of 
countermeasures (i.e. lighting, medication).  
 
Product/Deliverables: 
1) Operational use of Actigraph during missions (MRID).  
2) Update to Standards. 
3) Recommendations to Mission Ops based on evidence.  
Required Delivery Milestone: 
Tool to be delivered for ISS operations by 2011 (or before if possible); recommendations based 
on evidence delivered and due for Lunar Mission Ops by 2013; actigraph technology required 
prior to 2014 for Lunar Operations Mission Design, unless functions of actigraph are fulfilled 
by the fatigue meter. If so, actigraph operations to cease once fatigue meter becomes 
operational. If not, actigraph operations to continue and follow-on validation and optimization 
for Mars Missions to occur in lunar ops. 
Required Platforms:  
Requires the STS and ISS because of sleep-related issues associated with spaceflight. Requires 
continued participation by STS crews because of the wide variation across missions. Requires 
ISS because to date, relatively little is known about sleep quantity and quality on the ISS. Study 
provides information important for exploration planning. There is a high acceptability for 
participating in this study and high compliance among the astronauts participating in study.  
Project/Organization Responsible for Implementation of Activity: 
NRA 
 
BHP 1.1.3 How can individual astronauts’ vulnerabilities to sleep loss and circadian rhythm disruption 
best be determined? (Priority 3) 
 
Activity: 
Develop and Integrate Mathematical Models 
Literature review to determine objective predictors of sleep vulnerabilities and resistances. 
Mathematical model development incorporating individual vulnerabilities, identification of the best 
countermeasure application, timing, etc., to ensure performance during critical mission tasks.  
Verification of objective predictors (e.g., biomarkers) of vulnerabilities to sleep loss and its effects in 
spaceflight. Workshop to enhance collaborations between investigators and integration of models. 
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Product/Deliverables: 
Integrated mathematical model to determine optimal timing of countermeasures to ensure 
performance, based on individual vulnerabilities to sleep loss and circadian desynchronization.  
Required Delivery Milestone: 
Required and delivered by 2013 for Lunar Mission Ops Requirements Definition; it is 
anticipated that integration efforts will continue every two years in preparation for Lunar 
Habitat Mission Ops Implementation. Requirements due by 2013 for Lunar Missions and 2023 
for Lunar Habitat. 
Required Platforms: 
This effort is primarily ground studies, and data mining effort. 
Project/Organization Responsible for Implementation of Activity: 
NSBRI 
 
BHP 1.2.1 How can light be used to optimally minimize circadian problems in space? (Priority 3) 
Preliminary studies indicate that light exposure can correct difficulties in sleep patterns that occur with shift 
work, jet lag and sleep disorders. The timing, duration, and wavelength of the light impact countermeasure 
effectiveness. Acute and long-term safety and performance effects should be evaluated. 
 
Activity:  
Studies to Determine Optimal Light Spectrum 
These studies will evaluate safety and performance to determine whether blue-enriched fluorescent 
light can be used to regulate circadian rhythm in the low-lighting levels common to spacecraft. If 
successful, then onboard artificial lighting systems may serve the dual purpose of maintaining 
circadian entrainment while providing illumination that supports vision. 
 
Product/Deliverables: 
1) Hardware Requirements Lunar Lander lighting spectrum. 
2) Recommended update to Standards. 
3) Requirements on best operational approach for utilizing light for circadian 
entrainment/fatigue. 
4) Hardware Requirements Lunar Habitat lighting spectrum. 
5) Requirements to maintain alertness on Exploration Missions 
Required Delivery Milestone: 
Hardware Requirements due by 2012 for Lunar Lander design; hardware requirements for 
Lunar Lander to be delivered in 2012. Standards update by 2012. 
Requirements on the best operational approach for utilizing light in-flight (duration, timing, 
etc.), due by 2013 for Mission Ops implementation. Research activity to be completed by 2014. 
Hardware updates for the Lunar Habitat to be delivered by 2020.  
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Required Platforms: 
The activity will be conducted in various ground laboratory studies and the blue light (and/or 
bright light) requirements will be validated in analogs that provide an operational tempo similar 
to spaceflight, such as NEEMO, MPL, or actual testing during MOD ground support 
operations. Other analogs offering isolation and lighting challenges, such as Antarctica or HMP 
will be utilized also if feasible. Involves collaboration with SHFH. 
Project/Organization Responsible for Implementation of Activity: 
Directed studies with NSBRI 
HRP-47065 
Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study AnalysisBHP
Gap 1.1.1: What are the best measures and tools to 
use for assessing decrements in cognitive
function due to fatigue and other aspects of 
spaceflight? (Priority 1)
Gap 1.1.5 (new gap):How is performance in space 
flight affected by sleep loss, circadian 
desynchronization, fatigue and work 
overload? (Priority 1)
Risk of Performance Errors Due to Sleep 
Loss, Circadian Desynchronization, Fatigue, 
and Work Overload
BHP Cognitive Assessment Tool
(Directed Study
/ NSBRI)
STS
Field 
Test 
Validate PVT 
Analogs:  
NEEMO,HMP 
PML, RC
Are additional CM 
needed to address 
decrements?
NO
YES
Lunar Study
Are cognitive 
performance CM 
adequate? NO
Lunar CM 
Studies
Ground-based CM Studies Flight Validation Studies
Select best CM
YES
Cognitive Performance 
Studies (comparison 
with analogs)
(Directed Study
/ NSBRI)
BHP
(4) CM(s)To maintain 
Cognitive performance on
Exploration mission
Validated in new lunar outpost 
environment
(1)Recommended Update
to Fitness for Duty Standard 
&/or new standard
3
Mission Ops
Implementation 4
Update Lunar
Ops & Input to 
Mars
Ops Dev’t
(Date Required
TBD)
PVT - ISS Data 
Collection 
Develop Fatigue Meter 
– unobtrusive risk 
assessment tool
(NRA)
BHP
Review Tools; Feasibility
Studies/ Validate in
Analogs: PML, HMP, RC
Flight Validation
Studies 
Analogs: 
NEEMO 
HMP, PML, 
RC 
(3, 4) Fatigue Meter to provide 
countermeasure- real time 
feedback regarding readiness to 
perform
(3) PVT tool to monitor cognitive 
performance prior to critical tasks
Standards Update 1
(2) Recommendations re: fatigue 
and cognitive performance, based 
on evidence gathered
Mission Ops 
Req’ts
Definition
2 (4) CM(s)To maintain cognitive performance 
on Exploration missions
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study AnalysisBHP
1.3.1 How can physical and cognitive 
workloads be optimally managed in 
space relative to fatigue and 
recovery? (Priority 2)
Risk of Performance Errors Due to Sleep 
Loss, Circadian Desynchronization, Fatigue, 
and Work Overload
BHP Optimal Work-Rest Schedules in High 
Tempo, Autonomous 
Environment 
(NRA/Directed)
Lunar Study
NO
Lunar CM 
Studies
YES
NSBRI
(3) Recommendations
To aid schedules/autonomy
Exploration mission
Validated in lunar 
environment
(1)Recommended Updates
To Crew Health &/or 
new standard
Mission Ops Req’ts
Definition2 3
Update Lunar
Ops & Input to 
Mars
Ops Dev’t
(Date Required
TBD)
(2) Requirements-
Optimal Work / 
Rest Schedules for 
Flight and Ground 
Crews(1)
Flight validation studiesAnalog studies NEEMO, HMP, PML
1.3.3 What duration of physiological sleep is 
needed to recover from chronic 
partial sleep loss and/or slam 
shifting? (Priority 2)
Sleep Recovery 
Schedule (NSBRI) Lab studies
BHP Performance Data Mining and Subjective 
Assessment of Sleep / 
Recovery / Work 
Schedules (BHP with 
SHFH and ExMC)
Performance 
v. Schedule
YES
Evidence of 
existing optimal 
schedules in 
flight?
NO
Are work/rest/recovery 
schedules adequate in 
Lunar environment?
Standards Update 1
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study AnalysisBHP
1.3.2 How can sleep loss be administratively 
controlled? (Priority 2)
Risk of Performance Errors Due to Sleep 
Loss, Circadian Desynchronization, Fatigue, 
and Work Overload
(4) Recommendations
To aid administrative control 
of sleep loss for
Exploration missions
Validated in lunar 
environment
Lunar Habitat
Development
(I/F defined
Earlier)Mission Ops Req’ts
Definition
2 3 4
Update Lunar
Ops & Input to 
Mars
Ops Dev’t
(Date Required
TBD)
(2) Recommendations for 
updating policies affecting 
sleep; Develop education 
materials for crews, flight 
med ops
BHP Assessment of Sleep Hygiene / Policies in 
flight (BHP with MOD 
and Flight Med Ops)
Ground 
Studies 
MOD,  Ques
N
O
YES
Ground 
Studies- assess 
effectiveness
Are 
recommendations 
effective?
Lunar Validation 
Studies 
Lunar CM 
Studies
NO
Are 
recommendations  
effective?
Ground-based Studies
YES
(2)
(1)
(3) Requirements for 
Lunar Habitat to 
contribute to control of 
sleep loss
Standards Update 1
(2) Update 
recommendations for 
updating policies affecting 
sleep; Develop education 
materials for crews, flight 
med ops
(2,4) Recommendations
To aid administrative control 
of sleep loss for
Exploration missions
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study Analysis
4.1.1; 5.2
HHC
(NEW) Gap 1.1.4:To what extent is sleep loss 
encountered during space flight due to 
acoustic and photic environmental 
disturbances during space flight? 
(Priority 2) Gap 1.2.4: What are the 
environmental materials and conditions 
that minimize sleep disruption in space 
flight? (Priority 2)
Risk of Performance Errors Due to 
Sleep Loss, Circadian 
Desynchronization, Fatigue, and 
Work Overload
BHP
Acoustic impact studies
(NSBRI) 
Lab 
Simulations ISS Study
NO
YES
Lunar Study
Are environmental CM 
adequate?
NO
Lunar CM 
Studies
Ground-based CM Studies Flight Validation Studies
Select best CM YES
(4)Physical CM to maintain
adequate
Envionmental conditions during
Exploration mission
(5) CM(s)To minimize
environmental
Disturbances on
Exploration mission
Validated in lunar env.
Lunar Habitat
Development
(I/F defined
Earlier)Standards
2
3 4 5
Update Lunar
Ops & Input to 
Mars
Ops Dev’t
(Date Required
TBD)
CM needed?
NO
Lander Env
Req’ts 1 Mission Ops 
Req’ts
Definition
(1)Update Standards; 
(2) Requirements for Lander 
Acoustic/Photic challenges
(2)Recommended Update To Crew Health &/or 
new standard
(3) Requirements On Best 
Operational Approach  for 
Minimizing environmental 
disturbances;
(4) Requirements for Lunar 
Habitat Acoustic/Photic
challenges
(1,2) (3,4)
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study AnalysisBHP
Gap 1.2.2 What are the performance 
risk/benefits of specific sleep/wake 
Medication during sleep in flight?
(Priority 2) Gap 1.2.3 What are the 
best individual dosing 
requirements/protocols for Sleep and 
alertness medications during 
spaceflight? (Priority 2)
Risk of Performance Errors Due to Sleep 
Loss, Circadian Desynchronization, Fatigue, 
and Work Overload
BHP Sleep Wake Medication Studies (Directed)
Lunar Study
Are 
requirements/recs
adequate in Lunar 
Environment? NO
Lunar CM 
Studies
YES
BHP
(3) Sleep Wake medication
requirements for 
Exploration mission
Validated in Lunar
environment
Mission Ops Req’ts
Definition
2 3
Update Lunar
Ops & Input to 
Mars
Ops Dev’t
(Date Required
TBD)
(2)
(2) Individualized 
Recommendations for 
Sleep/Wake Medications
Ground-based 
studies
Flight validation 
studies
(2) Requirements for Best 
Operational Approach  for 
Utilizing Sleep/Wake 
Medications during 
Training / Flight 
(2)
NO
YES
Are recommendations/ 
requirements validated in 
flight?
Data collection –effects of microgravity 
on Sleep Wake medications
Best Practices Sleep 
Wake Medication
(Directed)
(3)
Rev. 
of 
med
(1)
Up-
dates
Up-
dates
Up-
dates
Up-
dates
(2) Review medical/scientific 
literature on 
performance/safety when 
sleep/wake medications are 
active in brain (3)
Standards Update 1
(1)
(3) Updated 
Requirements / 
Recommendations
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study AnalysisBHP
Risk of Performance Errors 
Due to Sleep Loss, Circadian 
Desynchronization, Fatigue, 
and Work Overload
BHP Sleep / Wake Activity 
Studies (NRA)
YES
Lunar Validation 
Studies 
YES
Lunar CM 
Studies
ISS/STS Data Collection
Gap 1.1.2: Does sleep loss 
continue on long duration 
missions or is there 
adaptation? (Priority 3)
(2) Recommendations Based on 
Adaptation (2)CM to aid in adaptation 
validated in lunar environment
Ops CMs needed
To design long-
duration
missions
2
(3) Actigraph: Tool to monitor Sleep/ 
wake activity included in ISS 
Operations ; provides real time 
feedback to flight surgeons
Are functions of 
Actigraph now being used 
in Operations, satisfied by 
Fatigue Meter?
NO
NO
Are additional CM 
needed?
NO
YES(0,2, 3) Are CM  adequate?
Ground-based CM Studies Flight Validation Studies
Select best CM
(2)Actigraph validated in 
lunar environment
to monitor sleep/wake 
activity and light exposure
Standards Update 1
Mission Ops
Implementation3
Mission Ops 
Req’ts
Definition
2
(1)
Operational for ISS 0
(2)CM to aid in adaptation
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study AnalysisBHP
Gap 1.1.3: How can individual astronauts’
vulnerabilities to sleep loss and 
circadian rhythm disruption best be 
determined? (Priority 3)
Risk of Performance Errors Due to Sleep 
Loss, Circadian Desynchronization, Fatigue, 
and Work Overload
BHP Integration of mathematicalmodels
Lunar Study
Are models 
adequate?
NO
Lunar CM 
Studies
YES
(4) Mathematical models that 
predict vulnerabilities to sleep 
loss and circadian 
desynchronization specific to 
Lunar and Mars environment
(1)Recommended 
Update
To Crew Health
&/or new standard
Mission Ops 
Req’ts
Definition
2 4
Update Lunar
Ops & Input to 
Mars
Ops Dev’t
(Date Required
TBD)
(2) Mathematical 
models that predict 
vulnerabilities to sleep 
loss and circadian 
desynchronization
Refine and validate 
models; incorporate 
additional factors
(NASA/NSBRI)
Standards 
Update
1
Wrk
-shp
(2)(1)
3
Information 
provided to 
ISS as needed
(3), (4) (3), (4) (4)
Updates
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Major Milestone/ 
Event/Accomplishment
E
H
lement:
RP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
onstellation
Orion
EVA Suit
C
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
Informing 
Health Stds
CMInforming Missions Ops
Updating 
Health Stds
Requirements
Ground Study STS/ISS Study Lunar StudyOther Flight Study AnalysisBHP
p 1.2.1: How can light be used optimally 
to minimize circadian problems in 
space? (Priority 3)
isk of Performance Errors Due to Sleep 
ss, Circadian Desynchronization, Fatigue, 
d Work Overload
P Studies to DetermineOptimal Light Spectrum
Ga
R
Lo
an
BH
Lunar Study
Are light 
requirements 
adequate? NO
Lunar CM 
Studies
YES
(5) Requirements to maintain 
Alertness on
Exploration mission
Validated in lunar and planetary
environment
(2)Recommended 
Update To Crew 
Health &/or new 
standard
Lunar Habitat
Development
(I/F defined
Earlier)
Mission Ops 
Req’ts
Definition
3 4 5
Update Lunar
Ops & Input to 
Mars
Ops Dev’t
(Date Required
TBD)
(1) (4) Requirements 
for Lander & Habitat 
Lighting Spectrum 
(3) Requirements On 
Best Operational 
Approach  for Utilizing 
Light for Circadian 
Entrainment/Fatigue
Ground-based studies
(2)  (1,4)
Lander 
Lighting   1 
Req’ts
(NASA/NSBRI)
Standards 
Update
2
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28.0 RISK OF OPERATIONAL IMPACT OF PROLONGED DAILY 
REQUIRED EXERCISE -D X D  
Muscle atrophies in microgravity and strength decreases.  Currently, significant daily time is 
scheduled to crew exercise.  Making the exercise more efficient may allow similar beneficial 
effects to be achieved more simply, and in shorter time, which would provide more crew time for 
operational support.  Benchmarking crew strength requirements, and testing exercise equipment 
and regimens against these benchmarks, will promote the development of more efficient, yet 
equally safe, exercise regimens. 
 
Operational Relevance and Risk Context  
At present the crews aboard ISS spend up to two hours a day exercising.  However, neither the 
exercise regimens, nor the measurement of the efficacy of these regimens have been standardized. 
In flight exercise prescriptions have not been systematically evaluated.  It is possible that the 
amount of time spent exercising is more than is required to maintain strength and fitness levels.  
If more efficient protocols can be developed, then crew time can be recovered for other mission 
activities.  Until in-flight measurements of VO2max, and muscle mass, strength and endurance are 
accurately measured, the current exercise prescription cannot be evaluated, and optimization of 
prescriptions may not be possible.   
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Desirable to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
M2: What is the current status of in-flight and post-flight exercise performance capability? 
What are the goals/targets for protection with the current in-flight exercise program? 
M7: Can the current in-flight performance be maintained with reduced exercise volume? 
M8: What is the minimum exercise regimen needed to maintain fitness levels for tasks? 
M9: What is the minimum set to equipment needed to maintain those (M8) fitness levels? 
CV2:  In-flight and immediate post-flight VO2 max is unknown. 
 
Activity: 
ISS ARED Muscle Function Study 
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gaps 7-9 
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Activity: 
Bed Rest Exercise Countermeasures Optimization 
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gaps 7-9 
 
Activity: 
ISS/VO2max Study 
See Risk of Unnecessary Operational Limitations Due to Inaccurate Assessment of 
Cardiovascular Performance – Gap CV2 
HRP-47065 
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29.0 RISK OF UNNECESSARY OPERATIONAL LIMITATIONS DUE TO 
INACCURATE ASSESSMENT OF CARDIOVASCULAR PERFORMANCE -D 
X D  
Current in-flight indicators of cardiac performance may not accurately reflect astronauts’ cardiovascular 
performance. Making operational decisions based on inaccurate cardiac performance measures may 
unnecessarily restrict crewmembers for critical activities or, more seriously, could subject crewmembers to 
activities for which they are not physically prepared. Accurate measurement of crewmember aerobic capacity 
can eliminate this risk. 
 
Operational Relevance and Risk Context  
In-flight VO2 max measurements should be collected to determine cardiac performance.  These measurements 
will allow medical operations personnel to better determine if the crew is capable to completing various 
mission tasks. 
 
Priority: 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Desirable to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
CV2: Unknown in-flight and immediate post-flight VO2 max 
 
Activity:  
ISS/VO2max Study 
The measurement of aerobic capacity (VO2max) and cardiac output will be performed during and 
after long-term spaceflight.  
 
Product/Deliverables: 
Results from this study will determine if the current countermeasures adequate and need only 
optimization (e.g., reduced volume, time) or if improved countermeasures and flight 
validation studies are needed. 
Required Delivery Milestone: 
The SFHSS cardiovascular standard will be validated/updated in 2013; if no countermeasure 
is necessary, flight medicine will be informed in 2013; deliver countermeasure, if necessary, 
in 2020; and update the SFHSS cardiovascular standard in 2020. All products are required by 
FY13 to support mission operations requirements development. 
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Required Platforms: 
ISS is required for the initial flight study; ground-based flight analog bed rest is required if 
improved countermeasures are needed.  The improved countermeasures will be validated on 
board the ISS. 
Project/Organization Responsible for Implementation of Activity: 
  ECP – via directed study 
HRP-47065 
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30.0 RISK OF BONE FRACTURE -D X D  
 
Bone mineral loss occurs in microgravity due to unloading of the skeletal system, with average 
loss rates of approximately 1% per month.  It is unclear whether this bone mineral density will 
stabilize at a lower level, or continue to diminish.  It is also unknown if fractional gravity, present 
on the moon and Mars would mitigate the loss. This level of bone loss does not create an 
unacceptable risk of fractures for ISS missions, but longer missions could create higher fracture 
risk. The risk of fracture during a mission cannot be accurately estimated until mechanisms and 
probabilities of bone overloading during the missions are understood.   Mission-related bone loss 
cannot be corrected by post-mission rehabilitation; crewmembers could be at greater risk of 
osteoporosis-related fractures in later life. Greater understanding of the mechanisms of bone 
demineralization in microgravity is necessary to frame this risk, as well as to understand how 
current and future osteoporosis treatments may be employed. 
 
Operational Relevance and Risk Context  
DXA scans of astronauts and cosmonauts following long duration missions reveal an averaged 
monthly rate of BMD loss at 1-1.5% bone mass in lower limbs, hip, spine and pelvis.  QCT 
further delineates a greater percentage loss in the cancellous bone compartment, relative to loss in 
cortical bone, as well as geometric changes in the proximal femur.  Temporal recovery of 
preflight bone mass exceeds the duration of spaceflight exposure with a 50% restoration on the 
order of 200-250 days, based on a mathematical fit of postflight DXA BMD measurements.  
Thus, the recovery model, based upon fitted data, suggest that substantial recovery could occur in 
about 3 years following a 6 month flight. The fracture risk for bone is related to the ratio of 
applied load to bone to the fracture load of bone.  The most critical work needed for assessment 
of this risk is measures of inflight changes in bone mass over the course of ISS missions so that 
temporal changes in bone mass can be predicted during longer missions.  Those data will provide 
a basis for evaluating whether the expected loads/torques to the bones during a mission will 
exceed the failure load of bone (i.e., fracture load).  This knowledge will drive mission operations 
planning and postflight rehabilitation.    
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Desirable to Quantify and Reduce Prior to the Mars Mission.  
 
 
 
Gaps 
 
B1:  Is bone strength completely recovered with recovery of BMD? 
B2: What new technologies are available for in-flight fracture diagnosis? 
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B10: What is the time course of bone demineralization during flights greater than 90 days 
on ISS and during Lunar Outpost missions? 
 
Activity:  
Review of medical records to document the frequency of fracture in long duration crew 
(Russian, Mir and ISS) 
 
Activity:  
Bone Recovery Studies – TBD  
See Risk of Accelerated Osteoporosis – Gaps 1 and 10 
 
Activity:  
Technology to Monitor Bone Quality Changes – study TBD 
See Risk of Accelerated Osteoporosis – Gaps 1 and 10 
 
Activity: 
Expanded Analysis of Bone Turnover – study TBD 
See Risk of Accelerated Osteoporosis – Gaps 1 and 10 
 
Activity: 
Vertebral Compression Fractures – Directed Study TBD 
A flight study will be conducted to assess whether or not there are postflight vertebral 
compression fractures following long duration missions. This study will share data with 
Medical Requirement-035L Bone Densitometry. 
 
Product/Deliverables: 
If the results of this flight study indicate that vertebral fractures are a true flight 
issue, clinical countermeasures may be developed and implemented.   
Required Delivery Milestone: 
Validation / updates to the health standard will occur in FY11 which will affect 
the Constellation Program SRR in FY11.  If countermeasure development studies 
are required, mission operations will be informed in FY14 on lander and vehicle 
load constraints and a validated countermeasure will be delivered in FY18; both 
are required in FY14 for lander CDR and mission operations requirements 
development.  
Required Platforms: 
ISS is required as the Mars transit analog for initial work and countermeasure 
validation.   
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Project/Organization Responsible for Implementation of Activity: 
NxPCM – via directed study 
 
N5:  Can a single test monitor net bone calcium changes? 
 
Activity: 
Calcium Isotope Study – TBD  
 
B12: How does the EVA suit influence characteristics of falling? 
 
Activity: 
Center of Gravity Studies 
Conduct a series of studies to systematically understand the role of suit center of 
gravity (CG) on human performance and stability in partial gravity environments.  
Conduct a parabolic flight study to identify the location and measure the forces 
imparted to the body due to falling in an EVA suit. 
Prototype suits will also be evaluated. 
 
Product/Deliverables: 
Recommendations for suit design to avoid falling 
Data for fall frequency and contact forces model 
Required Delivery Milestone: 
Work will be complete by FY10 to provide inputs to Configuration 2 suit 
Systems Requirements Review.  Follow-on studies will be performed as needed 
to evaluate prototype suits. 
Required Platforms: 
Partial Gravity Simulator (Pogo), Neutral Buoyancy Laboratory (NBL), 
NEEMO, parabolic flight 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
Activity: 
Model Fall Frequency 
Analyze Apollo EVA video to estimate percentage of falls.  Create model to analyze 
worst case falls, such as from a ladder.  Combine results with data collected in CG and 
fall forces study to develop model of fall frequency and contact forces based on surface 
ops concepts. 
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Product/Deliverables: 
Model of fall frequency and contact forces based on concept of mission 
operations and operations concepts to limit falls 
Required Delivery Milestone: 
Initial modeling will be complete by FY11 to provide inputs to Surface Ops 
Systems Design Review.  Model will be updated based on results from 
evaluation of prototype suites.  Additional analysis will be performed as needed. 
Required Platforms: 
Statistical analysis and modeling capability 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
B13: What are acceptable load and torque ranges a crewmember can experience during a 
specific mission? 
 
Activity: 
Quantification of Joint Loads 
Analyze inverse dynamics data collected during suit tests conducted for EPSP1 and 
other ground studies to define joint load and torque ranges experienced during nominal 
and off-nominal EVA.   
 
Product/Deliverables: 
Quantification of joint load and torque ranges 
Required Delivery Milestone: 
TBD 
Required Platforms: 
Biomechanics analysis software packages 
Project/Organization Responsible for Implementation of Activity: 
EPSP – via directed study 
 
B11:  What are the effects of radiation on bone? 
 
Activity:  
The HHC Element will negotiate with the Space Radiation Project (SRP) to quantify 
the effects of radiation on bone. 
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Product/Deliverables: 
Required Delivery Milestone: 
Required Platforms: 
Project/Organization Responsible for Implementation of Activity: 
SRP 
 
B15: Can exercise hardware and protocol be designed to provide loads necessary to 
stimulate bone formation? 
 
Activity: 
Bed Rest Exercise Countermeasures Optimization 
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gaps M7-9 
 
Activity: 
ISS ARED Muscle Function Study 
See Risk of Impaired Performance Due to Reduced Muscle Mass, Strength and 
Endurance – Gaps M7-9 
HRP-47065 
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31.0 RISK OF RENAL STONE FORMATION -D X D  
 
Kidney stone formation and passage has the potential to greatly impact mission success and 
crewmember health for long-duration missions.   Alterations in hydration state (relative 
dehydration) and bone metabolism (increased calcium excretion) during exposure to microgravity 
may increase the risk of kidney stone formation and it is unclear which mitigation strategy would 
be the most effective. 
 
Operational Relevance and Risk Context  
Countermeasures for renal stone formation must be validated prior to Mars exploration missions 
because of reduced level of care and prolonged evacuation time.  Inflight monitoring may be 
developed and instituted so that crew members will have a means to track their renal stone 
markers.  
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Desirable to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
B5:  What is the current state of knowledge regarding renal stone formation? 
B6:  What are the contributing factors other than loss of bone mineral density? 
B7:  Is it necessary to increase crew fluid intake and, if possible, to what extent will it 
mitigate stone formation? 
B8:   Do pharmaceuticals work effectively in spaceflight to prevent renal stones? 
B9:   What is the frequency of post-flight stone formation; the incidence and types of stones; 
and the time course of stone formation?  How does stone formation correlate with food 
intake and hydration status? 
B16:  Can inhibitors of stone formation be sufficiently provided through dietary sources? 
N13: Can renal stone risk be decreased using nutritional countermeasures? 
 
Activity: 
Data Mining for Incidence of Renal Stone Formation Following Spaceflight  
The evidence establishing the risk factors and/or the likelihood of risk occurrence for 
renal stone formation is either known or in-progress.  This study will compile data 
related to the risk of renal stone formation from medical data and raw research data 
used for previously published reports) and determine primary and other risk factors for 
renal stone formation, particularly regarding the types of stones formed (to identify the 
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specific risk factor and appropriate countermeasure), the correlation with diet and the 
time course for formation. 
 
Product/Deliverables: 
Final report of findings; if data (combined with Renal Stone study results) 
indicate that new or additional countermeasures are required, then ground-based 
studies will be solicited to find suitable candidate countermeasures.  The best of 
these countermeasures will then be validated through solicited flight studies.  
Required Delivery Milestone: 
Final report in 2008; inform medical operations of results in 2008; deliver 
validated countermeasure(s) to mission operations in 2016. If the data indicate 
there is a valid risk of renal stone development, then a countermeasure to 
mitigate this risk is required as soon as possible. 
Required Platforms: 
If further countermeasures are needed, the bed rest ground analog is required to 
demonstrate countermeasure efficacy.  ISS is required as the Mars transit analog 
for countermeasure validation if new countermeasures are developed.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – directed study 
 
Activity: 
Renal Stone Risk During Spaceflight: Assessment and Countermeasure Validation 
The studies planned in this investigation will not only provide a better understanding of 
the stone-forming risk crewmembers experience during and after space flight, but will 
take the next step to test the efficacy of potassium citrate as a countermeasures to 
reduce this risk. Based on the known increased risk crewmembers experience, it is 
imperative that countermeasures to reduce or alleviate this risk are developed and 
tested. 
 
Product/Deliverables: 
Final report of findings.  If data (combined with data mining studies) indicate that 
new or additional countermeasures are required, then ground-based studies will 
be solicited to find suitable candidate countermeasures.  The best of these 
countermeasures will then be validated through solicited flight studies.  
Required Delivery Milestone: 
Final report in 2008; inform mission operations in of findings in 2008; deliver 
validated countermeasure(s) in 2016. If the data indicate there is a valid risk of 
renal stone development, then a countermeasure to mitigate this risk is required 
as soon as possible. 
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Required Platforms: 
If further countermeasures are needed, the bed rest ground analog is required to 
demonstrate countermeasure efficacy.  ISS is required as the Mars transit analog 
for countermeasure validation if new countermeasures are developed.   
Project/Organization Responsible for Implementation of Activity: 
NxPCM – via NRA 
 
N14: What nutritional countermeasures can be used to mitigate bone loss? 
 
Activity: 
Nutrition Countermeasures for Bone – study TBD 
See Risk of Accelerated Osteoporosis – Gap N1
HRP-47065 
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32.0 RISK OF URINARY TRACT DYSFUNCTION -D X D  
Multiple cases of urinary retention and subsequent urinary tract infections have been observed 
during short duration space flight, chiefly among females.  It is not clear why exposure to 
microgravity adversely affects the functioning of the urinary tract.  Further research into this area 
could explain this phenomenon, and assist with the clinical management of these cases. 
 
Operational Relevance and Risk Context  
Urinary tract infections have impacted mission operations in the past.  It is not known if a 
combination of altered immune function and urinary tract dysfunction might work together to 
cause these infections to become intractable during longer missions.  Such an occurrence could 
have a large and impact on the mission and on crew health. 
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Desirable to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
MO1: Determine how and why exposure to microgravity adversely affects urinary tract 
function. 
 
Activity: 
Data Mining Activities 
Data review activities are required to determine any known issues associated with 
urinary tract infections; this includes literature searches and searching the LSAH 
database.   
 
Product/Deliverables: 
Space normal data to indicate if any known urinary tract issues exist.  If issues do 
exist, the medical operations will be informed in FY09and countermeasures will be 
delivered in FY15. 
Required Delivery Milestone: 
Data mining will occur during FY08 and if the data indicates no risk, flight 
medicine will be informed by FY09 to retire the risk.  Countermeasures to mitigate 
the risk will be delivered in FY15.  Data is required as soon as possible to 
determine if a countermeasure is required for ISS crews. 
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Required Platforms: 
Ground-based databases initially.  If further work is required, ground analogs will 
be required as well as ISS. 
Project/Organization Responsible for Implementation of Activity: 
HHC Element
HRP-47065 
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33.0 RISK OF IMPAIRED VISION DUE TO REFRACTIVE VISUAL 
CHANGES DURING LONG-DURATION SPACEFLIGHT -D X D  
 
Significant changes in visual refraction have been documented among ISS crewmembers.  These 
changes appear to be due to senescent accommodative changes that may be exacerbated by the 
small volume of spacecraft cabins.  Vascular engorgement of retinal support layers also appears 
to play a role.  Not all crewmembers suffer from this problem.  Identification of associated risk 
factors, underlying pathophysiology, and mitigation strategies are necessary for maintaining crew 
vision during long-duration missions. 
 
 
Operational Relevance and Risk Context  
An understanding of the changes in visual acuity, and countermeasures for the changes, could 
affect all aspects of mission design, including vehicle and tools design, tasks and procedures, 
EVA suit design.  In addition it is necessary to determine if these changes will have long term 
effects on crew health. 
 
Priority 
 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Desirable to Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
MO2: Determine the associated risk factors, underlying pathophysiology, and mitigation 
strategies for maintaining crew vision. 
 
Activity: 
Data mining Activities 
Data mining activities are required to determine any known issues associated with 
vision problems; this includes literature searches and searching the LSAH database.  If 
issues exist, further ground-based countermeasure development studies will be 
conducted followed by flight validation studies. 
 
Product/Deliverables: 
Space normal data to indicate if any known visual acuity issues exist.  If issues do 
exist, the medical operations will be informed in FY09 and countermeasures will 
be delivered in FY15. 
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Required Delivery Milestone: 
Data mining will occur during FY08 and if the data indicates no risk, flight 
medicine will be informed by FY09 to retire the risk.  If additional flight data is 
required, those studies will take place in 2009-2013 and countermeasures to 
mitigate the risk will be delivered in FY15. Data is required as soon as possible to 
determine if a countermeasure is required for ISS crews. 
Required Platforms: 
Ground-based databases initially.  If further work is required, then ISS is needed. 
Project/Organization Responsible for Implementation of Activity: 
HHC Element 
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Major Milestone/ 
Event/Accomplishment
Element:
HRP PRD Requirement:
ISS & Shuttle
Lander
Human Lunar Return
PDR CDR
PDR-suit2 CDR-suit2
Lunar Architecture Baseline
SRR
PDR CDRProgram Level
Constellation
Orion
EVA Suit
PDR CDR Initial Ops (Orion)
PDR-init cap
CDR-init cap
PDR-suit1 CDRsuit1
Mission Operations SRRPDR CDR
SRR-suit2
FY’08 FY’09 FY’10 FY’11 FY’13FY’12
End of US CommitmentShuttle Retired6 Crew Capability
FY’14 FY’15 FY’16 FY’17 FY’18 FY’19 FY’20 FY’21 FY’22 FY’23 FY’24 FY’25
Major Decision 
Point
CMInforming 
Missions Ops
Updating 
Health Stds
Informing CxP
Loss of Mars Analog Transit
1
Risk of Impaired Vision due to Refractive Visual Changes During Long Duration Spaceflight
Gap: (MO2) Determine the associated risk factors, underlying 
pathophysiology, and mitigation strategies for maintaining 
crew vision.
HHC
HHC
5.1.4; 5.2.3; 5.3.3
Data mining 
activities
Gather additional in-flight data CM Studies
CM required?
Inform Flight Medicine
Data Mining required ASAP. If CM 
req’d then CM needed ASAP for ISS1
(1) Phys or pharm CM to mitigate risk
 
                    Graphics 
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34.0 RISK OF ADVERSE HEALTH EFFECTS DUE TO EXPOSURE 
TO HYPOXIC ENVIRONMENTS -D X D  
  
Spacecraft designers strive to maintain a normal terrestrial atmosphere for crewmembers; 
however, frequent EVA’s necessitate decreasing the atmospheric nitrogen levels to decrease the 
risk of decompression sickness.  Decreasing nitrogen partial pressure without decreasing oxygen 
partial pressure creates a significant fire risk.  Concerns exist whether crew performance could be 
adversely affected if cabin oxygen pressures are decreased.  Research into human performance at 
lower oxygen partial pressures could lead significant safety improvements in the design of future 
vehicles and missions. 
 
Operational Relevance and Risk Context  
It has been shown that in the South Pole (elevation of 10,000 feet above sea level) people get 
mountain sickness.  People may have cognitive and/or exercise issues living at the South Pole 
elevation.  There is a gap in our knowledge base for this issue; data mining activities are required 
to determine any known issues associated with hypoxic environments.  This risk is more similar 
to risk mitigation. 
 
Priority 
Lunar Outpost Mission: Desirable to Quantify and Reduce Prior to the Lunar mission.  
Mars Mission: Desirable To Quantify and Reduce Prior to the Mars Mission.  
 
Gaps 
 
MO4: Determine whether crew performance is adversely affected if cabin oxygen pressures 
are decreased. 
 
Activity: 
Data Mining Activities 
Data mining activities are required to determine any known issues associated with 
hypoxic environments; this includes literature searches and searching the LSAH 
database. If issues exist, further ground-based countermeasure development studies will 
be conducted followed by flight validation studies. 
 
Product/Deliverables: 
Space normal data to determine if there are any known issues with hypoxic 
environments.  If issues do exist, the medical operations will be informed in FY09 
and countermeasures will be delivered in FY15 
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Required Delivery Milestone: 
Data mining will occur during FY08 and if the data indicates no risk, flight 
medicine will be informed by FY09 to retire the risk.  Countermeasures to mitigate 
the risk will be delivered in FY15. Data is required as soon as possible to determine 
if a countermeasure is required for ISS crews. 
Required Platforms: 
Ground-based databases initially.  If further work is required, ground analogs will 
be required as well as ISS. 
Project/Organization Responsible for Implementation of Activity: 
SHFH Element 
HRP-47065 
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APPENDIX  A: TBR & TRL 
 
In this version of the IRP, some gaps and activities are noted as To Be Reviewed (TBR). The Science Management 
Panel, along with Program Management and the appropriate Element Management will conduct a review in 
CY2008 of these activities to determine the proper representation of the gap or activity and the criticality to the risk. 
The table to follow is a list of the current TBRs represented in this document (IRP-1). 
 
In some cases, due to the low TRL nature of some NSBRI studies, the direct connectivity or relevancy of the item to 
the risk has not been fully established. This version of the IRP identifies research and technology projects that are 
either heritage studies from previous selections or are low TRL studies. These studies are labeled To Be Reviewed 
(TBR-NSBRI) meaning that a thorough review for relevancy to the risk will be conducted in CY2008. Reference 
the figure at the end of this section for a visual definition of TRLs. 
 
Further, the IRP currently contains some studies that are conducted under Small Business Innovative Research 
(SBIR) awards. These studies are typically low TRL investigations, and are labeled TBR-SBIR meaning that a 
review for relevancy of these items will occur in CY2008. 
 
TBR Table 
Table # Name of Gap/Activity 
Inability to Adequately Treat an Ill or Injured Crew Member 
TBR-1 (SBIR) (Activity) Wearable Health Monitoring Systems 
TBR-2 
(NSBRI) 
(Activity) Guided High Intensity Focused Ultrasound (HIFU) for mission 
critical care 
TBR-3 
(NSBRI) 
(Activity) Prototype testing for non-invasive determination of intracranial 
pressure 
TBR-4 
(NSBRI) 
(Activity) Improved bubble detection for EVA 
Risk Factor of Inadequate Nutrition 
TBR-5 (Activity) The HHC Element will collaborate with the Space Medicine Division 
(SD) to determine how various countermeasures impact nutrition. 
Risk of Inadequate Food System 
TBR-6 (Gap) AFT3: What are the psychosocial requirements for the food system for 
different mission lengths? 
TBR-7 (Activity) Variety, acceptability, and usability requirements development. 
HRP-47065 
TBR-8 (Gap) AFT6: How can the mass and volume of the Lunar food system be 
reduced and how can it serve as a test bed for future Mars missions? 
TBR-9 (Activity) Food processing vs. packaged food system trade study. 
Risk of Behavioral and Psychiatric Disorders 
TBR-10 
(NSBRI) 
(Activity) Refine and Validate Tool for Early Detection and Mitigation of 
Depression 
Risk of Performance Errors due to Poor Team Cohesion and Performance, Inadequate 
Selection/Team Composition, Inadequate Training, and Poor Psychosocial Adaptation 
TBR-11 (Gap) 2.3.1 What are the best methods for training crews for maintaining 
cohesion and optimal performance during exploration missions? 
TBR-12 (Gap) 2.3.2 What are the best methods and tools for selecting and composing 
crews for optimal team performance during exploration missions? 
 
Definition of Technical Readiness Levels (TRL) 
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